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ABSTRACT 
 HIV associated cardiovascular disease is likely due to multiple factors ranging from 
accelerated aging, the direct effects of HIV proteins, and increased inflammation and immune 
activation.  Monocytes/macrophages play roles in the development and progression of HIV and 
cardiovascular disease.  Increased monocyte/macrophage inflammation and immune activation 
associated with HIV infection likely contributes to the increased risk of cardiovascular disease 
development associated with HIV infection.  To further understand the role of 
monocytes/macrophages in the development of HIV-associated cardiovascular disease we: 1) 
assessed monocyte activation longitudinally to determine if they correlate with and can be 
predictive of cardiac fibrosis and inflammation; 2) we examined cardiac tissues from the SIV-
infected CD8+ T-lymphocyte depleted animals to determine the effects of 
monocyte/macrophage inflammation on cardiac fibrosis; 3) in parallel we examined 
cardiovascular tissues from HIV+ individuals on durable cART to determine if aortic and cardiac 
inflammation persists with infection and if soluble factors (sCD163) correlated with intima-
media thickness and fibrosis; 4) we next examined the effects of blocking leukocytes trafficking 
to the heart on SIV-associated cardiac inflammation and fibrosis;  5) and finally we examined if 
targeting monocyte/macrophage activation (as opposed to traffic) directly using MGBG 
decreases SIV-associated cardiovascular pathology, inflammation and fibrosis.  We found that 
early increased monocyte activation was predictive of animals that developed cardiac fibrosis 
and SIV encephalitis (SIVE).  Animals with both cardiac fibrosis and SIVE had increased 
macrophage inflammation in the heart, suggesting that there is a link between cardiac and CNS 
inflammation seen with HIV infection (Chapter 2).  We found in a SIV-infected CD8+ T-
lymphocyte depletion model of rapid AIDS increased prevalence of cardiac disease compared to 
nondepleted animals, and increased cardiac inflammation that correlated with cardiac fibrosis.  
Monocyte/macrophage traffic to the heart occurred later with SIV infection, possibly with the 
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development of AIDS (Chapter 3).  In post-mortem human tissues studies we found that 
inflammation in aorta and heart correlated with increased soluble CD163, and correlated with 
aortic intima-media thickness and cardiac fibrosis with HIV infection (Chapter 4).  Blocking 
leukocyte traffic to the heart using an anti-α4 antibody decreased macrophage inflammation in 
the heart that correlated with decreased cardiac fibrosis (Chapter 5).  Using MGBG, a polyamine 
biosynthesis inhibitor that directly targets monocyte/macrophage activation, we found 
decreased inflammation in the carotid artery and heart correlated with decreased carotid artery 
intima-media thickness and cardiac fibrosis (Chapter 6).  Overall these studies provide evidence 
for ongoing monocyte/macrophage cardiovascular inflammation with HIV and SIV infection.  
Macrophage inflammation correlates with markers of cardiovascular disease (fibrosis and 
intima-media thickness, cardiomyocyte damage).  Directly targeting monocyte/macrophage 
traffic (anti-α4 antibody) and activation (MGBG) decreased cardiovascular pathology, 
inflammation, fibrosis, and intima-media thickness.  Taken together, the data in this thesis 
indicate that targeting monocytes/macrophages in conjunction with combination anti-retroviral 
therapy could alleviate cardiovascular disease in HIV-infected individuals. 
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CHAPTER 1. Introduction 
I. HIV Biology 
 A. HIV clinical progression in the Pre-cART era 
 Approximately 80% of HIV infections are accounted for through gastrointestinal and 
reproductive tract mucosal exposure with the remaining 20% of infections due to percutaneous 
or intravenous infections or direct mother to infant transmission1-3.  While the exposure route 
can differ from person to person, the timing of detection of viral and host biomarkers of 
infection in untreated cases of HIV is relatively uniform.4    During the first 7 to 21 days, while 
HIV is replicating in the mucosa, submucosa, and lymphatic tissue (Figure 1.1), the virus cannot 
be detected in plasma1.  During this early asymptomatic phase, there is uncontrolled viral spread 
within the body and establishment of viral reservoirs 2,3.  Acute infection occurs within 2 to 4 
weeks after infection and is characterized by a rapid increase in plasma HIV RNA as well as 
decreases in CD4+ T-lymphocytes in the blood and gut.  Following this, the virus enters into a 
latent stage where viral RNA is decreased and remains relatively stable while there is a recovery 
of CD4+ T-lymphocytes.  This period can last on average 10 years, which is then followed by 
progression to AIDS, the final stage.  Here, viral RNA in the blood increases rapidly along with 
continued decrease of CD4+ T-lymphocytes.  It is at this time where individuals experience 
symptoms of AIDS and development of opportunistic infections (Figure 1.2) 5,6.   
 2 
   
Figure 1.1 Replication of HIV virus in mucosa and submucosa tissue.  A schematic diagram of 
HIV-1 virus infection and replication during the early stages of disease  
(Reproduced with permission from Cohen MS et al.  Acute HIV-1 Infection. N Engl Med 
2011,364:1943-1954, Copyright Massachusetts Medical Society) 
 
Upon initial HIV infection, the host mounts an immune response that includes the 
production of acute-phase reactants and inflammatory cytokines and the beginning of CD8+ T-
lymphocyte cytotoxic response7.  Interferon (IFN)-α and interleukin (IL)-15 are both elevated 
prior to peak viremia along with tumor necrosis factor (TNF)-α and IFN-γ that are secreted by a 
mix of dendritic cells (DCs), monocytes, and natural killer (NK) cells7-10.  Cytotoxic CD8+ T-
lymphocyte responses appear days before peak viremia along with the production of cytokines 
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and contribute to the initial control of the spread of the virus11-13.  Approximately 3 months after 
infection, neutralizing antibodies begin to be detected within the blood1,14.  The initial 
neutralizing antibodies recognize the surface glycoprotein (gp)41 of HIV-1, but many neutralizing 
antibodies are eventually generated that recognize gp120.  It is during the asymptomatic period 
when the virus is in a latent stage, that the host immune responses are able to keep viral 
replication in control15.  However, continued viral replication eventually leads to reduced CD4+ 
T-lymphocytes and chronic dysregulated immune activation that can result in susceptibility to 
opportunistic infections (OIs), including tuberculosis, Kaposi sarcoma, and cytomegalovirus 
(CMV) .  Both infected and uninfected CD4+ T-lymphocytes die during HIV infection, with 
uninfected cells dying through apoptosis, possibly due to cytotoxicity of HIV proteins.  CD4+ cells 
can also enter apoptosis due to an abortive infection or due to expression of HIV proteases after 
viral integration.   AIDS is defined by the number of CD4+ T-lymphocytes falling below 200 
cells/mL of blood.  As numbers of CD4+ T-lymphocytes decrease, plasma virus also increases, 
along with the development of OIs (Figure 1.2). 
   
Figure 1.2 Time course of typical HIV infection.  Patterns of CD4+ T cell decline and viremia  
vary greatly from one patient to another  
(Reprinted by permission from Cold Spring Harbor Laboratory Press, Cold Spring Harb Perspect 
Med, 3(1), Coffin J, Swanstrom R, HIV Pathogenesis: Dynamics and Genetics of Viral Populations 
and Infected Cells, a012526-a012526, 2013) 
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 B. HIV Genome and replication 
 HIV is a complex enveloped retrovirus that encodes for 15 distinct proteins.  The 
genome has 9 open reading frames, 3 of which encode Gag, Pol, and Env polyproteins, which are 
proteolyzed into proteins that are common to all retroviruses16.  The core of the virion and the 
outer membrane are made of the four Gag proteins, MA (matrix), CA (capsid), NC 
(nucleocapsid), and p6, along with the two Env proteins, SU (surface or gp120) and TM 
(transmembrane of gp41).  PR (protease), RT (reverse transcriptase), and IN (integrase) are the 
three Pol proteins that are encapsulated within the virion and provide necessary enzymatic 
functions for genome integration and replication of the virus.  The remaining proteins encoded 
by the genome are 6 accessory proteins.  Vif, Vpr, and Nef, which are found within the viral 
particle.  Tat and Rev assist in gene regulatory functions while Vpu assists in the assembly of the 
viron.  Long terminal repeats (LTR) at the 5’ and 3’ ends of the genome help to regulate 
transcription of the viral genes (Figure 1.3)16-18.   
  
  
Figure 1.3 Organization of HIV-1 genome and virion showing the 15 proteins and open reading 
frames (Reproduced with permission from Frankel AD and Young JAT. HIV-1 Fifteen Proteins and 
an RNA. Ann Rev Biochem 1998,67:1-25).   
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 Historically, the CD4 cell surface molecule was initially discovered to be the main cellular 
receptor for HIV-1 shortly after the virus was isolated19-21.  Following this, it was discovered that 
HIV uses one of two coreceptors to gain entry into a cell, either the CXC-chemokine receptor 4 
(CXCR4) or the CC-chemokine receptor 5 (CCR5)22,23.  Viral infection of a cell first begins with the 
recognition of the envelope protein gp120 to the CD4 receptor on a target cell24.  Binding of the 
CD4 receptor on a target cell results in a conformational change in gp120 that allows it to 
interact and bind with the CXCR4 or CCR5 co-receptor, followed by the insertion of the gp41 
protein into the host cell membrane25.  When the membranes of the virion and the target cell 
fuse, the core proteins begin to uncoat and the HIV genome, reverse transcriptase, and 
integrase are released into the cytoplasm of the target cell26,27.   Within the nucleus of the target 
cell, the viral enzyme, integrase, allows incorporation of HIV intermediate DNA (provirus) into 
the cellular DNA where it is used as a template for the production of new virions.  New viral 
transcripts and the full length RNA genome of HIV are transcribed and exported from the 
nucleus and into the cytoplasm.  Using both viral and cellular proteins, HIV RNA is spliced and 
assembled into new virions that bud from the surface of the target cell and can then infect new 
cells (Figure 1.4) 28-30. 
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Figure 1.4 Overview of the HIV-1 replication cycle along with antiretroviral drugs and the steps 
that they target (green boxes)  
(Reprinted by permission from Macmillan Publishers Ltd: Barre-Sinoussi F et al., Past, present 
and future: 30 years of HIV research, Nat Rev Microbiol, 11(12) 877-883, 2013). 
 
II. HIV infection in the cART era 
A. Increased lifespan with effective cART  
With the emergence of combination anti-retroviral therapy (cART) the health and 
lifespan of HV infected individuals has dramatically increased31-34 (Figure 1.5).  The goal of an 
effective drug regimen is to improve immune function and decrease plasma viral load below the 
limit of detection of commercial assays, 50 copies of HIV RNA/mL (Figure 1.6)35,36.  Because of 
effective cART, reduced plasma viral load, and recovery of CD4+ T-lymphocytes, the patterns of 
morbidity and mortality with HIV infection has shifted in the post-cART era37,38.  Previously, in 
the pre-cART era the healthcare focus in AIDS management centered on AIDS specific 
malignancies such as Kaposi sarcoma and lymphomas, tuberculosis, CMV, Pneumocystic carinii, 
and complications arising from eary anti-retroviral therapy associated drug toxicities, drug-drug 
interactions, and drug resistance.  In the cART era, with a longer lifespan, HIV has become a 
chronic condition, leading to a rise in a number of significant non-AIDS co-morbidities39.  These 
entail, but are not limited to, AIDS-related cancers, renal40, hepatic41, neurological42-44, and 
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cardiovascular complications45-50.  While the cause of these secondary diseases is most likely 
multi-factorial, growing evidence in recent years has implicated prolonged immune activation 
and chronic inflammation as central to the development of chronic HIV pathologies, with 
monocytes/macrophages postulated to play an important role.  
 
Figure 1.5 Mortality and cART use over time  
(Palella FJ et al., Mortality in the Highly Active Antiretroviral Therapy Era Changing Causes of 
Death and Disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr. 2006;43(1):27-34). 
 
 
Figure 1.6 Time course of HIV infection with combination antiretroviral therapy   
(Reprinted from Lancet, 384(9939), Maartens G, et al., HIV infection: epidemiology, 
pathogenesis, treatment, and prevention, 258-271, 2014, with permission from Elsevier) 
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B. Increased immune activation with HIV infection 
Durable cART can decrease plasma viral load to low or undetectable levels in patients 
that adhere to the drug regimen.  However, low level viremia still exists51-53 in these patients 
possibly due to ongoing viral replication or release of virus from latent tissue or cellular 
reservoirs54,55.  Low level viral replication can lead to prolonged immune activation.  Several 
studies have showed that HIV infected individuals on suppressive cART still have elevated 
markers of immune activation that remain elevated after initiation of cART and do not return to 
levels seen in HIV negative indivudals.56-58 (Figure 1.7).  In particular, soluble CD163 (sCD163) in 
the blood has become a useful biomarker of HIV activity.   CD163 is a hemoglobin/haptoglobin 
receptor that is expressed solely on monocytes/macrophages59-61.  Soluble CD163 is 
proteolytically cleaved from the surface of activated CD163+ macrophages in response to pro-
inflammatory stimuli62,63.   Serum levels of sCD163 correlated with HIV-1 activity where they are 
elevated in acutely (<1yr) and chronically (>1yr) infected individuals and remain elevated even 
after initiation of cART in chronically infected individuals64.  Chronic immune activation, based 
on elevated sCD163, is also seen in HIV-1 elite controllers (who spontaneously control virus 
without being on cART) with higher sCD163 in elite controllers than in patients on durable 
cART.65   
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Figure 1.7 Increased levels of biomarkers of immune activation sCD163 and sCD14 in HIV 
infected individuals on cART  
(Left. Burdo TH, et al., Soluble CD163 made by monocyte/macrophages is a novel marker of HIV 
activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis. 
2011;204(1):154-163, by permission of Oxford Press.  Right. Reprinted from Lancet, 384(9939), 
Maartens G at al., HIV infection: epidemiology, pathogenesis, treatment, and prevention, 258-
271, 2014, with permission from Elsevier) 
 
III. Cardiovascular manifestations of HIV infection  
A. Pre-cART era 
 The focus of research on cardiovascular disease associated with HIV infection has shifted 
in the pre- and post-cART era.  In the pre-cART era many of the manifestations have been 
associated with the cardiac muscle itself.  In the pre-cART era dilated cardiomyopathy (DCM), an 
enlargement of the heart resulting in deficiencies in pumping blood, had been diagnosed in 8-
30% of HIV infected individuals and in 25% of patients at necropsy66-68.  Myocarditis, 
inflammation of the heart muscle, has been documented in as low as 6% and as high as 50% of 
HIV infected individuals66,69,70.  Magnetic resonance imaging (MRI) showed that with HIV 
infection there is increased inflammation in early stages of HIV infection and increased fibrosis 
in the later stages71.  The prevalence of myocarditis and fibrosis among HIV+ individuals has 
increased as HIV+ individuals on cART live longer.    Similar rates of endocarditis and pericardial 
effusion are seen in HIV+ individuals as well72,73.  It was initially believed that much of the 
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myocardial disease associated with HIV and AIDS was due to Kaposi Sarcoma, a tumor caused by 
infection with human herpesvirus-874,75.  However, with effective cART, many of these 
manifestations of  the myocardial disease has been significantly reduced, in some cases by as 
much as 30%69,76,77. 
 
B. Post-cART era 
While the prevalence of some types of  myocardial disease associated with HIV have 
decreased with cART,76,77 recent reports have begun to show that there still exists a significant 
burden of myocardial disease associated with chronic HIV infection50,78.  Magnetic resonance 
spectroscopy (MRS) studies demonstrated that HIV infected individuals continue to have 
subclinical myocardial disease, fibrosis, and alterations in cardiac function50,78-80.  Significant 
myocardial fibrosis was prevalent in 76% of HIV infected individuals on cART compared to only 
13% of age-matched control individuals78.  Similar findings were presented in a recent study 
examining asymptomatic HIV infected individuals on suppressive cART with HIV plasma RNA 
below 200 copies/mL and CD4+ T-lymphocytes greater than 400 cells/μL where cardiac 
magnetic resonance (CMR) showed that myocardial fibrosis was seen in 82.1% of HIV infected 
individuals compared to 27.3% of healthy controls81,82. 
HIV has become there has also been an increase in vascular disease due to continued 
immune activation and systemic inflammation. Compared to the general population, HIV 
infected individuals are at an increased risk of atherosclerosis83-85.  FDG-PET imaging of HIV 
infected individuals showed increased inflammation in the ascending aorta consistent with 
atherosclerosis which correlated with elevated serum levels of sCD163, suggesting a role for 
inflammation, specifically monocytes/macrophages, in the development of HIV-associated 
cardiovascular disease (CVD)86.  It has previously been shown that traditional risk factors of CVD, 
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( elevated D-dimer, C-Reactive protein (CRP), and interleukin (IL)-6) are not associated with 
atherosclerotic plaques in HIV patients, but markers of immune activation, sCD14 and sCD16364 
are, suggesting that chronic immune activation of monocytes/macrophages play a role in the 
development of HIV-associated CVD.    
Levels of sCD14 are associated with coronary artery calcium (CAC), a marker of CVD, 
among HIV infected individuals87.  In a study examining men with and without HIV, it was found 
that sCD14 and scD163 are elevated in those with HIV and associated with subclinical 
atherosclerosis88.  Early during the cART era it was thought that drug toxicities were responsible 
for the increase in CVD associated with HIV infection89-92.  However, it is interesting to note that 
HIV-1 elite controllers, who spontaneously maintain low levels of viremia without cART still 
experience an increase in CVD93.  Reportedly elite controllers had an increase in non-calcified, 
vulnerable plaques that are prone to rupture compared to uninfected controls, as well as 
chronically infected individuals on cART, accompanied by elevated serum markers of 
inflammation and immune activation, sCD14, sCD16365,94.  This supports the notion that cART 
toxicity is not the sole cause of HIV-associated CVD, but inflammation and immune activation 
play a role in the development of CVD. 
As the prognosis of HIV+ individuals has improved with the development  of effective 
cART this population is now aging, with approximately 50% of HIV+ individuals in the United 
States and Europe being  50 years old or older.95  Data shows that mortality due to AIDS-related 
causes has decreased in the cART era but there has been a proportional increase in mortality 
due to non AIDS-related illnesses,45,96,97 and in particular the proportion of deaths due to CVD 
among HIV+ individuals has increased.45  In a large population study examining HIV+ individuals 
on cART compared to uninfected controls it was demonstrated that with HIV infection there is 
an increase in noninfectious comorbidities, in particular CVD, compared to controls.98,99  
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Additionally, HIV+ individuals were more likely to suffer from multiple pathologies 
simultaneously (polypathology).  The prevalence of polypathology among HIV+ individuals was 
similar to that seen in uninfected individuals that are 10 to 15 years older98.  The results from 
this study suggest that HIV infection can lead to the early aging of an infected individual, 
potentially leading to the development of CVD at an earlier age compared to the general 
population. 
 
IV.  Role of Immune Cells in Cardiovascular Disease 
A.  T-lymphocytes 
Early evidence of increased expression of MHC-II molecular human leukocyte antigen D-
related (HLA-DR) in human atheromas along with large numbers of T-lymphocytes provided 
insight into the role of the adaptive immune system in the development of atherosclerosis100-102.  
The majority of T-lymphocytes within the atheroma are CD4+ T helper cells103.  T-lymphocytes 
are one of the first cell types to be recruited into a developing atheroma and they are increased 
in unstable plaques that are prone to rupture compared to more stable atherosclerotic 
plaques104,105.   
Within atherosclerotic plaques the most abundant subset of T-lymphocytes are CD4+ T-
lymphocytes.  Naïve T-lymphocytes mature into effector or helper cells (Th), with the most well 
known Th cells being Th1, that express IFN-γ, Th2, which produce and secrete interleukin (IL)-5, 
IL-4, and IL-3, and Th17, cells which secrete IL-17 and IL-22106,107.  In a large proportion of 
plaques, Th-1 T-lymphocytes were found to be the most abundant subset and IFN-γ has been 
shown to be expressed and play a role in promoting atherosclerosis and ongoing 
inflammation108.  IFN-γ promotes atherosclerosis by altering endothelial function, necessary for 
the recruitment of inflammatory cells to the developing lesion, and alters cholesterol export 
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from macrophages resulting in increased foam cell formation109.  Conversely, Th2 cells appear to 
have a protective effect in regards to the development of atherosclerosis.  Th2 cells secrete IL-4 
which can inhibit Th1 differentiation as well as IFN-γ production110,111.   While not as abundant as 
CD4+ T-lymphocytes, CD8+ cytotoxic T-lymphocytes are also present in atherosclerotic plaques 
and have a pro-atherogenic effect by initiating cell death (Figure 1.8) 106.   
  
 
 
Figure 1.8 The role of T-lymphocytes within atherosclerotic plaque development 
(Reprinted by permission from John Wiley and Sons, Clin Exp Immunol, 179(2), Ammirati E et al., 
The role of T and B cells in human atherosclerosis and atherothrombosis, 173-187, 2015) 
 
Within the heart itself, T-lymphocytes are also important in the development of cardiac 
inflammation and fibrosis, accumulation of fibrillar extracellular matrix (ECM) in the 
myocardium112,113.  It has been proposed that Th2 cells promote the development of cardiac 
fibrosis while Th1 cells, and the cytokines that they produce, are anti-fibrotic under 
inflammatory conditions114.  However, other reports have shown evidence that Th1 T-
lymphocytes have pro-fibrotic effects as well115.  IFN-γ produced by Th1 cells is known to help in 
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the differentiation, migration, and activation of macrophages as well as expressing MCP-1 which 
aids in the recruitment of cells to the heart leading to active inflammation and the development 
of fibrosis (Figure 1.9) 116,117. 
                        
Figure 1.9 Adaptive immune pathways in the development of fibrosis  
(Reprinted by permission from Macmillan Publishers Ltd: Nat Med, 18(7), Wynn TA and 
Ramalingam TR, Mechanisms of fibrosis: therapeutic translation for fibrotic disease, 1028-1040, 
2012) 
 
B.  B-lymphocytes 
Much of the clinical research involving the immune system and its role in the 
development of atherosclerosis and subsequent CVD has focused on T-lymphocytes.  However, 
rodent studies suggest that B-lymphocytes may play a protective role in atherosclerosis118,119.  
While T-lymphocytes are numerous in a developing plaque, there are fewer B-lymphocytes but 
their numbers are increased in the outer adventitial layer of the vessel wall120,121.  B-
lymphocytes are found in both the intima and adventitia of a vessel wall in human and animal 
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studies, but they are more prevalent in the adventitia than the intima122.  In the adventitia 
associated with an atherosclerotic plaque, B and T-lymphocytes have been described as forming 
tertiary lymphoid organs (TLO)123.  B-lymphocytes present in the intima produce antibodies 
against low-density lipoprotein (LDL,) which can aid in LDL clearance by 
monocytes/macrophages and neutrophils123.  B-lymphocytes in the adventitia are thought to 
accumulate later during the course of the disease, and their numbers are increased when TLO 
are present (Figure 1.10).   
  
 
 
Figure 1.10 The role of B cells and immunoglobins within atherosclerotic plaque development  
(Reprinted by permission from John Wiley and Sons, Clin Exp Immunol, 179(2), Ammirati E et al., 
The role of T and B cells in human atherosclerosis and atherothrombosis, 173-187, 2015) 
 
 
  Similar to T-lymphocytes, which can be classified as Th1 and Th2, B-lymphocytes can be 
classified as either B1 or B2 that potentially have different functions 101,118.  B2 cells are thought 
to be pro-atherogenic.  When B2 cells were isolated, purified, and transferred into lymphocyte-
deficient mouse models atherosclerosis was significantly increased, suggesting a proatherogenic 
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role for B2 cells in the absence of other immune cells types119.  Conversely B1 cells that secrete 
nonspecific natural IgM antibodies are protective against atherosclerosis.  Natural IgM 
antibodies inversely correlate with atherosclerotic burden in carotid arteries and carotid artery 
intima-media thickness101,120.  This suggests a protective role for B1 cells in human 
atherosclerosis. 
In contrast to their possible protective role in preventing or reducing atherosclerotic 
disease, B-lymphocytes may contribute to cardiac disease.  B-lymphocytes  can generate cardiac 
specific antibodies that can bind to cardiomyocytes causing apoptosis124.  Additionally, in mice 
that are lacking both T and B-lymphocytes, there is a delay in the development of acute 
cardiomyopathy as well as decreased levels of myocardial fibrosis.  With injury to the heart, B-
lymphocytes selectively secrete the chemokine CCL7 which triggers monocyte mobilization and 
recruitment from the bone marrow.  In mice depleted of B-lymphocytes, there is decreased 
CCL7 and subsequently a reduction in monocyte/macrophage infiltration of the heart and 
improves myocardial function125. 
 
C.  Monocytes/Macrophages 
Monocytes are mononuclear phagocytes that comprise 5-10% of leukocytes in 
circulation in humans126.  They are a heterogeneous population and classified based on their 
expression of various surface antigens, size, morphology, and function 126-130.  Monocytes have 
been identified by their expression of CD14, the lipopolysaccharide co-receptor, and their 
expression of CD16, the low affinity Fcγ-III receptor that acts as a marker of activated 
monocytes,127,131-133 resulting in populations of monocytes as being defined as either 
CD14+CD16- or CD14+CD16+.  More recently, research showed that CD16+ monocytes are a 
heterogeneous population, leading to new nomenclature dividing monocytes into three 
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populations: CD14++CD16- (classical), CD14++CD16+(intermediate) and CD14+CD16++(non-classical) 
monocytes.  Monocytes are a key component in the development of CVD and previously have 
been shown to be predictive of CVD134,135.  CD14++CD16+ monocytes were independently 
related to the occurrence of myocardial infarction and non-hemorrhagic stroke135, and 
CD14+CD16+ monocytes were associated with the development of coronary artery disease136.  
CD14++CD16+ monocytes are also increased in patients experiencing congestive heart failure 
and increased numbers in circulation could reflect deterioration of the heart muscle137.  Studies 
have defined the role of monocytes/macrophages that express surface markers such as CD68, 
CD163, and CD206 in the development of coronary artery disease,138 cardiac fibrosis,139 
myocarditis76,140 and atherosclerotic plaque progression141,142,143-145.  In the initial stages of 
atherosclerosis, activated endothelium results in increased expression of surface adhesion 
molecules, such as E-selectin, P-selectin146,  and VCAM-1138,147, and secrete chemokines CCL2, 
CCL5, and CX3CL1148, promoting the recruitment of leukocytes and monocytes to the arterial 
wall103,149.  Here, monocytes differentiate into macrophages where they can phagocitize low 
density lipoprotein (LDL) and develop into foam cells,150 which contribute to the development of 
an atheroma core149,151.  Within atherosclerotic plaques there are a range of 
monocyte/macrophage phenotypes, where M1 inflammatory macrophages are thought to play 
a role in plaque rupture152, while M2, characterized by CD163 and CD206 expression, 
macrophages are thought to be athero-protective153.  However, the distinction between M1 and 
M2 polarized macrophages based on their surface markers is not distinct and 
monocytes/macrophages should be distinguished based on their actual function within tissues.  
Studies using optical coherence tomography have shown that vulnerable plaques have a lipid 
rich core and more macrophages present in the cap and shoulder regions than stable plaques 
within the same individual154.  Histological studies showed that macrophages in vulnerable 
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plaques (those that are prone to rupture) M2 CD163 and CD206 positive macrophages155.  It is 
possible that while these macrophages express classical markers of M2 polarized cells they are 
in fact having a pro-inflammatory effect and that the definitions of M1 and M2 macrophages will 
need to be altered based on actual function.  Work by our lab showed that numbers of CD163+ 
and CD206+ macrophages in the intima of the aorta correlate with increased intima-media 
thickness, a CVD marker (Chapter 4). Additionally, macrophages within an atherosclerotic 
plaque secrete matrix metalloproteinases (MMPs), promoting plaque instability and rupture 
(Figure 1.11) 156,157. 
                 
 
Figure 1.11 Monocyte recruitment and macrophage differentiation within an atherosclerotic 
lesion (Reprinted from Immunobiology, 218(11), Fenyo IM and Gafencu AV. The involvement of 
the monocytes/macrophages in chronic inflammation associated with atherosclerosis, 1376-
1384, 2013, with permission from Elsevier) 
 
 
In the normal heart there are few macrophages present in the ventricles and atria that 
express CD68 and are likely resident tissue macrophages.158  Numbers of macrophages are 
increased with cardiovascular disease with and without HIV infection159,160.  Growing evidence 
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supports the role of monocytes and macrophages in the development of cardiac fibrosis.  In 
response to injury or infection monocytes traffic to the myocardium and develop into tissue 
macrophages that secrete pro-inflammatory and fibrotic factors.  We showed that increased 
numbers of macrophages in the heart correlate with increased cardiac fibrosis161.  
Monocytes/macrophages can secrete high levels of pro-inflammatory cytokines interleukin (IL)-
1β162, tumor necrosis factor (TNF)-α163,164 as well as pro-fibrotic growth factors transforming 
growth factor (TGF)-β165,166.  TNF-α and IL-1β are expressed in fibrotic heart tissue and levels of 
TNF-α in circulation correlated with collagen turnover suggesting a role for the cytokine in 
cardiac remodeling167.   
 
V.  Plaque stability is influenced by immune cells 
  A. Characteristics of stable and unstable atherosclerotic plaques 
 Atherosclerosis comprises the bulk of CVD and is now considered a chronic 
inflammatory disease affecting the walls of mid to large arteries 168.  Typically, atherosclerotic 
plaques remain dormant for years and may not even result in clinical manifestations such as 
myocardial infarction (MI).  However, the surface of a plaque can be damaged or degraded and 
is then prone to rupture resulting in a thrombosis and eventually result in myocardial infarction 
(MI) (Figure 1.12) 169.  Stable plaques tend to be more calcified and have reduced macrophage 
content compared to unstable, vulnerable, plaques which have large lipid filled cores with 
apoptotic cells and increased numbers of macrophages in the shoulder and cap regions (Figure 
1.13) 154,155.  Macrophages located in atherosclerotic plaques secrete matrix metalloproteinases 
(MMPs) which can degrade collagen and other components of the ECM that give a plaque its 
strength170-172.  While MMPs can be secreted by numerous cells types within a plaque, 
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macrophages have been shown to secrete MMP-1, -3, and -8, which colocalized with cleaved 
collagen suggesting that MMPs are not only secreted but also activate173,174.   
 
            
 
Figure 1.12 Pathophysiology of plaque progression and rupture  
(Reprinted from Heart Lung Circ, 22(6), Sakakura K et al., Pathophysiology of atherosclerosis 
plaque progression, 399-411, 2013, with permission from Elsevier) 
 
B. Atherosclerotic plaques associated with HIV infection 
Within HIV infected populations there is an increased risk of CVD due in part to 
monocyte/macrophage accumulation175-177, resulting in a phenotype of plaques that are 
vulnerable, non-calcified, and prone to rupture64,86.  FDG-PET imaging showed that HIV infection 
results in increased inflammation in the ascending aorta, which correlated with increased levels 
of sCD163, proteolytically cleaved specifically by monocytes/macrophages86.  In addition to 
increased aortic inflammation in HIV patients, there is elevated high-risk plaque morphology 
defined as an increase in the number of low attenuated plaques and positive remodeling 178.   
Noncalcified vulnerable plaques among HIV+ individuals are linked to markers of 
monocyte/macrophage activation including sCD16386.  This suggests that targeting 
 21 
monocytes/macrophages in HIV infected individuals could provide a benefit in reducing the 
number and extent of noncalcified plaques and decrease clinical sequelae of CVD such as MI. 
                      
 
Figure 1.13 Comparison of stable and unstable atherosclerotic plaques  
(Reprinted by permission from Macmillan Publishers Ltd: Nat Med, 20(2), Tahara N et al., 2-
deoxy-2-[F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis, 215-
219, 2014) 
 
VI. Imaging modalities to diagnose cardiovascular disease 
A. Positron Emission Tomography 
Radiolabeled 18F-fluordeoxyglucose (FDG) with positron emission tomography (PET) has 
been employed as a technique to visualize vascular inflammation in animal models and human 
cases of atherosclerosis179-181.  Metabolically active cells readily take up and accumulate the 
radiolabeled glucose through glucose transporters (GLUTs).  Because macrophages are more 
metabolically active than surrounding cells they will take up glucose in excess and can then be 
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visualized using PET imaging to show vascular inflammation due to macrophage 
accumulation155.  Macrophages are polarized into either M1 pro-inflammatory or M2 anti-
inflammatory subsets that express different surface markers153,182.  M2 macrophages express 
the mannose receptor (MR), CD206, on their cell surface, which provides a target for using 
radiolabeled mannose, 18[F]FDM, as an imaging agent.  As previously discussed, CD206+ 
macrophages present in unstable atherosclerotic plaques155.  Animal studies showed that 
18[F]FDM was readily taken up by M2 macrophages in atherosclerotic plaques at a higher rate 
than 18[F]FDG resulting in better sensitivity and diagnosis following PET imaging155.  In addition, 
by using 18[F]FDM it is possible to specifically target those macrophages that are responsible for 
plaque stability and distinguish high risk plaques. 
 
B. Use of Tilmanocept as a direct diagnostic imaging agent 
99mTc-tilmanocept (Lymphoseek®, Navidea Biopharmaceuticals, Inc.) is a sensitive and 
specific diagnostic imaging agent the binds specifically to CD206, the MR on the surface of 
macrophages and dendritic cells183.  Tilmanocept has previously been approved for and used in 
human studies in sentinel lymph node (SLN) biopsies to detect various types of cancers that 
express CD206184-186.  Expression of CD206 on macrophages is not specific to cancers, but is also 
expressed on macrophages in various other diseases such as rheumatoid arthritis and 
cardiovascular disease183.  As numbers of macrophages expressing CD206 are increased in 
unstable atherosclerotic plaques it is possible that 99mTc-tilmanocept to directly identify 
macrophages in vascular inflammation and discriminate between stable and unstable 
atherosclerotic plaques155. 
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C. B-mode ultrasound to measure intima-media thickness of arteries 
The development of ultrasound techniques has made it possible to noninvasively 
measure the intima-media thickness (IMT) of an artery in vivo187.  Measurements in both the 
carotid artery and aorta of IMT effectively determine the risk of atherosclerosis in people 188-190.  
A longitudinal study using therapies designed to reduce vascular inflammation in HIV+ patients 
effectively reduced IMT, reducing CVD risk due to atherosclerosis191. 
 
D. Cardiac magnetic resonance spectroscopy 
Cardiac magnetic resonance spectroscopy (MRS) not only can be used to gain 
anatomical and functional information about the heart, but also information on the composition 
of the tissue itself including the presence of inflammation and fibrosis 81,192.  Cardiac biopsy 
samples from healthy individuals were stained with picrosirius red to quantify the amount of 
myocardial fibrosis.  The amount of fibrosis measured in the biopsy samples strongly correlated 
with results from cardiac MRS 193. 
 
VII. Therapies targeting macrophage inflammation for cardiovascular disease 
A. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) 
Statins are commonly used to lower low-density lipoprotein (LDL) cholesterol to prevent 
CVD194,195, but have also been shown to have pleiotropic properties that are anti-inflammatory 
and immune modulatory196.  In monkeys fed a pro-atherogenic diet for 12 months, pravastatin 
and simvastatin decreased the number of macrophages present in developing atheromas, 
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independent of their effects to lower plasma LDL cholesterol197.  Here, monkeys were divided 
into groups and fed atherogenic diets to keep levels of plasma total cholesterol, HDL, and LDL 
similar.  Statin treatment reduced expression of IL-1β that can increase vascular cell adhesion 
molecule-1 (VCAM-1) on endothelial cells and result in increased adhesion of monocytes to the 
vessel wall.  Additional studies using apolipoprotein E*3 (apoE*3)-Leiden mice, which develop 
atherosclerotic plaques similar to humans, showed that rosuvastatin and atorvastatin treatment 
reduced the density of macrophages within atherosclerotic plaque regions and prevented their 
progression198,199.  In humans, rosuvastatin use in the Measuring Effects on Intima-Media 
Thickness (METEOR) trial resulted in a decreased rate of progression of carotid artery intima-
media thickening,200 and specifically among HIV+ individuals on ART with a moderate risk of 
CVD, rosuvastatin decreased cIMT thickness over a two year period191.  However, these studies 
did not examine if a reduction in cIMT was related to decreased macrophage inflammation the 
carotid artery.  A study using atorvastatin on HIV+ individuals with subclinical atherosclerosis 
showed that over a 12 month time period while non-calcified plaque volume was decreased 
arterial inflammation of the aorta was not201.   
 
B. Altering macrophage polarization 
Macrophages are divided into either M1 or M2 phenotypes based on the expression of 
surface molecules and, in CVD, based on their different functions in the development of cardiac 
fibrosis and atherosclerotic plaque development and rupture.  Because it has been suggested 
that M1 and M2 macrophage phenotypes may actually be the ends of a spectrum it might be 
possible to alter macrophage polarization to diminish tissue specific pathologies.  In one such 
attempt, fasudil, a rho-kinase inhibitor, inhibited M1 macrophages in EAE mice and increased 
expression of M2 macrophage markers while decreasing expression of pro-inflammatory 
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cytokines IL-1β, TNF-α, and MCP-1202.  Small interfering RNAs (siRNAs), in animals,  have been 
used to inhibit TNF-α expression by macrophages.  When delivered orally, siRNAs decreased 
expression of TNF-α and IL-1β when mice were challenged with lipopolysaccharide (LPS) and  
successfully decreased inflammation203.   
 
VIII. SIV-infected, CD8+ T-lymphocyte depletion model of AIDS in rhesus macaques 
Simian immunodeficiency virus infection (SIV) in rhesus macaques induces a disease that 
is similar to HIV in humans204.  SIV infected macaques follow a similar progression to HIV in 
humans including loss of CD4+ T-lymphocytes, opportunistic infections with progression to AIDS, 
and SIV encephalitis (SIVE)205-207.  SIV infection of rhesus macaques could be used to effectively 
study the effects of CVD associated with HIV infection91,208-210.  Intravenous (iv) infection with 
SIVmac251 in rhesus macaques results in the development of AIDS in 1 to 3 years, and a high 
incidence of macrophage mediated disease, including CNS and cardiovascular disease211.  
Administration of a chimeric humanized mouse anti-CD8 monoclonal antibody at days 6, 8, and 
12 post infection (dpi) successfully depleted CD8+ T-lymphocytes and NK cells212.  This leads to 
viremia by 12 dpi that does not subside and the development of AIDS in 3-4 months with 
increased incidences of macrophage mediated diseases when animals are persistently depleted 
of CD8+ T-lymphocytes211.   
We have previously used the CD8+ T-lymphocyte depletion model of AIDS to study SIVE 
213-218, and cardiovascular inflammation161.  SIV infection of nonhuman primates results in 
cardiovascular pathology similar to that seen with HIV infection161,208,219.  Studies showed that 
SIV infected nonhuman primates develop a spectrum of cardiovascular disease found in HIV 
infected individuals, ranging from myocarditis, fibrosis, atherosclerosis and acute MI220-222.    
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The pathophysiology and etiology of CVD associated with HIV is poorly understood and  
limitation of studying the cardiovascular effects of HIV is due to the high number of confounding 
factors in patients223.  In humans, cardiovascular disease could be due to HIV or the effects of 
cART224-226.  As most of the HIV infected individuals are treated it is difficult to distinguish 
cardiovascular disease being caused by the virus itself or the toxic side effects of cART that can 
result in changes in lipid levels or be directly toxic to the vasculature223.  Using a nonhuman 
primate model to study HIV is beneficial in that it allows the study of and relationships between 
HIV infection and increased immune activation and inflammation and CVD without any 
confounding factors.  Due to the shorter time course for the development of SIV-associated 
CVD, it can also be used as a model to test new therapies used in conjunction with cART to 
alleviate HIV-associated CVD. 
 
IX. Summary of studies in this thesis 
Monocytes/macrophages play important roles in both atherosclerosis and myocardial 
fibrosis.  We hypothesized that the increased CVD risk seen among HIV+ patients is due to 
chronic monocyte/macrophage activation and inflammation.  Studies in this thesis examined 
how monocytes/macrophages contribute to the development of cardiovascular disease with SIV 
and HIV.  We first asked if changes in monocyte activation predict development of cardiac 
disease, specifically cardiac fibrosis (Chapter 2).  We also asked if there is a link between SIVE 
and cardiac inflammation that could possibly be due to increased monocyte/macrophage traffic 
and accumulation (Chapter 2).   We next asked if increased macrophage inflammation in the 
heart of SIV-infected correlates with cardiac fibrosis (Chapter 3).  In parallel we examined 
cardiovascular inflammation in post-mortem human tissues of HIV-infected individuals on 
durable cART and whether soluble factors correlate with markers of cardiovascular disease 
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(Chapter 4).  The final two chapters of this thesis examined whether or not blocking traffic of 
monocytes/macrophages (Chapter 5) to the heart and monocyte/macrophage activation 
(Chapter 6) can alleviate cardiovascular disease. 
 We first began by examining if changes in circulating monocytes can predict the 
development of cardiac fibrosis in SIV-infected CD8+ T-lymphocyte depleted animals (Chapter 
2).  In these studies, we show that there are indeed early changes in the numbers of activated 
CD14+CD16+ monocytes in animals that develop cardiac disease compared to those that do not.  
As early as 8 days post infection (dpi) the numbers of circulating CD14+CD16+ monocytes are 
significantly increased, and remain elevated through infection.  The numbers of CD14+CD16+ 
monocytes at 8 dpi and terminally correlated with cardiac fibrosis, suggesting that monocytes 
can predict cardiac fibrosis development.  In the studies in this chapter we also show an 
increased prevalence of CNS disease in animals with cardiac disease compared to those without.  
Animals with SIV encephalitis (SIVE) have increased cardiac fibrosis compared to animals 
without encephalitis and increased inflammation in the heart (myocarditis).  These data suggest 
a link between cardiac and CNS disease, possibly caused by increased inflammation associated 
with SIV and HIV infection. 
 In chapter 3 of this thesis we examined the role of macrophage inflammation and traffic 
to the heart.  In these studies we found that SIV-infected, CD8+ T-lymphocyte depleted animals 
had a higher prevalence of cardiac disease and inflammation compared to non-depleted 
animals.  This further suggests that the immune system plays a role in the development of 
cardiac disease.  In these experiments plasma viral load for all CD8+ T-lymphocyte depleted 
animals peaked at 8 dpi and remained elevated throughout infection, regardless of whether the 
animal developed cardiac disease or not.  Additionally, we did not find evidence of either SIV 
RNA or protein in inflammatory cells in cardiac tissues, which had previously been reported to 
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occur infrequently in other studies.209,210,219  In this study we still found significant inflammation 
in the heart which correlated with increased cardiac fibrosis.  As we do not find virally infected 
cells in the heart but still saw significant inflammation we can conclude that damage to the 
heart is not due solely to toxic effects of viral proteins and that macrophages themselves are 
mediating damage, possibly due to secreting pro-fibrotic cytokines.  We found that increased 
inflammation in cardiac tissues correlated with increased cardiac fibrosis.  Using BrdU we found 
that there is increased traffic to the heart of macrophages later (>21 dpi) during infection with 
the development of AIDS.   
 In parallel to the studies in chapter 3, we examined age and sex-matched samples from 
HIV+ and HIV- individuals (Chapter 4).  Here we found that inflammation in the heart and 
inflammation in the aorta are correlated.  We found that with HIV infection there was an 
increase in cardiac fibrosis which correlated with increased inflammation in the heart and 
increased aortic intima-media thickness (aIMT) correlated with increased inflammation as well.  
We also found that increased blood levels of soluble CD163 (sCD163) seen with HIV infection 
correlated with increased cardiac fibrosis and aIMT. 
 In the previous chapters of this thesis we show evidence that monocytes/macrophages 
play a role in the development of cardiovascular associated with HIV.  In chapters 5 and 6 of this 
thesis we next examined the effects on the heart and vasculature when we block 
monocytes/macrophages.  In chapter 5, we blocked leukocyte traffic to the heart using an anti-
α4 antibody, natalizumab.  We found that when natalizumab was administered at the time of 
SIV infection, there were no differences in numbers of macrophages in the heart or degree of 
fibrosis in treated animals compared to untreated.  We showed in chapter 3 that the majority of 
macrophage traffic to the heart occurs later (>21 dpi) during infection and that numbers of 
macrophages correlate with fibrosis.  Blocking traffic to the heart early showed no significant 
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differences compared to SIV+ infected animals that were sacrificed at 21 dpi because there is 
little cardiac inflammation at this time point.  When animals began treatment with the 
natatlizumab late, at 21 dpi, we found that there was a significant decrease in macrophage 
inflammation compared to uninfected animals which correlated with a decrease in cardiac 
fibrosis.   
 In chapter 6 we targeted macrophages specifically using a polyamine biosynthesis 
inhibitor, methylglyoxal-bis-guanylhydrazone (MGBG).  SIV-infected, CD8+ T-lymphocyte 
depleted macaques were treated daily with either an oral placebo or MGBG beginning at 21 dpi, 
when cardiac inflammation occurs, as shown in chapter 3.  Sections of the aorta from treated 
and control animals were all normal, possibly due to the acute infection model used in this 
study.  In the carotid artery and the heart we found that MGBG significantly decreased 
macrophage inflammation compared to paired placebo control animals.  We noted that MGBG 
also decreased cardiac fibrosis and carotid artery intima-media thickness (cIMT), both markers 
of cardiovascular disease.  Used in conjunction with cART, these experiments show that 
therapeutics targeting macrophages directly could be beneficial in treating HIV-associated CVD. 
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ABSTRACT 
 HIV infection with cART is associated with subclinical myocardial disease and increased 
prevalence of HIV-associated neurological disorders (HAND).  Increased frequency of activated 
CD14+CD16+ monocytes in circulation are associated with cardiovascular disease, HAND, and SIV 
encephalitis (SIVE).  Cross sectional studies implicated monocytes/macrophages with 
cardiovascular disease, but longitudinal studies have not been done.  We conducted a 
longitudinal study of 14 SIV-infected, CD8+ T-lymphocyte depleted rhesus macaques with AIDS 
and assessed circulating monocyte subsets as possible correlations of cardiac disease and SIVE.  
Cardiac tissues were examined for inflammation, fibrosis, and cardiomyocyte degeneration and 
CNS tissues were assessed for the presence of SIVE.  Five of 14 (36%) animals had no significant 
findings in the heart while 9 of 14 (64%) had increased inflammation, fibrosis, and 
cardiomyocyte degeneration.   Six of 9 (66%) animals with cardiac disease had SIVE compared to 
1 of 5 (20%) animals with no significant findings in the heart.  In animals with SIVE there was a 
significant 2.46-fold increase in numbers of circulating CD14+CD16+ monocytes as early as 8 dpi.  
There was a significant increase in cardiac macrophage inflammation in SIVE animals compared 
to those without encephalitis (SIV no E).  There was a significant 2.26-fold increase in the 
percentage of collagen and a significant 2.28-fold increase in the absolute numbers of activated 
CD14+CD16+ monocytes in animals with cardiac disease as early as 8 dpi.  There were positive 
correlations between numbers of CD14+CD16+ monocytes and cardiac fibrosis seen as early as 8 
dpi and continued throughout infection.  These data show that numbers of activated circulating 
monocytes could predict cardiac fibrosis, cardiac inflammation, and SIVE.  Cardiac inflammation 
and fibrosis and SIVE could potentially be linked by increased monocyte/macrophage traffic and 
accumulation. 
 
 
 57 
INTRODUCTION 
 Monocytes are mononuclear phagocytes that comprise 5-10% of leukocytes in 
circulation in humans.1  They are a heterogeneous population and classified based on their 
expression of surface antigens, size, morphology, and function.1-5  Monocytes are identified by 
their expression of CD14, the lipopolysaccharide co-receptor, and expression of CD16, a low 
affinity Fcγ-III receptor that acts as a marker of activated monocytes,2, 6-8  Three populations of 
circulating monocytes are recognized in humans and rhesus macaques based on CD14 and CD16 
expression: CD14+CD16- classical monocytes, CD14+CD16+ intermediate monocytes, and 
CD14+CD16++ nonclassical monocytes.3, 4  Under normal physiological conditions, classical 
CD14++CD16- monocytes are the predominant phenotype and activated monocytes expressing 
CD16 comprise are a minor population.2-4, 8  Increased CD16 expression in monocytes occurs 
with inflammation and infection, 7, 9, 10 leading to their status as “pro-inflammatory”.  With HIV 
and SIV infection, there is increased monocyte egress from the bone marrow9,  an increased 
turnover rate11, and activation.2, 12-14  Expansion of the circulating CD14+CD16+  monocyte 
population is a marker of HIV and SIV disease progression to AIDS.9, 15, 16   
Monocytes/macrophages are implicated in the development of cardiac fibrosis and 
myocarditis with and without HIV infection.17-21  In response to injury or infection monocytes 
traffic to the myocardium and develop into tissue macrophages which secrete pro-inflammatory 
and pro-fibrotic factors22-27 that are increased with HIV infection.28-30 Increased macrophage 
inflammation and pro-inflammatory cytokine production in the heart play roles in the 
approximate two-fold increase in relative risk of atherosclerosis, stroke, and myocarditis among 
HIV+ individuals on combination anti-retroviral (cART) era.31-37  Although the prevalence of  
myocardial disease in HIV infected patients decreased with cART,38, 39 a significant burden  of 
myocardial inflammation and fibrosis still exists in this population.40-43  Magnetic resonance 
spectroscopy (MRS) studies found increased  subclinical myocardial disease, fibrosis, and a 
 58 
decline in cardiac function in HIV infected individuals compared to uninfected individuals.40, 44  
We examined post-mortem tissue of HIV infected individuals and demonstrated significant 
macrophage inflammation in cardiac tissues which correlated with inflammation in the aorta 
and increased levels of plasma sCD163 (Unpublished data).   
In addition to a greater risk of CVD with HIV infection, there is an increased prevalence 
HIV-associated neurological disorders (HAND),45 for which chronic monocyte/macrophage 
activation and inflammation plays a role.  HAND with HIV results in increased accumulation of 
intracranial and/or spinal cord CD14+ CD16+ CD163+perivascular macrophages, and increased 
soluble CD14 (sCD14) and soluble CD163 (sCD163) in plasma.16, 46-49  Soluble CD163, a marker of 
monocye/macrophage activation, is increased in chronically HIV-infected individuals with 
neurocognitive impairment, despite being on cART.50  Additionally, sCD14 and sCD163 are 
associated with noncalcified plaques in HIV+ individuals on cART.51  Increased plasma sCD163 is 
associated with aortic inflammation with HIV.52   Studies reported that increased CVD risk 
factors, high density lipoprotein (HDL), smoking and Framingham Risk Score (FRS), are 
associated with neuroinflammation in HIV+ individuals.45, 53  Carotid artery intima-media 
thickness, a measurement of CVD54-56 is increased with HIV infection34, 57 and associated with a 
decline in neurocognition.58  It is possible that there is a link between cardiovascular disease and 
neurocognitive decline in the setting of HIV where chronic monocyte/macrophage activation 
plays a role.  
We reported in a model of rapid AIDS in rhesus macaques that increased numbers of 
CD163+ ,CD68+ and newly infiltrating macrophages expressing MAC387, cardiac macrophages 
correlated with increased cardiac fibrosis.59  In the current study we used 14 SIV-infected rhesus 
macaques and examined blood monocyte/macrophage activation longitudinally to determine if 
they are predictive of cardiac fibrosis,  cardiac inflammation, cardiomyocyte degeneration and 
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SIV encephalitis (SIVE).  Sections of the left ventricle were examined blindly by histology and 
scored for the degree of cardiac fibrosis, inflammation, and cardiomyocyte degeneration.  
Animals with cardiac disease (based on the presence of fibrosis, inflammation, and 
cardiomyocyte degeneration at necropsy) had significantly elevated numbers of circulating 
activated CD14+CD16+ monocytes as early as 8 days post infection (dpi), which remained 
consistently elevated throughout the course of infection and correlated with cardiac fibrosis.  
Additionally C-C chemokine receptor 2 (CCR2) mean fluorescence intensity (MFI) was also 
increased in animals with cardiac disease compared to those without.  Early increases in 
CD14+CD16+ monocytes also separated animals with SIVE compared to animals without 
encephalitis (SIV no E).   There was a higher incidence SIVE in animals with cardiac fibrosis and 
inflammation (66%) compared to animals with no significant findings in the heart (20%), 
suggesting that development of cardiac and encephalitis are linked by monocyte/macrophage 
activation and accumulation.    
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RESULTS 
Assessment of cardiac and CNS pathology 
All 14 animals used in this study were sacrificed with AIDS.  Nine of 14 (64%) animals 
had cardiac inflammation and fibrosis.  Four of these 9 (44%) animals had cardiomyocyte 
degeneration.  Five of 14 (36%) animals had no significant findings with regards to inflammation, 
fibrosis, and cardiomyocyte degeneration (Table 2.1).  Of the 9 animals with cardiac 
inflammation, fibrosis, and cardiomyocyte degeneration, 6 also had SIVE (66%).  Four had mild 
SIVE and 2 had severe SIVE.  Only 1 of the 5 animals with no cardiac findings had SIVE (20%), 
which was mild (Table 2.1).   
 
There is increased macrophage inflammation and fibrosis in animals with cardiac and CNS 
disease 
Cardiac disease     
By immunohistochemistry there was a significant 1.62-fold increase in CD163+ 
macrophages, a 1.97-fold increase in CD68+ macrophages, a 1.57-fold increase in 
MAC387+monocytes/macrophages, and a 2.72-fold increase in CD206+ macrophages in cardiac 
tissues of animals with cardiac pathology.  There were no differences in the numbers of CD3+ T-
lymphocytes in cardiac tissues between those monkeys with and without cardiac disease (Table 
2.2).  We did not find SIV-p28+ or SIV-RNA+ cells in cardiac tissues consistent with our previous 
findings59, 64 and others that show a low level of cardiac infection.67-69  We found a 2.26-fold 
increase in cardiac fibrosis, measured as the percentage collagen per tissue area, in animals with 
cardiac pathology (Fig. 2.1A, left) compared to animals with no significant findings (NSF) (Fig. 
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2.1A, right).  Animals with cardiac pathology had an average percent collage per total tissue area 
of 18.99±1.56% (n=9) compared to 8.38±0.52% (n=5) in (Fig. 2.1B). 
CNS disease 
Animals were grouped based on whether or not they developed SIV encephalitis (SIVE).  
Previously we reported that the animals in this study with SIVE had increased numbers of 
CD163+ macrophages and MAC387+ monocytes/macrophages in the CNS meninges, perivascular 
space, and SIVE lesions compared to SIV no E animals.  It is possible that cardiac and CNS disease 
are linked by increased monocyte/macrophage inflammation in both tissue compartments.  We 
found that animals with SIVE (n=7) had significant macrophage inflammation in the heart 
compared to SIV no E animals (n=7).  There was a significant 1.53-fold increase in CD163+ 
macrophages, a 1.49-fold increase in MAC387+monocytes/macrophages, and a 1.96-fold 
increase in CD206+ macrophages in cardiac tissues in animals that developed SIVE compared to 
animals without CNS disease (Table 2.3).  There was a significant 1.54-fold increase in the level 
of cardiac fibrosis in SIVE animals compared to SIV no E animals. 
 
SIV+ animals with cardiac disease and encephalitis have significant early increases in activated 
CD14+CD16+ monocytes that persist throughout infection  
The absolute numbers of activated CD14+CD16+ monocytes increased for animals with 
and without cardiac fibrosis after 0 dpi.  There was a significant 2.28-fold increase in the number 
of blood CD14+CD16+ monocytes in animals with cardiac fibrosis compared to those with no 
cardiac findings.  While the numbers of  CD14+CD16+ monocyte subsets fluctuates over the 
course of disease significant differences between animals with and without cardiac fibrosis were 
found at 8, 19, 26, 35, 42, 54, and 61 dpi (Fig 2.3A).  There were no differences in the absolute 
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numbers of classical CD14+CD16- monocytes between these groups.  The percentage of classical 
CD14+CD16- monocytes decreased after infection but was not statistically different between the 
groups (Fig. 2.3B).  There was a significant 2.46-fold increase in the number of CD14+CD16+ 
monocytes in animals with SIVE (n=7) compared to SIV no E (n=7) animals that was detected as 
early as 8dpi (Fig. 2.3C).  The numbers of CD14+CD16- monocytes did not significantly differ with 
infection between the two groups (Fig. 2.3D).   Plasma viral load for all animals peaked at 8 dpi 
and remained elevated.  Plasma viral load did not distinguish between animals with and without 
cardiac disease or with and without SIVE (Fig. 2.4). 
     
There are positive correlations between increased number of CD14+CD16+ monocytes early and 
late and increased cardiac fibrosis in animals with cardiac pathology 
 By 8 dpi there are significant differences in the percentage of CD14+CD16+ monocytes 
between animals with and without cardiac pathology as well as significant differences in the 
percentage of collagen per total tissue area (fibrosis).  Examining the percentage of CD14+CD16+ 
monocytes at 8 dpi, we found positive correlations between increased CD14+CD16+ monocytes 
and increased cardiac fibrosis (r=.65, p<0.05) (Fig. 2.3C).  A positive correlation between 
numbers of CD14+CD16+ monocytes at necropsy and fibrosis was found (r=.60, p<0.05) (Fig. 
2.3D). 
 
SIV+ animals with increased cardiac fibrosis have increased expression of CCR2 on CD14+CD16+ 
 Chemokine receptor 2 (CCR2) is unregulated on activated monocytes.  Expression of 
CCR2 mean fluorescence intensity (MFI) on CD14+CD16+ monocytes was analyzed by flow 
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cytometry and compared between animals housed at NERPC or TNRPC.  In both cohorts (Fig. 
2.5A, B), there was an increase in CD14+CD16+ CCR2 MFI mean fluorescence during late 
infection.  For cohort 1 at NERPC (Fig. 2.5A), CCR2 expression was increased at 35, 42, 47, and 54 
dpi for animals with cardiac fibrosis compared to those with no significant findings.  For cohort 2 
at TNRPC (Fig. 2.5B), CCR2 expression was increased at 54, 61, 82, and 89 dpi.   
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DISCUSSION 
 In this study we found early expansion of activated CD14+CD16+ monocytes correlated 
with the development of SIV-associated cardiac and CNS disease.  Increases in activated 
CD14+CD16+ monocytes correlated with increased cardiac fibrosis, inflammation, cardiomyocyte 
degeneration, and the presence of SIVE. 
Results from this study demonstrate a correlation between cardiac disease, encephalitis, 
and activated monocytes.  Of the 9 animals with cardiac disease (increased cardiac fibrosis and 
inflammation) 6 also developed SIVE.  In contrast only 1 of 5 animals that had no significant 
cardiac findings developed SIVE, which was found to be mild.  Additionally, when animals are 
grouped based on SIVE or SIVE no E we found that animals with SIVE had significantly more 
macrophage inflammation in the heart compared to SIV no E animals.  SIVE animals also had 
significant early increases in numbers of CD14+CD16+ monocytes in blood and significantly more 
cardiac fibrosis in the heart.  This suggests that the development of CNS and cardiac disease are 
possibly linked and caused by increased monocyte/macrophage accumulation with HIV and SIV 
infection.     
HIV has been associated with a spectrum of cardiac disease comprising but not limited 
to dilated cardiomyopathy, myocarditis, and pericardial effusion.70  Comparing the incidences of 
the pre- and post-cART era, the rates of cardiac disease has declined.38, 39, 71  However, recent 
studies have shown that even in the cART era incidences of subclinical myocardial disease in 
patients with HIV remains.43, 44, 72, 73   
 In a CD8+ T-lymphocyte depletion model of rapid AIDS, plasma SIV viral load of all 
animals peaked early during infection (8 days post infection), and remained consistently high 
due to the lack of CD8+ T-lymphocyte immune control,74-76 thus there was no difference in 
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plasma viral load between animals with myocardial fibrosis and animals that had no significant 
findings in the heart.  Although plasma viral load has been shown to correlate with functional 
cardiac decline67, few studies have found infection of cardiac macrophages.67, 68  The few SIV-
infected and HIV-infected cells in the heart are consistently demonstrated as CD163+ 
macrophages.67-69   
In the CNS, virus enters the brain as early as 3 to 7 days after infection in both humans 
and nonhuman primates.61, 77  Levels of viral RNA in the CNS decrease during acute infection 
while the levels of viral DNA remain unchanged.77, 78  During the later stages of infection it is 
believed that viral replication is reactivated, which coincides with macrophage activation and 
recruitment of perivascular macrophages to the CNS.78  Additionally, our lab has shown that in 
SIV-infected rhesus macaques that MAC387+ macrophages (a marker of active inflammation) 
are recruited to the CNS after 21 dpi, possibly when viral replication is reactivated and 
encephalitis begins to develop.79  These data suggest that the presence of actively replicating 
viral RNA is necessary for the development of HIV and SIV encephalitis.  In the heart itself we did 
not find SIV protein or RNA, but significant inflammation was present.  This suggests that 
monocyte/macrophage accumulation more so than viral replication is important for the 
development of cardiac pathology with AIDS.  However, we do acknowledge that the level of 
viral infection in the heart may be below the detection limit of immunohistochemistry or in situ 
hybridization. 
Previous cross sectional studies have demonstrated the ability of monocytes to indicate  
a previous history of cardiovascular80-84 and CNS disease.2, 11, 15  In this study we show that 
activated monocytes longitudinally correlated with increased fibrosis and inflammation in 
cardiac tissues.  Significant early changes in the absolute number of activated CD14+CD16+ 
monocytes were found in animals with increased cardiac fibrosis, inflammation, and 
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cardiomyocyte degeneration compared to animals that had no significant findings in the heart.  
While the total number of activated CD14+CD16+ monocytes fluctuated throughout infection, 
they remained significantly elevated in animals with cardiac and CNS disease.  Additionally we 
found positive correlations between the number of CD14+CD16+ monocytes early and late and 
levels of cardiac fibrosis suggesting that monocyte/macrophage activation is predictive of 
myocardial disease.  
In this study we found that expression of chemokine receptor-2 (CCR2) on CD14+CD16+ 
monocytes was increased later in infection in animals with increased cardiac fibrosis.  CCR2 
signaling is necessary for cells to leave the bone marrow and be recruited to sites of active 
inflammation.85, 86  CCR2 is highly expressed on a subset of monocytes/macrophages and when it 
is reduced there is a delay in the development of atherosclerosis and myocarditis in rodent 
models.87, 88  In patients with myocarditis the number of blood monocytes/macrophages positive 
for CCR2 are also increased.87  CCR2 expression is also increased on CD14+CD16+ monocytes 
from patients with HAND, suggesting that it is a marker for HAND.89  Increased CCR2 expression 
on monocytes from a subset of animals in this study may account for increased traffic to the 
heart and the CNS.  Previously, using BrdU, we showed that there is an increase in 
monocyte/macrophage traffic to the heart later during SIV infection (>21 dpi), possibly with the 
development of AIDS.59  Data of CCR2 expression from this study appears to support this idea of 
monocytes/macrophages trafficking to the heart later during infection and possibly resulting in 
increased fibrosis as we do not see early differences in CCR2 expression between the two 
groups of animals.      
In our study we examined if changes in monocytes correlate with increased cardiac 
fibrosis during SIV infection.  We found an increased incidence of encephalitis in animals that 
developed cardiac disease.  In animals with SIVE, characterized by accumulation of perivascular 
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macrophages and multinucleate giant cells (MNGCs), we found increased macrophage 
inflammation in the heart suggesting a possible link between the development of encephalitis 
and cardiac disease with HIV and SIV infection mediated by monocyte/macrophage 
accumulation.  We found that in SIV-infected animals with increased cardiac fibrosis and SIVE 
there indeed were significant early changes in the numbers of  CD14+CD16+ monocytes that 
persisted throughout the course of infection.  Increased numbers of CD14+CD16+ monocytes 
correlated with increased cardiac fibrosis.  There was also an increase in CCR2 MFI in animals 
with cardiac disease used in this study.  CCR2 MFI on activated CD14+CD16+ could be used as 
biomarker to predict cardiac inflammation similar to how it has been used to predict monocyte 
traffic to the CNS.89   While this would have to be examined in HIV-infected individuals, it is 
possible that  absolute numbers CD14+CD16+ monocytes and CCR2 expression could be used as a 
non-invasive method to determine the presence of cardiac fibrosis and inflammation with HIV 
infection.    
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MATERIALS AND METHODS 
Ethical treatment of animals 
Animals were housed at Harvard University’s New England  Primate Research Center 
(NEPRC) or Tulane University’s National Primate Center (TNPRC) and handled in strict 
accordance with Harvard University’s and Tulane University’s National Primate Research Center 
Institutional Animal Care and Use Committee (IACUC). Animal IACUC approval from NEPRC and 
TNPRC was granted for all procedures.  The NERPC protocol number for this study was 04420 
and the animal welfare assurance number was A3431-01.  The TNRPC the protocol number is 
3497 and the animal welfare assurance number is A4499-01. 
 
Animals, SIV infection, and CD8+ T-lymphocyte depletion 
Fourteen rhesus macaques were utilized in this study. Five were housed at Harvard 
University’s New England Primate Research Center (NEPRC) and nine were housed at Tulane 
University’s National Primate Research Center (TNPRC) in accordance with standards of the 
American Association for Accreditation of Laboratory Animal Care. The animals were 
intravenously (i.v.) inoculated with SIVmac251 (20ng of SIV p28) provided by Ronald Desrosiers. 
Blood samples were taken prior to, on the day of infection, and weekly thereafter. CD8+ T 
lymphocyte depletion was achieved with subcutaneous administration of human anti-CD8 
antibody cM-T807 (10mg/kg) at day 6 post-infection, and i.v. administration (5mg/kg) on days 8 
and 12 post-infection.  Animals were anesthetized with ketamine-HCl and euthanized with AIDS 
with intravenous pentobarbital overdose and exsanguinated.  
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Plasma viral load and viral infection in the heart 
 Plasma SIV-RNA was quantified using real-time PCR for all animals used in this study, as 
previously described.60  500μL of EDTA plasma was collected and SIV virons were pelleted by 
centrifugation at 20,000 g for 1 hour.  The threshold sensitivity was 100 copy Eq/mL, with an 
average interassay coefficient variation of less than 25%.  The presence of SIV infected cells in 
the heart was evaluated by immunohistochemistry with an SIV-p28 antibody (SIVmac251, 
Fitzgerald Industries) and in situ hybridization with dixogenin-labeled riboprobes to detect SIV-
RNA  as previously described.59 
 
Assessment of inflammation and fibrosis in cardiac tissues and SIV Encephalitis in CNS 
Following exsanguination, standard necropsy was performed and lymph nodes and 
critical organs including heart and brain, were fixed in 10% neutral buffered formalin. Following 
fixation, tissues were paraffin embedded, sectioned at 5µm, and stained with hematoxylin and 
eosin.  Sections of cardiac tissue (left ventricle) were analyzed blindly by a veterinary 
pathologist.  Cardiac tissues were scored based upon 10 randomly chosen 400x fields.  The 
degree of inflammation, fibrosis, and cardiomyocyte degeneration in each tissue section was 
assessed graded as having: A) no significant findings (NSF); B) mild; C) moderate; D) or severe.  
SIV encephalitis (SIVE) was diagnosed based on the presence of multinucleated giant cells 
(MNGCs), accumulation of perivascular macrophages, and productive SIV infection.11, 61-63 
 
Single label immunohistochemistry of cardiac tissues 
 Numbers of macrophages and T-lymphocytes in formalin-fixed, paraffin-embedded 
cardiac tissues for all animals were determined through immunohistochemistry and cell 
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counting, as previously described64.  Macrophages were identified using monoclonal antibodies 
against CD163 (clone EdHu-1, Serotec), CD68 (clone KP1, Dako), Myeloid/Histiocyte Antigen 
(clone MAC387, Dako), and CD206 (clone 685645, R&D systems) and T-lymphocytes were 
identified using a polyclonal antibody against CD3 (Dako).  Data are presented as the mean 
positive number of cells/mm2  from 20 non-overlapping fields of view plus or minus the 
standard error of the mean (SEM). 
 
Measurement of myocardial fibrosis 
 Myocardial fibrosis was determined as the percent collagen per tissue area of cardiac 
tissue.65, 66  Sections were analyzed using a modified Massons Trichrome stain as previously 
described.64  Sections were imaged using a Zeiss Axio Imager M1 microscope using Plan-
Apochromat x20/0.8 Korr objectives.  The percent collagen (blue dye) per total tissue area was 
determined using ImageJ Analysis software from 20 non-overlapping 200x microscopic fields 
(field area=0.148mm2).  Data are presented as the percent collagen per total tissue area plus or 
minus the SEM. 
 
Flow cytometry 
Flow cytometric analysis was conducted on 100ul aliquots of peripheral whole blood 
collected in EDTA-coated tubes from all animals.  Blood samples were taken at -7, 0, 5, 8, 12, 
weekly thereafter, until necropsy.  Samples from animals housed at the NERPC were shipped 
and analyzed the same day and samples from animals at the TNPRC were shipped overnight.  
Erythrocyte lysis was performed (ImmunoPrep Reagent System, Beckman Coulter), followed by 
2 washes with PBS, and incubation with fluorochrome-conjugated antibodies including anti-
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CCR2-APC (clone: 48607, R&D Systems), anti-CD14-APC (clone: M5E2, BD Pharmingen), anti-
CD16-PE (clone: 3G8, BD Pharmingen) anti-HLA-DR-PerCP-Cy5.5 (clone: L243, BD Pharmingen).   
All samples were fixed in 2% paraformaldehyde and results acquired on a BD FACS Aria (BD 
Biosciences) and analyzed with Tree Star Flow Jo version 8.7.  Monocytes are first selected 
based on size and granularity (FSC vs SSC), followed by selection of HLA-DR+ CD14+ cells.  From 
this gate the percentage of monocyte subsets expressing CD14 and/or CD16 could be 
determined.   
 
Absolute Monocyte counts from whole blood 
 The absolute number of peripheral blood monocytes for each animal was calculated by 
multiplying the total white blood cell count by the total percentage of each monocyte subset as 
determined by flow cytometric analysis.   
 
Statistical analysis 
 Statistical analyses were done using Prism version 5.0a (Graphpad Software, Inc., San 
Diego, CA) software.  Comparisons between groups at each time point were made using a non-
parametric Mann-Whitney t-test with significant accepted at p<0.05.  A Spearman rank test was 
used for all correlations. 
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Table 2.1.  Cardiac and CNS pathology of animals used in this study. 
          
Animal 
ID 
 Cardiac 
Inflammation 
 Cardiac 
Fibrosis 
Cardiomyocyte 
Degeneration 
 Fibrosis 
(Percent collagen per 
total tissue area) 
 CNS Pathology 
185-05  NSF  NSF NSF  10.01%  SIV no E 
          
168-05  NSF  NSF NSF  8.8%  SIV no E 
          
288-07  NSF  NSF NSF  8.6%  SIV no E 
          
FD80  NSF  NSF NSF  7.4%  SIVE (Mild) 
          
FT73  NSF  NSF NSF  7.1%  SIV no E 
FD05  Severe  Severe Moderate  28.72%  SIVE (Mild) 
          
55-05  Moderate  Severe Mild  21.90%  SIVE (Mild) 
          
DB79  Mild  Mild NSF  20.5%  SIVE (Severe) 
          
FB92  Mild  Severe NSF  19.98%  SIV no E 
          
CM07  Mild  Moderate NSF  18.93%  SIVE (Mild) 
          
FR56  Mild  Mild Mild  17.54%  SIVE (Mild) 
          
FC42  Mild  Mild Moderate  15.7%  SIV no E 
          
244-96  Moderate  Mild NSF  14.32%  SIVE (Severe) 
          
FD37  Mild  Mild NSF  13.4%  SIV no E 
 
Fourteen SIV-infected, CD8+ T-lymphocyte depleted rhesus macaques were used in this study, all 
of which were sacrificed with AIDS.  Sections of left ventricular tissue (cardiac tissue) were 
examined by a veterinary pathologist to determine the presence and severity of cardiac 
inflammation and cardiomyocyte degeneration.  Each criteria was scored as having no 
significant findings (NSF) or mild, moderate, or severe.  Five animals were found to have no 
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significant cardiac findings.  Nine animals were found to have cardiac pathology.  Fibrosis was 
determined as the percentage of collagen per total tissue area after sections of cardiac tissue 
were stained with a Massons Trichrome stain.   SIV encephalitis (SIVE) was diagnosed post 
mortem and based on the presence of SIV virus in the CNS and multi-nucleated giant cells.  Of 
the 5 animals with no significant cardiac findings only 1 animal had SIVE (20%)  compared to 6 of 
9 (66%) animals with cardiac pathology having SIVE. 
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Table 2.2.  Numbers of macrophages and T-lymphocytes present in cardiac tissues 
  With Cardiac 
Pathology 
(n=9) 
 NSF 
 
(n=5) 
 p-value 
       
CD163  269.81±26.72  166.2±18.48  * 
       
CD68  109.30±8.66  55.7±10.24  ** 
       
MAC387  22.62±2.51  14.35±1.40  * 
       
CD206  154.27±14.56  84.56±25.33  * 
       
CD3  19.44±4.69  15.08±5.41  NS 
Sections of cardiac tissue from all animals were immunohistochemically stained with antibodies 
recognizing CD163+, CD68+, MAC387+, CD206+ macrophages and CD3+ T-lymphocytes.  Twenty 
random, non-overlapping 200x fields of view were sampled for each animal and the average 
number of cells/mm2 were calculated and expressed as plus or minus the standard error of the 
mean.  P-values were calculated using a non-parametric Mann-Whitney t-test with significant 
accepted at p<0.05 (*p<0.05, **p<0.01). NSF, no significant findings. 
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Table 2.3  Numbers of  cardiac macrophages and T-lymphocytes present in animals 
with and without SIV encephalitis 
  SIVE 
(n=7) 
 SIV no E 
(n=7) 
 p-value 
       
CD163  181.18±22.13  281.42±30.51  * 
       
CD68  73.3±13.85  107.83±10.59  NS 
       
MAC387  14.92±1.21  22.26±2.99  * 
       
CD206  87.41±9.03  171.35±9.03  ** 
       
CD3  20.03±3.11  17.17±3.11  NS 
Animals were grouped based on if they developed SIV encephalitis (SIVE, n=7) or did not 
develop encephalitis (SIV no E, n=7).  Sections of cardiac tissue from all animals were 
immunohistochemically stained with antibodies recognizing CD163+, CD68+, MAC387+, CD206+ 
macrophages and CD3+ T-lymphocytes.  Twenty random, non-overlapping 200x fields of view 
were sampled for each animal and the average number of cells/mm2 were calculated and 
expressed as plus or minus the standard error of the mean.  P-values were calculated using a 
non-parametric Mann-Whitney t-test with significant accepted at p<0.05 (*p<0.05, **p<0.01). 
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Figure 2.1.  There is a significant increase in myocardial fibrosis in SIV-infected, CD8+ T-
lymphocyte depleted rhesus macaques with cardiac pathology 
(A).  Sections of cardiac tissue were stained with a Massons trichrome stain to visualize 
cardiomyocyte cytoplasm (red) and collagen (blue) from SIV-infected CD8+ T-lymphocyte 
depleted rhesus macaques that had no significant findings (NSF) in the heart (left n=5) or had 
cardiac pathology based on scorings from a veterinary pathologist (right n=9) (400x 
magnification).  Fibrosis, determined as the percentage of collagen per total tissue area was 
quantified for each animal.  (B) For animals with no significant findings in the heart, the average 
percentage of collagen per total tissue area was 8.38±0.52% (n=5) compared to 18.99±1.56% 
(n=9), a significant 2.26-fold increase (non-parametric Mann-Whitney t-test, ** p<0.01).  The 
percentage of collagen per total tissue area was averaged from 20 non-overlapping 200x fields 
of view and expressed as the average plus or minus the standard error of the mean.  
 
 
 
 
 
 
 
 
 
 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 79 
 
 
 
Figure 2.2.  Gating strategy to identify monocyte subsets in blood plasma 
Following infection, blood was drawn weekly until necropsy.  Using Flow Jo version 8.7, 
monocytes were selected based on forward and side scatter.  Cells positive for CD14 and HLA-
DR expression were selected, followed by analysis of monocyte subsets based on CD14 and 
CD16 expression. A) non-classical CD14+CD16+, B) intermediate CD14++CD16+ monocytes, C) 
classical monocytes CD14+CD16-. 
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Figure 2.3.  Elevated CD14+CD16+ monocyte expression early correlates with myocardial 
fibrosis in SIV-infected, CD8+ T-lymphocyte depleted rhesus macaques with cardiac pathology 
and SIVE 
Animals were grouped based the presence of absence of cardiac pathology (NSF=square, 
Cardiac pathology=circle).  (A) By 8 dpi CD14+CD16+ monocyte subset were significantly 
differences between animals with cardiac pathology and those without.  The absolute number 
of CD14+CD16+ monocytes in animals with no significant findings in the heart was 32.68±5.89 
cells/μL of blood, compared to 74.70±15.02 for animals with cardiac pathology, a significant 
2.28-fold increase (*, p<0.05).  There were significant differences in the numbers of CD14+CD16+ 
monocytes at day 8, 19, 26, 35, 42, 54, 61 post infection (non-parametric Mann-Whitney t-test, 
* p<0.05).  (B) While the absolute number of CD14+CD16- monocyte subsets decreased over the 
course of SIV infection, there were no significant differences between the groups.  Animals were 
also grouped and analyzed based on if the developed SIV encephalitis (SIVE) or did not develop 
CNS disease (SIV no E).  (C)  There were significant increases in the numbers of CD14+CD16+ 
monocytes at days 5, 8, 26, 35, and 42 post infection in animals that developed SIVE compared 
to SIV no E animals (non-parametric Mann-Whitney t-test, *p<0.05).  (D)  There were no 
significant differences in numbers of CD14+CD16- monocytes during infection between animals 
that did and did not develop SIVE.  Spearman rank correlation was used to examine correlations 
between the percentage of CD14+CD16+ monocytes and myocardial fibrosis (E, F) There were 
positive correlations between the number of CD14+CD16+ monocytes at early (r= .65, p<0.05) 
and terminally and cardiac fibrosis (r=.60, p<0.05).   
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Figure 2.4.  Plasma SIV-RNA does not distinguish between animals with and without cardiac 
disease or with and without SIV encephalitis. 
Plasma SIV-RNA was quantified using real time PCR for all animals used in this study.  Animals 
were first grouped based on if they were found to have developed cardiac disease at necropsy 
(A) and then grouped based on whether or not they developed SIV encephalitis (SIVE) (B).  
Plasma SIV-RNA did not distinguish between animals that developed cardiac disease (n=9, open 
square) and those that had no significant findings in the heart (n=5, closed triangle).  Plasma SIV-
RNA did not distinguish between animals that developed SIVE (n=7, open circle) and animals 
that did not develop SIVE (SIV no E) (n=7, closed diamond).  By 8 days post infection levels of 
SIV-RNA peaked and remained consistently elevated during infection for all animals. 
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Figure 2.5.  Animals with cardiac disease have increased CCR2 expression on activated 
CD14+CD16+ monocytes. 
Animals in this study were further divided into two cohorts based on if they were housed at the 
NERPC or TNRPC to examine the expression of the chemokine receptor 2 (CCR2) on activated 
CD14+CD16+.  (A, B).  In both cohorts, there was a significant increase in CCR2 expression on 
CD14+CD16+ later during infection in animals with increased cardiac fibrosis compared to those 
with no significant findings in the heart (*, p<0.05). 
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ABSTRACT 
The role of macrophage activation, traffic, and accumulation on cardiac pathology was 
examined in twenty-three animals.  Seventeen animals were SIV-infected, 12 were CD8-
lymphocyte depleted, and the remaining 6 were uninfected controls (2 CD8-lymphocyte 
depleted, 4 non CD8-depleted).  One of five SIV-infected, non-CD8 lymphocyte depleted animals 
had minor cardiac pathology (20% of animals) with increased numbers of macrophages in 
ventricular tissue compared to controls.  Seven of twelve (58%) SIV-infected, CD8-lymphocyte 
depleted animals had cardiac pathology in ventricular tissue, including macrophage infiltration 
and myocardial degeneration.  Fibrosis (measured as the percentage of collagen), was increased 
41% in animals with cardiac pathology compared to animals without pathological abnormalities 
in SIV-infected, CD8-depleted animals.  CD163+ macrophage numbers increased significantly in 
SIV-infected, CD8-lymphocyte depleted animals with cardiac pathology compared to ones 
without (1.66 fold) and controls (5.42 fold).  The percent of collagen positively correlated with 
macrophage numbers in ventricular tissue in SIV-infected animals.  There was an influx of BrdU+ 
monocytes to the heart during late SIV infection, regardless of pathology. These data implicate 
monocyte/macrophage activation and accumulation in the development of cardiac pathology 
during SIV infection. 
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INTRODUCTION 
Effective anti-retroviral treatment (ART) has decreased mortality due to HIV infection 
resulting in an increase survival rate of HIV-infected patients.1,2  This increased survival has 
resulted in new, tissue-specific complications due to HIV infection and chronic immune 
activation.3,4  Previous studies have shown a link between coronary artery disease (CAD) and HIV 
infection, with HIV-infected individuals having approximately a two-fold increase in the 
incidence of myocarditis, ventricular dilation and myocardial infarction, compared to age-
matched uninfected individuals.5-7  Factors correlating with HIV-associated CAD are likely 
multifactoral and include anti-retroviral drugs,8-10 microbial translocation resulting in chronic 
immune activation,11,12 increased levels of cardiac myosin specific auto-antibodies,13 
opportunistic infections,14,15 and increased inflammation due to immune activation.16,17  
Consistent observations in HIV infected individuals with CAD include mononuclear cellular 
infiltrates observed in cardiac parenchymal tissue and coronary vessels.12,18   
Monocytes/macrophages have been shown to play a role in SIV- and HIV-associated 
CAD, in particular atherosclerosis and myocarditis.5,19  Developing in the bone marrow, 
monocytes are released into the blood where they function in immunosurveillance and traffic to 
specific tissues, normally and in response to infection.  Monocytes develop into macrophages in 
tissues5,20 some of which play roles in inflammation while others that are alternatively activated 
may have anti-inflammatory roles.21  Monocytes are prime sources of cytokines and chemokines 
that can alter cardiac function and,22,23 monocyte/macrophage-associated pro-inflammatory 
cytokines including interleukin (IL)-1, IL-6, and tumor necrosis factor α (TNF-α) are elevated 
during HIV infection and CAD.24,25  The number of CD14+CD16+ pro-inflammatory blood 
monocytes are increased with CAD and HIV infection, suggesting that chronic immune activation 
with HIV infection may increase the risk of CAD.26,27  
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CD163, a hemoglobin/haptoglobin receptor involved in the clearance of hemoglobin is 
expressed on the surface of monocytes/macrophages28,29 and proteolytically cleaved from the 
surface of activated CD163+ monocytes/macrophages in response to pro-inflammatory 
signaling.30,31  Levels of soluble CD163 (sCD163) in plasma inversely correlate with the levels of 
membrane bound form of CD163 on monocytes/macrophages32 and is a biomarker for diseases 
where macrophage activation and inflammation play a central role.31  We have shown that 
sCD163 levels in plasma correlate with the rate of AIDS progression in SIV infected rhesus 
macaques.33  Levels of sCD163 in acute ( <1 year) and chronic ( >1 year) HIV infection functions 
as a novel marker of HIV activity on monocyte/macrophages activation.34  Additionally,  levels of 
sCD163 in HIV-infected individuals correlated with the percentage of non-calcified, vulnerable, 
coronary plaques when compared to uninfected age-matched controls, while traditional risk 
factors of CAD such as d-dimer, C-reactive protein, and IL-6 did not.35  Lastly, there are increased 
percentages of non-calcified coronary plaques in HIV infected elite controllers not on ART, 
further underscoring the role of monocytes/macrophages in lesion formation.  While causes of 
CAD in HIV infected individuals are likely multifactoral, we sought to examine the role of 
macrophage activation and accumulation with SIV-infection on CAD.  We used a CD8-
lymphocyte depletion model of SIV infection in rhesus macaques, which results in rapid 
progression to AIDS (3-4 months) with a high rate of macrophage-mediated disease36 as a model 
to examine the role of macrophage activation in the development of cardiac inflammation and 
damage during AIDS. 
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RESULTS 
 
Increased numbers of macrophages in the heart with SIV infection in non-CD8 lymphocyte 
depleted animals 
To investigate the role of monocytes/macrophage activation and traffic on cardiac 
pathology with SIV infection, twenty-three rhesus macaques were used in this study.  Six 
animals (2 CD8-lymphocyte depleted, 4 non-depleted) were uninfected controls. Seventeen 
animals were SIV infected, of these 12 were CD8-lymphocyte depleted (Table 3.1).  
Immunohistochemistry revealed a significant increase in the number of CD163+, CD68+, and 
MAC387+ macrophages in SIV infected non-CD8 lymphocyte depleted animals compared to 
uninfected controls.  There was a 1.32 fold increase in the number of activated CD163+ 
macrophages, a 1.91 fold increase in the number of resident CD68+ macrophages, and a 1.45 
fold increase in the number of newly infiltrating MAC387+ macrophages in cardiac tissue of SIV- 
infected non-CD8 lymphocyte depleted animals compared to uninfected controls.  In CD8-
lymphocyte depleted animals we found a 4.52, 9.44, and 2.36-fold increase (P<0.05) in the 
number of CD163+, CD68+, and MAC387+ macrophages respectively.  CD3+ T-lymphocytes in 
SIV-infected, CD8-lymphocyte depleted animals were also significantly increased 7.91-fold 
(P<0.05) compared to uninfected controls (Table 3.2).  
 
Increased numbers of macrophages in the heart of CD8-lymphocyte depleted versus non-CD8 
lymphocyte depleted animals 
SIV-infected, CD8- lymphocyte depleted animals had significantly elevated numbers of 
macrophages and T-lymphocytes in cardiac tissue compared to SIV- infected non-lymphocyte 
depleted rhesus macaques (Table 3.2).  CD163+ macrophages were increased 3.41-fold, CD68+ 
macrophages increased 4.93-fold and MAC387+ cells increased 1.63-fold in SIV-infected, CD8-
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depleted animals compared to non-CD8 lymphocyte depleted animals (P<0.05).  The number of 
T lymphocytes in SIV-infected CD8-depleted animals was elevated 4.78-fold over SIV infected 
non-CD8 lymphocyte depleted animals.  Overall, when compared to controls, SIV-infected, CD8- 
lymphocyte depleted animals show even greater numbers of macrophages and T- lymphocytes 
in cardiac tissue (Table 3.2). 
 
Increased numbers of macrophages in the hearts of animals with cardiac pathology 
SIV-infected, CD8-lymphocyte depleted animals were divided into two groups based on 
the presence or absence cardiac pathology as determined by a veterinary pathologist.  Five of 12 
animals had normal histology, while the remaining 7 had mild, moderate, or severe 
inflammation and degeneration.  Animals with cardiac pathology had a 1.66 fold increase of 
CD163+ macrophages, and CD68+ and MAC387+ macrophages were increased by 2.46 and 1.70-
fold, respectively, when compared to SIV-infected, CD8-depleted animals without cardiac 
pathology (P<0.05).  In addition, SIV-infected, CD8-lymphocyte depleted animals with pathology 
had a 2.51-fold increase in the number of CD3 T-lymphocytes compared to animals without 
cardiac pathology (Table 3.3). 
 
Correlations between fibrosis and increasing numbers of macrophages in the heart 
We quantified the percent of collagen per total tissue area using Masson’s trichrome 
stain, as a measurement of fibrosis.  In SIV-infected non-CD8 lymphocyte depleted animals one 
animal had minor pathology and mild fibrosis with 12.6±5.6% collagen of total tissue area, as 
compared to the remaining 4 animals with normal histology with an average of 6.2±3.8% 
collagen.   The percent collagen in hearts of SIV-infected non-CD8 lymphocyte depleted animals 
was not significantly different from uninfected controls (P>0.05)  (Fig. 3.1B, 3.1C).  Overall, SIV-
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infected, CD8-lymphocyte depleted animals had increased levels of collagen compared to SIV-
infected, non-CD8 depleted animals (14.5±1.81 compared to 7.5±1.39) (Fig. 3.1A, 3.1B).  SIV-
infected, CD8-lymphocyte depleted animals with cardiac pathology had increased amounts of 
collagen and numbers of CD163+ macrophages (Fig. 3.1A, 3.1B left).  The percent collagen of 
total tissue area in SIV-infected, CD8-lymphocyte depleted rhesus macaques with cardiac 
pathology was significantly increased when compared to those  without pathology (Fig. 3.1B 
right) (19.2±3.4% vs. 7.93±4.7%, P<0.05).  All SIV infected animals had positive correlations 
between the percentage of collagen as a marker for fibrosis and the numbers of CD163+ (Fig. 
3.2A), CD68+ (Fig. 3.2B), and MAC387+ (Fig. 3.2C) macrophages.  Animals with severe cardiac 
pathology had the highest numbers of macrophages in the heart.  There was no correlation 
between the number of CD3+ T-lymphocytes and the amount of fibrosis in SIV-infected animals 
(Fig. 3.2D). 
 
Absence of SIV viral protein and RNA in the heart of SIV infected animals 
Extensive immunohistochemistry and in situ hybridization was done on cardiac tissues 
to determine if SIV-infected cells were present.  SIV-p28 and -RNA was found in matched brain 
and lymph node tissues, but not in cardiac tissues from the same animals (data not shown).   
 
Increased traffic to the heart during late SIV infection 
We used BrdU to examine the traffic of recently released macrophages to the heart in 
SIV-infected, CD8-depleted animals.  Animals were grouped based on when they received BrdU, 
early (6 and 20 dpi) or late (48 dpi and 24 hours prior to necropsy).  In animals that received 
BrdU late we found a 4.72-fold increase in the number of BrdU+ macrophages present 
compared to animals that received BrdU early (Fig 3.3).  
 104 
DISCUSSION 
We examined in a retrospective study, the role of macrophage activation and traffic to 
the heart with SIV infection leading to cardiac inflammation and pathology.  Examining 
macrophage populations in SIV infected, non-CD8 lymphocyte depleted rhesus macaques we 
found increased numbers of macrophages in cardiac tissues compared to uninfected controls.  
Twenty percent of SIV infected, non-CD8 lymphocyte depleted animals had minor interstitial 
fibrosis while the remaining had no significant signs of fibrosis when compared to controls.  A 
single animal that had increased levels of fibrosis also had increased numbers of macrophages in 
the heart when compared to other SIV-infected, non-CD8 lymphocyte depleted animals without 
fibrosis.  This suggests that macrophage accumulation plays a role in the observed cardiac 
pathology in a subset of SIV infected animals.   
Compared to SIV-infected, non-CD8 lymphocyte depleted rhesus macaques CD8- 
lymphocyte depleted animals had significantly increased numbers of macrophages in the heart 
and a higher incidence of cardiac pathology.  While viral load in plasma has been implicated in 
the progression of cardiac pathology in SIV-infected animals,41 we observed no differences in 
plasma viral load between SIV-infected, CD8-lymphocyte depleted animals with and without 
cardiac pathology.  Additionally, we did not find SIV infected macrophages in the hearts of our 
animals.  Kelly et. al., found scattered SIV-infected macrophages in hearts of a subset of infected 
animals (12 of 22) using a SIV-gp41 antibody that recognizes productively infected cells.41 But, 
the number of infected cells did not correlate with functional decline.41 Yearley et. al., found 1-4 
SIV infected macrophages/mm2 in hearts of 7 of 21 animals42. These authors used an antibody 
against SIV-nef that detects latent and productively infected macrophages.  We found SIV-p28 
and –RNA positive macrophages in brains and lymph nodes of the animals in our study.  Results 
from our study suggest plasma virus, protein, or RNA alone do not drive cardiac pathology, and 
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other factors, including macrophages, likely do.  We found positive correlations between the 
number of macrophages and the amount of fibrosis as a maker of damage to the heart, where 
animals with the most severe fibrosis had the highest numbers of macrophages.   
While we have reported increased numbers of CD163+ macrophages, in SIV-infected 
animals with cardiac pathology and fibrosis, others have shown decreased numbers of CD163+ 
macrophages in the heart of SIV infected animals with active and borderline myocarditis43 and 
an increase in CD3+ T-lymphocytes.42  In these studies, there were increased numbers of 
CD163+ macrophages in SIV infected animals with normal, uninflammed heart tissue, and fewer 
CD163+ macrophages in SIV infected animals with active or borderline myocarditis.  Because 
CD163+ macrophages can be considered to be anti-inflammatory, and CD163 is upregulated by 
the anti-inflammatory cytokines IL-6 and IL-1044, 45 these authors concluded that CD163+ 
macrophages are protective.  Their observations are in contrast to ours and others, increased 
numbers of CD163+ macrophages are present with active inflammation and lesion formation in 
cardiac and CNS tissues.  Another observation to account for differences in the number of 
CD163+ macrophages in the heart between other studies and ours is that we used CD8-
lymphocyte depleted animals which could alter the mechanisms of inflammation with SIV 
infection.  The differing results underscore the fact that, at present, the function of CD163+ 
macrophages in the heart with SIV infection is not fully understood.   
Previous studies have shown that chronic inflammation and T cell activation, without 
HIV infection, plays a role in the formation of atherosclerotic plaques.7  In HIV+ individuals, 
atherosclerosis is associated with T cell activation and markers of inflammation predict cardiac 
events.46,47  In SIV infected animals CD8+ T-lymphocytes are present and correlate with 
myocarditis.18,42  Animals in our study were persistently CD8+ T-lymphocyte depleted and we 
found few CD3+ T-lymphocytes in cardiac tissues.  Thus, our results show there is cardiac 
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pathology and fibrosis without CD8+ T-lymphocytes and few CD3+ T-lymphocytes, further 
underscoring the role of monocytes/macrophages in pathology and fibrosis. 
Using  FDG-PET imaging, we have shown that increased monocyte/macrophage 
accumulation in the ascending aorta with HIV infection correlates with the number of non-
calcified, vulnerable plaques.48  In addition, this accumulation of macrophages is associated with 
sCD163 in plasma, a marker of macrophage activation.48  We have also shown that sCD163 in 
plasma correlates with the presence of non-calcified, vulnerable, coronary plaques in HIV-
infected patients.35  Here, we demonstrate actual macrophage accumulation within ventricular 
tissue correlates with fibrosis suggesting that macrophage accumulation drives cardiac 
pathology with SIV infection.  While some studies have associated the toxic effects of ART on 
CAD progression in humans and monkeys,8-10 studies examining HIV-1 elite controllers have 
shown that these individuals have increased rates of atherosclerosis compared to uninfected 
and chronically HIV-infected individuals.49  HIV-1 elite controllers also had elevated levels of 
sCD163 in plasma 49.  These observations, taken together with data from this study, suggest that 
immune activation and macrophages play a role in HIV- and SIV-associated cardiac pathology. 
Using BrdU, we were able to examine the accumulation of monocytes newly released 
from the bone marrow.  Regardless of cardiac pathology, we show an increase of 
monocyte/macrophage traffic to the heart during late versus early SIV infection.  Due to the low 
number of animals receiving BrdU we could not determine statistically if increased traffic of 
macrophages to the heart with SIV infection led to increased damage.  
Our studies demonstrated an increase in macrophage numbers in cardiac tissue of SIV 
infected animals with cardiac pathology.  In particular, the numbers of CD163+ macrophages are 
significantly increased compared to animals without pathology and uninfected controls.  We 
found a strong correlation between numbers of macrophages and the degree of fibrosis 
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determined by increasing levels of collagen in animals with cardiac pathology.  The correlation 
between fibrosis and increased numbers of CD163+ macrophages demonstrate that the SIV-
infected, CD8-lymphocyte depleted animals can be a beneficial model to study the effects of 
macrophage activation and inflammation on cardiac pathology associated with HIV and SIV 
infection.  Our preliminary studies on HIV+ cardiac tissues also show an increase in the number 
of  CD163+ macrophages in the heart during HIV infection that correlates with fibrosis (data not 
shown).  While the causes of HIV and SIV associated CAD are likely multifactoral, our data 
suggests that macrophage accumulation and traffic to the heart plays a role in the developing 
cardiac pathology.  Data from this study suggest that therapeutic treatments targeting 
macrophage activation and traffic, along with effective ART, could potentially reduce 
inflammation and the resulting damage seen in the heart during infection. 
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MATERIALS AND METHODS 
Ethics Statement 
All animals were either housed at Harvard University’s New England Regional Primate 
Research Center or Tulane University’s National Primate Center and handled in accordance with 
Harvard University’s or Tulane University’s National Primate Research Center Institutional 
Animal Care and Use Committee (IACUC). 
 
Animals, viral infection and CD8+ T lymphocyte depletion 
Twenty-three Rhesus macaques were used in this study.  Seventeen were infected with 
SIVmac251 (SIV p27) by i.v. injection (kindly provided by Ronald Desrosiers, Harvard University).  
In order to achieve rapid progression to AIDS, 12 of the 17 infected animals were CD8-
lymphocyte depleted using a human anti-CD8 antibody, cM-T807, administered s.c (10mg/kg) at 
6 days post infection (dpi) and I.V. (5mg/kg) at 8 and 12 dpi, as previously described 4.  The cM-
T807 antibody was provided by the NIH Non-human Primate Reagent Resource (RR016001, 
A1040101).  Six of the twenty-three rhesus macaques served as uninfected controls, 2 of which 
were CD8-lymphocyte depleted (50mg/kg single bolus I.V. injection).  Animals were 
anesthetized with ketamine-HCL and euthanization with pentobarbital overdose intravenously, 
and exsanguinated.  Following exsanguinations, standard necropsy was performed with a 
standard set of major organs collected in 10% neutral buffered formalin.  Following fixation, all 
tissues were embedded in paraffin, sectioned at 5 μm, and stained with hematoxylin and eosin.  
Sections of left ventricular myocardium were blindly analyzed by a board certified veterinary 
pathologist (Andrew D. Miller, D.V.M, D.A.C.V.P).  Cardiac tissues were scored based on ten 
randomly chosen 400x fields.  Pathology was assessed based on the degree of change in the 
tissue and graded as mild, moderate, or severe inflammation and degeneration.   
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Plasma Viral Load Determination 
SIV RNA in plasma was quantified using real time PCR as previously described.37  Virions 
were pelleted from 500μL EDTA plasma from infected animals by centrifugation at 20,000 g for 1 
hour.  The threshold sensitivity was 100 copy Eq/mL.  Viral loads peaked at day 8 post infection, 
and no differences in viral load were observed between SIV infected, CD8-lymphocyte depleted 
animals. 
 
Immunohistochemistry and In Situ Hybridization for SIV-p28 and -RNA 
The presence of SIV viral proteins in heart tissues were identified using SIV gp41 (KK41 
1:500, NIH AIDS Research and Reference Reagent Program) and SIV p28  ( SIVmac251 1:2500, 
Fitzgerald Industries), along with in situ hybridization with digoxigenin-labeled antisense 
riboprobes to detect SIV RNA (Lofstrand Labs, Gaithersburg, MD), as previously described.38  
Extensive immunohistochemistry and in situ hybridization tissue revealed no SIV-p28 or RNA 
was found in the hearts of SIV infected animals.   
 
5-bromo-2’-deoxyuridine (BrdU) Administration 
To study monocyte/macrophage traffic to and accumulation in the heart with SIV 
infection, BrdU was administered to SIV infected, CD8-lymphocyte depleted animals as 
previously described.33  Briefly, a 30 mg/ml BrdU stock solution was prepared with 1X PBS, and 
was heated to 60°C in a water bath.  BrdU was administered as a slow bolus i.v. injection at a 
dose of 60 mg BrdU/kg body weight.  Animals were administered BrdU either early (6 and 20 
dpi), or late (48 dpi and 24 hours prior to necropsy). 
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Immunohistochemistry 
Formalin-fixed, paraffin-embedded cardiac tissue were cut in 5 μm sections, air dried 
overnight, then deparaffinized with xylenes, rehydrated in graded ethanols and finally with 
deionized water.  Following rehydration, antigen binding sites were unmasked using Antigen 
Unmasking Solution (Vector Laboratories), for antibodies recognizing CD3, CD68, and BrdU with 
20 minutes heat exposure followed by 20 minutes cooling at room temperature.  Antigen 
unmasking for HAM56 was accomplished by incubating slides at 37°C for 5 minutes with 
Proteinase K (Dako).  Following antigen unmasking cardiac tissues were blocked with a dual 
endogenous enzyme block (Dako).  Sections were then incubated with biotin solution 
(Avidin/Biotin block, Vector Laboratories) for fifteen minutes to block endogenous biotin, 
followed by protein block using serum free protein block (Dako) and incubated for ten minutes 
for monoclonal antibodies and thirty minutes for polyclonal antibodies. Antibodies used to 
identify macrophages were the pan macrophage marker mouse monoclonal antibody CD68 
(1:400, Dako, clone KP1).  The CD163 scavenger receptor was detected using mouse monoclonal 
CD163 (1:250, Serotec).  Recently infiltrated macrophages were identified by staining with 
mouse monoclonal antibody MAC387, an early marker of monocytes/macrophages (1:100, 
Dako).  Mature macrophages present during chronic inflammation were recognized with a 
mouse monoclonal MRP8 antibody (BMA Biomedicals).  A rabbit polyclonal CD3 antibody (1:300, 
Dako) was used to identify CD3 T lymphocytes.  To assess macrophage traffic to the heart, 
sections were stained with a mouse monoclonal BrdU antibody (1:100, Dako).  Slides were 
incubated for one hour at room temperature.  Sections were incubated with the corresponding 
anti-mouse or ant-rabbit horseradish peroxidase conjugated secondary antibody for thirty 
minutes at room temperature.  The color reaction product was developed using 3,3’-diamino-
benzidine tetrahydrochloride (DAB, Dako).  Slides were counterstained in hematoxylin, 
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dehydrated in washes of increasing concentration of ethanol, followed by xylenes, and 
mounted.  All slides were imaged using a Zeiss Axio Imager M1 microscope (Carl Zeiss 
MicroImaging Inc., Thornwood, NY) using Plan-Apochromat x20/0.8 Korr objectives.  Positive 
cells were counted manually for 20 random, non-overlapping fields of view to determine 
number of positive cells/mm2 with a field area of 0.148mm2  
 
Massons Trichrome Stain 
 Cardiac ventricular tissues were stained using a Massons Trichrome Stain kit 
(Newcomer Supply, Middleton,WI) was used according to manufacturer’s protocol and imaged 
using a Zeiss Axio Imager M1 microscope using Plan-Apochromat x20/0.8 Korr objectives.  
Twenty random, non-overlapping fields of view were imaged for each slide and the percent of 
collagen relative to total cardiac tissue area examined was calculated.  The percent collagen of 
total tissue area was quantified using ImageJ analysis software (v1.46, National Institute of 
Health) and color deconvolution vectors developed for Massons Trichrome that separate 
histological dyes into individual red, blue, and green colors.39  The area of red and blue dyes 
corresponding to cytoplasm and collagen were measured to determine the percentage of total 
tissue area for each.  The percentage of collagen serves as a qualitative measurement of 
fibrosis40 and damage to cardiac tissue.  
 
Statistical Analysis 
 Statistical analyses were performed using Prism version 5.0d (GraphPad Software, Inc., 
San Diego, CA) software.  A Mann-Whitney non-parametric U test was used to compare all 
groups.  Spearman’s rank correlation was used for all correlations.  Significance was accepted at 
p<0.05. 
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Table 3.1.  Rhesus Macaques Used in the Study 
Animal  
Type 
SIV Status N 
Heart  
Pathology 
Controls - 6 6 NSF* 
non-CD8 depleted + 5 
4 NSF 
1 Mild, myocardial fibrosis and immune cell 
infiltration 
 
CD8-depleted + 12 
5 NSF 
3 Mild 
3 Moderate 
1 Severe, myocardium degeneration, 
inflammation, and fibrosis 
 
*NSF- No significant findings 
Pathology was determined by a veterinary pathologist.  Cardiac tissue sections were scored 
based on ten randomly chosen 400x fields.  Inflammation was graded according to mild, 
moderate, and severe as it related to immunoreactive cells present within the section. 
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Table 3.2.  Comparison of the Numbers of Macrophages and T-lymphocytes in Uninfected, SIV+, and SIV+ CD8-lymphocyte Depleted Rhesus 
Macaques 
Immune 
Markers 
 SIV+  p value  Fold Change 
Uninfected 
(UN) 
(n=6) 
Non-Depleted 
(ND) 
(n=5) 
CD8-Depleted 
(CD8) 
(n=12) 
 UN 
vs. 
ND 
UN 
vs. 
CD8 
ND 
vs. 
CD8 
 ND 
UN 
CD8 
UN 
CD8 
ND 
CD163 56.33 (±5.30) 74.70 (±3.74) 254.83 (±21.37)  * ** **  1.32 4.52 3.41 
CD68 10.85 (±2.03) 20.76 (±1.63) 102.52 (±23.3)  * ** **  1.92 9.44 4.93 
HAM56 92.50 (±23.20) 77.12 (±10.19) 163.50 (±34.9)  ns ns *  - - 2.12 
MAC387 10.92 (±3.20) 15.83 (±1.96) 25.83 (±2.25)  * * *  1.45 2.36 1.63 
CD3 3.47 (±0.75) 5.74 (±1.07) 27.45 (±7.85)  ns * **  - 7.91 4.78 
 
Uninfected controls comprised of 2 uninfected, CD8 T-lymphocyte depleted animals and 4 uninfected, non-depleted animals.  
No differences were observed in the number of macrophages and T-lymphocytes between these two groups.  Numbers 
represent the mean number of positive cells (cells/mm2)  standard error of the mean (parentheses) based on counts from 
20 non-overlapping fields of view using 20X objective.   P values were calculated by comparing the mean number of positive 
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cells for controls and SIV+ animals using a Mann-Whitney U test (*, p<0.05, ** p<0.01).  Fold change was calculated based on 
the ratio of macrophages or T-lymphocytes present in the heart for the indicated groups.
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Table 3.3.  Increased Number of Macrophages and T-lymphocytes in SIV-Infected CD8+ T-
lymphocyte Depleted Rhesus Macaques with Cardiac Pathology Compared to SIV-Infected 
CD8+ T-lymphocyte Depleted Rhesus Macaques without Cardiac Pathology 
Immune 
Markers 
SIV+, CD8 Depleted (n=12) 
p value Fold Change w/o Pathology (n=5) w/ Pathology (n=7) 
CD163 183.40 (±34.20) 305.85 (±14.06) ** 1.66 
CD68 55.98 (±12.06) 137.75 (±6.20) ** 2.46 
HAM56 196.50 (±14.90) 131.90 (±12.40) ns - 
MAC387 17.34 (±1.99) 29.48 (±3.01) * 1.70 
CD3 14.60 (±4.72) 36.62 (±12.07) * 2.51 
 
Numbers represent the mean number of positive cells (cells/mm2)  standard error of the mean 
(parentheses) based on counts from 20 non-overlapping fields of view using 20X objective.   P 
values were calculated by comparing the mean number of positive cells for SIV+, CD8-depleted 
animals with and without cardiac pathology using a Mann-Whitney U test (* p<0.05, ** p<0.01).  
Fold change was calculated based on the ratio of cells in SIV+, CD8-depleted animals with 
cardiac pathology compared to animals without pathology. 
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Table 3.4 BrdU+ cells in the heart of SIV-infected, CD8-lymphocyte depleted rhesus macaques 
are of myeloid lineage 
     
Cell Phenotype  SIV- 
(n=2) 
SIV+ w/o pathology 
(n=5) 
SIV+ w/pathology 
(n=7) 
     
BrdU+ 
MAC387+ 
 75.60 (3.71) 
 
84.48 (5.83) 79.25 (4.98) 
 
BrdU+ 
CD68+ 
 26.75 (7.97) 14.51 (3.92) 19.31 (4.89) 
 
BrdU+ 
CD163+ 
 9.90 (5.71) 1.24 (0.53) 5.87 (1.80) 
 
BrdU+ 
CD3+ 
 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 
 
Note-Phenotype of BrdU+ positive cells in the heart of SIV-infected, CD8-lymphocyte depleted 
rhesus macaques.  All BrdU+ cells were counted for SIV-infected, CD8-lymphocyte depleted 
animals and the average percentage of double positive cells for each indicated group was 
calculated for each cell phenotype ± standard error of the mean, in parentheses. 
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     *from Walker et al. AIDS Res Human Retroviruses, 2014. 
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Figure 3.1. Increased numbers of CD163+ macrophages and amount of collagen in heart tissue 
in SIV infected rhesus macaques with cardiac damage Masson’s trichrome stain and 
immunohistochemistry were used to compare the amount of collagen and numbers of CD163+ 
macrophages present in the heart of uninfected, SIV infected, and SIV infected CD8-depleted 
rhesus macaques (A).  SIV infected, CD8-depleted animals with cardiac pathology show 
significantly increased levels of collagen  (19.2±3.4%) and increased numbers of CD163+ 
macrophages are present (305.85±14.06) (B, C).  Statistical analysis was done between the 
indicated groups using Mann-Whitney non-parametric U test (*, p<0.05, ** p<0.01). 
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     *from Walker et al. AIDS Res Human Retroviruses, 2014. 
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Figure 3.2. Correlations between the percentage of collagen per total tissue area and numbers 
of CD163+, CD68+ and MAC387+ macrophages in SIV infected rhesus macaques Spearman rank 
test was used to examine if there were correlations between the amount of cardiac damage 
based on the percentage collagen and the numbers of macrophages in the heart of SIV infected 
rhesus macaques (closed circle, SIV+ CD8-depleted w/o damage; open circle, SIV+ CD8-depleted 
w/damage; closed square, SIV+ non-depleted).  Positive correlations were found between the 
amount of damage in each section and the numbers of CD163+ (upper left), CD68+ (upper right), 
and MAC387 (lower left) macrophages in SIV infected rhesus macaques.  No correlations were 
found between the amount of damage and the number of CD3+ T-lymphocytes (lower right).  r= 
Spearman coefficient. p<0.05. 
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     *from Walker et al. AIDS Res Human Retroviruses, 2014. 
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Figure 3.3.  Increased traffic of macrophages to the heart during late SIV infection BrdU 
experiments were used to examine when macrophages traffic to the heart in SIV-infected, CD8-
depleted rhesus macaques.  Animals were grouped based on whether they received BrdU early 
or late.  Immunohistochemistry with an anti-BrdU antibody shows increased traffic of BrdU+ 
macrophages to the heart of SIV-infected, CD8-depleted rhesus macaques that received BrdU 
late compared to early (A).  Animals that received BrdU late during infection had 31.85±14.8 
BrdU+ macrophages in the heart compared to 6.68±2.9 BrdU+ macrophages in the heart of 
animals that received BrdU early. 
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Figure 3.4.  SIV plasma virus does not distinguish between animals with and without cardiac 
pathology  SIV plasma viral load was quantified for SIV+ CD8+ T-lymphocyte depleted animals 
using real-time PCR.  (A) For these animals, SIV plasma virus peaked at 8 dpi and remained 
consistently elevated during the course SIV infection and did not distinguish between animals 
that did and did not develop cardiac pathology.  Sections of cardiac tissue from SIV+ CD8+ T-
lymphocyte depleted animals were examined for the presence of SIV-RNA or SIV-p28 viral 
protein (B).  There were no SIV-RNA+ or SIV-p28+ cells found in cardiac tissues of the animals.                                                                                                                                                    
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ABSTRACT 
HIV+ individuals have an increased risk of cardiovascular disease (CVD) where chronic immune 
activation and monocyte/macrophage inflammation may play a role.  We examined matched 
aorta, left ventricle (cardiac tissue), and plasma from 16 chronically infected HIV+ individuals on 
combination antiretroviral therapy (cART) and 16 age and sex matched HIV -individuals.  Aorta 
and cardiac tissue were assessed for numbers of inflammatory macrophages and T-lymphocytes.  
Aortic intima-media thickness (aIMT) and cardiac fibrosis were measured following a modified 
Verhoeff Van Gieson and Modified Massons trichrome stain.  Plasma soluble CD163 (sCD163), a 
marker of monocyte/macrophage activation with HIV infection was measured by ELISA.  We 
found significant increases in the numbers of CD163+, CD68+, CD206+, and MAC387+ 
macrophages in aorta and cardiac tissue with HIV infection.  The number of macrophages in 
aorta correlated with numbers of macrophages in cardiac tissues.   There was a positive 
correlation between plasma sCD163 and numbers of all macrophages in aorta and cardiac 
tissues. Soluble CD163 correlated with the percentage of collagen (fibrosis) and aIMT.  These 
data underscore the role of monocyte/macrophage activation and inflammation in increased 
aIMT and cardiac fibrosis with HIV infection and point to the necessity to target 
monocytes/macrophages to reduce CVD inflammation and pathology with HIV. 
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INTRODUCTION 
Monocytes/macrophages are mediators of cardiovascular disease (CVD) with HIV 
infection and are mediators in fibrosis,1 myocarditis2,3 and atherosclerotic plaque progression.  
Monocytes can traffic to cardiovascular tissues and differentiate into macrophages where they 
phagocitize low density lipoprotein (LDL) and develop into foam cells,4 this drives the 
development of the atheroma core.5,6  A range of monocyte phenotypes are present within an 
atherosclerotic plaque, where M1 inflammatory macrophages are thought to be involved in 
plaque rupture7.   In contrast, alternatively activated M2 macrophages are thought to be athero-
protective.8    Monocytes/macrophages can influence the stability of an atherosclerotic plaque.9  
Macrophages within atherosclerotic plaques can secrete matrix metalloproteinases (MMPs) that 
promote plaque instability and rupture.10,11    Studies using optical coherence tomography show 
that vulnerable plaques are characterized by a larger lipid rich core and increased macrophage 
accumulation in the cap and shoulder regions compared to stable plaques within the same 
individual.12  While traditional risk factors of CVD are present among HIV+ individuals, they do 
not fully account for the increased risk of CVD among HIV+ individuals.13,14  It is thought that the 
increased CVD risk seen among this population is due in part to increased immune activation 
and monocyte/macrophage accumulation.15-17   In this population, there is an increase in 
vulnerable, non-calcified plaques that are prone to rupture.18,19 
Among HIV+ individuals with controlled viremia circulating CD14+CD16+ monocytes, are 
predictive of coronary artery calcium (CAC) progression, suggesting that they are pro-
atherogenic and associated with CVD.20  Monocyte chemoattractant protein-1 (MCP-1), tumor 
necrosis factor-α (TNF-α)21, and soluble CD14 (sCD14)22 also predict CAC progression 
independent of traditional CVD risk factors.21  We have shown that levels of soluble CD163 
(sCD163), a marker of monocyte/macrophage activation, is elevated with HIV infection and 
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correlate with the number of non-calcified, vulnerable plaques.18,19  In addition to increased 
inflammation, there is also an increase in high-risk plaque morphology defined as an increase in 
the number of low attenuated plaques and positive remodeling , and that inflammation in the 
aorta is representative of inflammation in the rest of the arterial tree.23  To date, correlations 
between sCD163 and macrophage inflammation in the aorta and heart have not been done.  
In this study we examined matched aorta, left ventricle (cardiac tissue), and plasma 
from age and sex matched HIV- and HIV+ individuals to determine if HIV infection results in 
increased monocyte/macrophage inflammation, increased aortic intima-media thickness (aIMT) 
and cardiac fibrosis than HIV- individuals.  We measured levels of sCD163 to determine if it 
correlated with increased aIMT and cardiac fibrosis with HIV infection.  We found that HIV+ 
individuals on combination anti-retroviral therapy (cART) had greater aortic and cardiac 
inflammation and increased aIMT and cardiac fibrosis.  Soluble CD163 positively correlated with 
increased aIMT and cardiac fibrosis, providing evidence that chronic immune activation plays a 
role in the development of HIV-associated CVD. 
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RESULTS 
HIV infection results in increased macrophage inflammation in the aorta and cardiac tissue. 
 Paired aorta and cardiac tissue sections were stained immunohistochemically with 
antibodies recognizing CD163+, CD68+, CD206+, and MAC387+ macrophages (Fig. 4.1).  We 
found a significant 2.02-fold increase in numbers of CD163+ macrophages, a 1.57-fold increase 
numbers of CD68+ macrophages, 1.59-fold increase in numbers of CD206+ macrophages, and a 
1.84-fold increase in numbers of MAC387+ macrophages in HIV+ aortic tissues compared to HIV- 
aortic tissues (Table 1, Fig. 4.1B left) (Mann-Whitney t-test).  In cardiac tissue we found a 
significant 2.05-fold increase in CD163+ macrophages, a 2.02-fold increase in CD68+ 
macrophages, a 2.21-fold increase in CD206+ macrophages, and a 1.87-fold increase in 
MAC387+ macrophages in HIV+ cardiac tissues compared to HIV- cardiac tissues (Table 4.2, Fig. 
4.1B right) (Mann-Whitney t-test).  There were no differences observed between the numbers 
of CD3+ T-lymphocytes in the aorta and cardiac tissues between HIV- and HIV+ individuals.  
Using Spearman rank correlation we found positive correlations between numbers of CD163+ 
(r=.70, p<0.01), CD68+ (r=.67, p<0.01), CD206+ (r=.57, p<0.01) and MAC387+ macrophages 
(r=.58, p<0.01) in aorta and cardiac tissue. (Fig.4. 1C). 
 
Increased numbers of macrophages in the aorta correlate with increased aortic intima-media 
thickness 
With HIV infection there is a significant 1.51-fold increase in aIMT compared to HIV- 
individuals (Fig. 4.2A, 4.2B) (Mann-Whitney t-test, *p<0.05).  Using a Spearman rank correlation 
we found that increased aIMT positively correlated with increased numbers of CD163+ (r=.58, 
p<0.05), CD68+ (r=.56, p<0.05), CD206+ (r=.47, p<0.05), and MAC387+ macrophages (r=.53, 
p<0.05) (Fig. 4.2C). 
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Increased numbers of macrophages in cardiac tissues correlate with increased levels of fibrosis 
Cardiac tissues from HIV+ individuals had a significant increase in the percentage of 
collagen per total tissue area compared to HIV- cardiac tissues (Fig. 4.3A).  There was a 
significant 1.62-fold increase in the percentage of collagen in HIV+ cardiac tissues (31.52±2.03%) 
compared to HIV- cardiac tissues (19.44±3.4% ) (Fig. 4.3B) (Mann-Whitney t-test, **p<0.01).  
Additionally, there was a positive correlation between increased numbers of CD163+ (r=.56, 
p<0.05), CD68+ (r=.52, p<0.05), CD206+ (r=.75, p<0.01) and MAC387+ macrophages (r=.53, 
p<0.05) and increased percentage of collagen per total tissue area (Fig. 4.3C). 
 
Increased plasma soluble CD163 correlated with macrophage inflammation, increased aortic 
intima-media thickness, and cardiac fibrosis 
 There was a significant 1.73-fold increase in plasma sCD163 from HIV+ individuals 
compared to HIV- individuals (Fig.4. 4A) (Mann-Whitney t-test).  There were positive 
correlations between plasma sCD163 and macrophage inflammation in the matched aorta (Fig. 
4.4B) and cardiac tissues (Fig. 4.4C).  Positive correlations were found between plasma sCD163 
and increased aIMT (Fig. 4.4D left) cardiac fibrosis aIMT were found (Fig. 4.4D right). 
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DISCUSSION 
 Despite effective cART HIV+ individuals still suffer from chronic immune activation28-30  
and secondary co-morbidities where activated monocytes/macrophages are implicated.9,16,30,31  
HIV+ individuals are at an increased risk of atherosclerosis compared to the general 
population.32-34  We have previously shown that sCD14 and sCD163 but not traditional 
cardiovascular risk factors (D-dimer, interleukin (IL)-6, and C-reactive protein (CRP)) were 
associated with atherosclerotic plaques with HIV infection18, suggesting that chronic immune 
activation is playing a role in CVD development.  There is also an increased risk of myocarditis 
and cardiomyopathy where 40-50% of AIDS patients at necropsy showed signs of the diseases.35  
However,  while this rate has declined in the cART era, myocarditis is still present, along with 
myocardial fibrosis shown through magnetic resonance imaging (MRI) and spectroscopy 
(MRS).36-38  Data from our study supports this, showing that increased inflammation in the heart 
is still present in HIV+ individuals.   
In this study we found significant increases in the numbers of macrophages in the aorta 
and cardiac tissues of HIV+ individuals compared to controls.  In particular, we see a significant 
increase in alternatively activated CD163+ and CD206+ macrophages.  It has previously been 
shown that these macrophages accumulate in the shoulder and cap regions of unstable 
atherosclerotic plaques.39  While CD163 and CD206 are thought to be markers of M2 polarized 
macrophages that are anti-inflammatory, it is possible that their accumulation leads to a 
weakening of the atherosclerotic plaque making it prone to rupture.  In rodent models, M2 
macrophage accumulation in the aorta results in increased fibrosis and elastin loss.40  
Macrophages also control fibrosis in cardiac tissues.  By themselves, macrophages control 
fibrosis by secreting MMPs, however studies on the heart are needed to determine what pro-
fibrotic factors are expressed by macrophages specifically.  Data from our studies support this in 
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the heart, where we found that increased numbers of macrophages correlate with increased 
cardiac fibrosis.  Additionally, we found positive correlations between the levels of inflammation 
in cardiac tissues and the aorta, suggesting that there is progressive and systemic inflammation 
in the cardiovascular system. 
 Previous studies have examined associations between soluble markers of immune 
activation and surrogate markers of CVD, in particular CAC and aIMT.  Studies have shown 
increased levels of sCD14 are associated with CAC progression with HIV infection22 and sCD14 
and sCD163 are increased and associated with atherosclerosis.41  Imaging studies have 
investigated the relationship between plasma markers and monocyte/macrophage 
accumulation in the aorta and cardiac tissues with HIV.  FDG-PET imaging showed increased 
arterial inflammation which is associated with elevated levels of sCD163,19 but it was not 
possible to colocalize glucose uptake with macrophage markers.  We showed that sCD163 
correlates with increased macrophage inflammation with HIV infection in aorta and heart using 
post-mortem tissues.  Levels of sCD163 also correlated with fibrosis and aIMT, actual markers of 
CVD.  These data support evidence that monocyte/macrophage activation plays a role in the 
development of HIV-associated CVD, and that sCD163 could potentially be a diagnostic marker 
and predictive of fibrosis and aIMT.  However, longitudinal studies would need to be examined 
to indeed see if sCD163 is increased along with markers of CVD with HIV infection. 
 Data from these experiments provide evidence supporting the notion that chronic 
immune activation plays a role in the development of HIV-associated CVD.  While cART is 
effective in decreasing viremia to undetectable levels, it does not target 
monocytes/macrophages that play a role in the development of CVD.  Studies have begun to 
examine therapeutic agents that effect monocyte/macrophage activation and could be 
beneficial in decreasing CVD.  Inhibitors of  3-hydroxy-3-methylglutaryl-coenzyme A reductase 
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inhibitors (statins) have been beneficial in deceasing levels of interleukin-6 (IL-6), interleukin-8 
(IL-8), and TNF-α, serum markers of immune activation and monocyte/macrophage activation.42  
A recent study using atorvastatin did not decrease arterial inflammation in HIV+ men with 
subclinical atherosclerosis and arterial inflammation,  but it did decrease  the volume of non-
calcified plaques.43   
 In this study we found that HIV infection results in significant aortic and cardiac tissue 
inflammation.  While we only examined the aorta, inflammation in the aorta has been shown to 
be representative of the arterial tree,23 suggesting that increased inflammation could be present 
in other arteries.  Additionally, we show that soluble factors of immune activation correlate with 
increased fibrosis in the heart and increased intima-media thickness of the aorta.  Overall, our 
data support the growing evidence that HIV+ individuals are at an increased risk for CVD where 
activated monocytes/macrophages play a role. 
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MATERIALS AND METHODS 
Cardiac tissues and plasma 
Matched tissue samples of aorta, left ventricle (cardiac tissue), and blood plasma from 
16 HIV- and 16 HIV+ males were provided by the National NeuroAIDS Tissue Consortium (NNTC) 
and the National Disease Research Institute (NDRI).  Samples from HIV- individuals had no 
history of CVD or inflammatory conditions.  The average age for the HIV- cohort was 53.3±3.55 
years and the average age for the HIV+ cohort was 50.82.70 years and there was no significant 
differences between the average ages of the groups.  The average duration for HIV infection 
10.6±1.33 years, with HIV+ individuals being on cART for an average of 8.6±2.43 years with no 
detectable virus. 
 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded tissue sections of paired aorta and cardiac tissues 
were assessed for CD163+, CD68+, CD206+, and MAC387+ macrophages, CD3+ T-lymphocytes as 
previously described.24  Slides were imaged using a Zeiss Axio Imager M1 microscope (Carl Zeiss 
MicroImaging Inc., Thornwood, NY) using Plan-Apochromat .20/0.8 Korr objectives. Positive cells 
were counted manually from twenty random, non-overlapping 200X fields of view 
(Corresponding to a field area of0.147mm2) and results presented as the number of positive 
cells/mm2.  The average number of positive cells was expressed as plus or minus the standard 
error of the mean (SEM).  
 
Measurement of Aorta Intima-Media Thickness (aIMT) 
 A modified Verhoeff Van Gieson elastic stain (Sigma) was used to differentiate the 
intima, media, and the adventitia of the aortic wall.25  Tissue sections were rehydrated in 
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xylenes and graded ethanols and stained following the manufacturer’s protocol.  Sections of 
aorta were incubated with a ferric chloride solution to differentiate the layers of the vessel wall.  
Differentiation was stopped when the internal and external elastic lamina were distinct from 
background tissue by incubating the sections in water.  Aortic intima-media thickness (aIMT) 
was determined by optical measurement using ImageJ Analysis software and calipers.  The aIMT 
was measured on ten non-overlapping 400x fields of view (corresponding to a field area of 
1.15mm2) and expressed as plus or minus the SEM.    
 
Quantification of Cardiac Fibrosis 
 Cardiac tissue fibrosis was measured as the percentage of collagen per total tissue 
area26, using a modified Massons Trichrome stain (Newcomer Supply, Middleton, WI) according 
to the manufacturer’s protocol. The percentage of collagen (blue) per total tissue area was 
determined using ImageJ Analysis Software.26 
 
sCD163 ELISA 
 Soluble CD163 (sCD163)  in plasma was quantified by ELISA according to manufacturer’s 
protocol (Trillium Diagnostics) and as previously described.27  Sample plasma was diluted 1:500. 
 
Statistical Analysis 
 Statistical analyses were performed using Prism version 5.0 (Graphpad Software Inc., 
San Diego, CA).  Comparisons were made between HIV- and HIV+ groups using a non-parametric 
Mann-Whitney t-test with significance accepted at p<0.05.  A non-parametric Spearman rank 
test was used to determine if there were correlations between the numbers of macrophages 
and levels of fibrosis in cardiac tissue and aIMT
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Table 4.1. Increased number of macrophages in the aorta and cardiac tissues with HIV infection  
               
  Aorta  Left Ventricle   
Immune 
Marker 
 HIV- 
(n=16) 
 HIV+ 
(n=16) 
p 
value 
Fold 
Change 
 HIV- 
(n=16) 
 HIV+ 
(n=16) 
p 
value 
Fold 
Change 
  
               
CD163  22.04 
(±2.75) 
 44.67 
(±3.07) 
* 2.02  38.52 
(±4.73) 
 76.18 
(±3.15) 
** 2.05   
               
CD68  16.48 
(±1.59) 
 25.73 
(±2.11) 
** 1.57  24.47 
(±3.03) 
 49.53 
(±3.51) 
** 2.02   
               
CD206  14.27 
(±1.62) 
 22.77 
(±1.85) 
* 2.21  35.88 
(±4.09) 
 79.27 
(±4.13) 
** 2.21   
               
MAC387  8.29 
(±0.89) 
 15.32 
(±0.99) 
* 1.84  11.97 
(±1.21) 
 22.41 
(±1.16) 
* 1.87   
               
Mean number of positive cells (cells/mm2) ± standard error of the mean (in brackets) in aorta 
and cardiac tissues from HIV- and HIV+ individuals.  Numbers of positive cells were counted 
from twenty, non-overlapping 200X fields of view for each tissue section with the mean number 
of positive cells being shown.  A non-parametric Mann-Whitney t-test was used to statistically 
compare the mean number of positive cells in the HIV- and HIV+ individuals (* p<0.05, ** 
p<0.01).   
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Figure 4.1.  HIV infection results in increased macrophage inflammation in aorta and cardiac 
tissue compared to uninfected individuals. 
(A)  Sections of aorta and left ventricle (cardiac tissue) from HIV+ and HIV- individuals were 
immunohistochemically stained with antibodies against CD163+, CD68+, CD206+, and MAC387+ 
macrophages. (B)  HIV infection resulted in significantly increased numbers of CD163+, CD68+, 
CD206+, and MAC387+ macrophages in the aorta and cardiac tissues compared to uninfected 
controls.  Statistical analysis was done a Mann-Whitney t-test with significance accepted at 
p<0.05 (* p<0.05, ** p<0.01).  Twenty random, non-overlapping 200X fields of view were 
imaged and positive macrophages were counted for each individual with the mean and standard 
error of the mean calculated.  (C)  There is a positive correlation between the numbers of 
CD163+, CD68+, CD206+, and MAC387+ macrophages in sections aorta and cardiac tissue  in 
HIV- (closed square) and HIV+ (open circle).   (Spearman rank correlation, r=Spearman 
coefficient, p<0.05).  Scale bar= 20 microns, 400X magnification. Vertical bars represent the 
mean plus or minus the standard error of the mean. 
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Figure 4.2.  HIV infection results in an increased intima-media thickness of the aorta that 
correlates with increasing numbers of macrophages. 
(A) A modified Verhoeff Van Gieson elastic stain kit was used to quantify aortic intima-media 
thickness (aIMT) in HIV- (left) and HIV+ (right) individuals.  B)  There was a significant 1.5-fold 
increase in aIMT in HIV+ individuals compared to uninfected controls (Mann-Whitney t-test, 
*p<0.05).   Vertical bars represent the mean plus or minus the standard error of the mean.  (C) 
There were positive correlations between the number of CD163+, CD68+, CD206+, and 
MAC387+ macrophages and increased aIMT with HIV infection.  r= Spearman coefficient, 
p<0.05. 
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Figure 4.3. HIV infection results in increased cardiac fibrosis that correlates with elevated 
numbers of macrophages. 
(A) Massons trichrome stain was used to measure the percentage of collagen (fibrosis) in cardiac 
tissues. (B) There was a significant 1.62-fold increase in the percentage of collagen per total 
tissue area cardiac tissues from HIV+ individuals compared to HIV- individuals (Mann-Whitney t-
test, ** p<0.01).  (C)  We found  positive correlations between increased numbers of CD163+, 
CD68+, CD206+ and MAC387+ macrophages present and increasing levels of fibrosis in HIV+ 
individuals (square) compared to HIV- individuals (circle).  r= Spearman coefficient, p<0.05. 
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Figure 4.4.  Soluble plasma CD163 correlates with increased inflammation, fibrosis, and aIMT 
in aorta and cardiac tissues. 
(A)  Soluble CD163 (sCD163) were measured in plasma from HIV- and HIV+ individuals using an 
ELISA.  HIV infection resulted in a significant 1.7-fold increase in sCD163 in plasma in HIV+ 
individuals compared to seronegative individuals ( Mann-Whitney t-test, *p<0.05).  Vertical bars 
represent the mean plus or minus the standard error of the mean.  Increased sCD163 positively 
correlates with macrophage inflammation in the aorta (B) and cardiac tissue (C) with HIV 
infection.  (D) Soluble CD163 positively correlates with increased aIMT (left) and increased 
cardiac fibrosis. (r= Spearman coefficient, p<0.05 .) 
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ABSTRACT 
Cardiovascular disease (CVD), myocarditis and fibrosis are co-morbidities of HIV+ individuals on 
durable anti-retroviral therapy (ART).  Although mechanisms for these vary, 
monocytes/macrophages are increasingly demonstrated to be key players.  We directly blocked 
monocyte/macrophage traffic to the heart in an SIV model of AIDS using an anti-alpha-4 integrin 
antibody (natalizumab).  Nineteen Rhesus macaques were with SIVmac251 infected and CD8-
lymphocyte depleted for rapid AIDS.  Ten animals received natalizumab once a week, for three 
weeks, and were sacrificed one week later.   Six animals began treatment at the time of 
infection (early) and the remaining four began treatment 28 days post infection (late), a time 
point we have previously established when significant cardiac inflammation occurs. Nine 
animals were untreated controls, of these three were sacrificed early and six were sacrificed 
late.  At necropsy we found decreased SIV-associated cardiac pathology in late natalizumab 
treated animals compared to untreated controls. Early and late treatment resulted in significant 
reductions in numbers of CD163+ and CD68+ macrophages in cardiac tissues compared to 
untreated controls, and a trend in decreasing numbers of newly recruited MAC387+ and BrdU+ 
(recruited) monocytes/macrophages.  In late treated animals, decreased macrophage numbers 
in cardiac tissues correlated with decreased fibrosis.  Early and late treatment resulted in 
decreased cardiomyocyte damage.  These data demonstrate the role of macrophages in the 
development of cardiac inflammation and fibrosis and suggest blocking monocyte/macrophage 
traffic to the heart can alleviate HIV and SIV-associated myocarditis and fibrosis.  They 
underscore the importance of targeting macrophage activation and traffic as an adjunctive 
therapy in HIV infection.     
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INTRODUCTION 
Combination anti-retroviral therapy (cART) has increased the life expectancy of HIV+ 
individuals but co-morbidities including neurological, 1 renal, 2 bone, 3 and cardiovascular 
disease4-9 exist.10-12  HIV-associated cardiovascular disease is a leading cause of HIV-associated 
mortality where there is a two-fold increase in the relative risk compared to non infected, age 
matched individuals.13  HIV-associated cardiovascular disease, that includes atherosclerosis, 
dilated cardiomyopathy, myocarditis, and myocardial infarction7, 14, 15, likely has multiple 
etiologies including toxic effects of cART ,16 opportunistic infections ,17 and chronic immune 
activation18 but monocyte/macrophages are emerging as central players. 
Dilated cardiomyopathy and myocarditis with HIV infection was evident in 40-50% of 
AIDS patients at necropsy in the pre-cART era.19  With effective cART in developed countries the 
incidence has decreased approximately 30% suggesting that dilated cardiomyopathy and 
myocarditis with HIV and cART has declined.7, 19, 20  Despite this, magnetic resonance imaging 
(MRI) and spectroscopy (MRS) show that HIV+ individuals continue to have subclinical 
myocardial disease with myocardial fibrosis and alterations in cardiac function.21, 22  Recent data 
comparing the rates of mortality in the pre- and post-cART era support these findings, where 
HIV+ individuals had a 6.3-fold increase in mortality due to cardiomyopathy and myocarditis in 
the post-cART era.  Additionally, a recent study examining myocardial and microvascular 
inflammation showed that myocarditis is still present with HIV infection.23  This suggests that 
HIV infection with effective cART can still lead to increased cardiac fibrosis and myocarditis. 
SIV-infected rhesus macaques are an excellent model to study the effects of SIV on 
cardiac inflammation and fibrosis.  Previous work established that SIV-infected monkeys have 
dilated cardiomyopathy and myocarditis.24, 25   Overall few SIV- or HIV- RNA or protein positive 
cells are found in cardiac tissues similar to what is found in HIV infected human cardiac 
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tissues.26, 27  Despite this, levels of SIV-RNA correlate with diastolic dysfunction underscoring the 
role of lentiviral infection and cardiac dysfunction with AIDS.27  We have previously 
demonstrated that SIV-infected, CD8-lymphocyte depleted animals develop rapid and consistent 
AIDS with macrophage accumulation in the heart, cardiomyocyte damage, and fibrosis 28 and 
accumulation of CD163+ macrophages correlated with increased fibrosis.28, 29  In these studies, 
BrdU labeled monocyte/macrophages, that were labeled in the bone marrow and traffic to the 
heart, were increased late in infection.  Overall, these observations support the hypothesis that 
macrophage activation and accumulation with SIV and HIV infection play a critical role in the 
development of cardiac pathology.  To date, no studies have directly blocked 
monocyte/macrophage traffic to the heart in experimental infection with SIV. 
While no studies have directly blocked monocyte/macrophage traffic to the heart with 
SIV or HIV infection, data from experimental and clinical studies that diminished macrophage 
activation or accumulation in the heart, support the notion that these cells are major players in 
cardiac pathogenesis.  Thus, studies that blocked chemokine receptor-5 (CCR5) using CCL5-
RANTES resulted in decreased monocyte/macrophage and T-lymphocyte accumulation 30, 31 
likely by indirect mechanisms.   Similarly, blocking CCR5 with the anti-CCR5 antibody maraviroc 
resulted in reduced cardiac CD163 expression by macrophages and prevented diastolic 
dysfunction in SIV-infected monkeys.32  Similarly, studies blocking macrophage inhibitory factor 
(MIP) showed decreased T-cell and macrophage migration and inhibition of the onset of 
myocarditis in a rodent model of experimental autoimmune myocarditis.33   Treatment with the 
statin pravastatin decreased macrophage numbers in abdominal aortic plaques of uninfected 
monkeys.34 Another statin, atorvastatin that did not reduce aortic inflammation in HIV+ infected 
individuals, did decrease the volume and high-risk features of noncalcified plaques. 35  In 
humans with coronary artery disease, angiotensin receptor blocker (ARB) treatment resulted in 
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decreased numbers of atherosclerotic lesions and significantly decreasing levels of soluble 
markers of inflammation C-reactive protein, Interleukin-6 (IL-6), and monocyte chemotactic 
protein-1 (MCP-1).36, 37 
In this study we examined whether directly blocking leukocyte and 
monocyte/macrophage traffic to cardiac tissues with the anti-α4 integrin antibody, natalizumab, 
decreased SIV-associated cardiac pathology (inflammation, fibrosis, and cardiomyocyte 
damage).  Natalizumab is an anti-α4 antibody that binds to the α4 subunit of α4β1 and α4β7 
integrins and blocks the interactions between α4 and its ligands.38  Natalizumab has been used 
effectively to treat Multiple Sclerosis 39 and Crohn’s disease,40 blocking accumulation of 
lymphocytes and monocytes/macrophages in the brain and gut, but not lymph nodes.  In 
rodents, blocking α4 integrins reduced macrophage homing to atherosclerotic plaques.41  We 
have shown that natalizumab treatment in SIV-infected rhesus macaques with AIDS blocked 
monocyte/macrophage traffic to the central nervous system (CNS) and leukocytes to the gut 
resulting in decreased numbers of SIV-RNA and SIV-p28 positive cells.42  Further, natalizumab 
treatment of monkeys at the time of SIV infection resulted in undetectable SIV- RNA, -DNA and -
p28+ cells in the CNS and gut in the majority of animals, and the absence of leukocyte 
inflammation.  In the current study, we examined if natalizumab treatment decreased 
monocyte/macrophage accumulation in the heart and whether such treatment decreased 
cardiac fibrosis and myocyte damage. 
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RESULTS 
Natalizumab treatment decreases the frequency and severity of pathology in SIV-infected, CD8- 
lymphocyte depleted rhesus macaque cardiac tissues 
 The relative degree of pathology in cardiac tissues was assessed based on the levels of 
inflammation, fibrosis, and cardiomyocyte degeneration.  Normal sections were scored as 
having no significant findings (NSF).  When present, inflammation, fibrosis, and cardiomycocyte 
degeneration were scored as mild, moderate, or severe.  We found no significant changes in the 
pathology of cardiac tissues in early natalizumab treated animals compared to untreated 
controls.  Of three SIV-infected untreated animals sacrificed early, 21 dpi (n=3), two had no 
significant findings with regards to inflammation or fibrosis.  The remaining SIV-infected 
untreated controls, sacrificed at 21 dpi, had mild inflammation and mild fibrosis.  In the early 
natalizumab treated group (n=6), sacrificed at 21 dpi, 4 animals had no significant findings in 
regards to inflammation and fibrosis and two animals had mild inflammation and fibrosis (Table 
5.1). 
Overall, natalizumab treatment decreased cardiac pathology in late treated animals 
(n=4), compared to late untreated controls (n=6) (Table 1).  Three of 4 late treated animals had 
no significant findings with respect to cardiomyocyte degeneration, and 2 of 4 had no significant 
findings with regard to fibrosis.   SIV-infected, untreated late control animals with cardiac 
pathology (n=3), had an increased severity compared to late treated SIV-infected animals (Table 
5.1).  Two of the late controls with pathology had moderate inflammation and one had mild 
inflammation.  All three late controls with pathology had moderate fibrosis while two had mild 
and one had moderate cardiomycocyte degeneration.  Compared to the late controls with 
pathology, the severity of pathology in SIV-infected, late natalizumab treated animals (n=4) was 
diminished (Table 5.1).  Three late treated animals had mild inflammation while the remaining 
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had moderate inflammation.  Two late treated animals had no inflammation and two had only 
mild inflammation.  Three late treated animals had no significant findings with regard to 
cardiomyocyte degeneration and one had mild cardiomyocyte degeneration (Table 5.1).  
 
Natalizumab treatment decreases the number of macrophages present in cardiac tissue in early 
and late treated animals. 
In animals that began natalizumab treatment early at 0 dpi, there was a significant 
decrease in the number of CD163+ and CD68+ macrophages in heart tissues compared to 
untreated controls sacrificed at the same time point (Fig. 5.1).  There was a significant 3.35-fold 
and 3.74-fold  decrease in the numbers of CD163+ and CD68+ macrophages, respectively, in 
cardiac tissue in early natalizumab treated animals compared to controls (Fig. 5.1B, Table 2, 
non-parametric Mann-Whitney t-test, * p<0.05).  While not significant, there were decreased 
numbers of newly infiltrating macrophages MAC387+ macrophages and CD3 T-lymphocytes in 
early treated animals (Fig. 5.1B, Table 2).   
Natalizumab treatment beginning on 28 dpi (late) resulted in a significant decrease in 
the numbers of CD163+ and CD68+ macrophages when compared to all SIV-infected untreated 
late control animals (Fig. 5.1).  We found a 3.53-fold and a 1.19-fold decrease in the numbers of 
CD163+ and CD68+ macrophages respectively in cardiac tissues of late natalizumab treated 
tissues compared to controls (Table 5.2, non-parametric Mann-Whitney t -test, *p<0.05, ** 
p<0.01).  We next examined if the numbers of macrophages in late natalizumab treated animals 
differed between late untreated control animals with and without cardiac pathology.  
 Late treated animals had decreased numbers of CD163+ macrophages compared to 
untreated late controls without cardiac pathology (Fig. 5.1A).  There was a 2.51-fold decrease in 
the number of CD163+ macrophages in cardiac tissue in late treated animals compared to 
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controls without cardiac pathology (Fig. 5.1B, Table 3, non-parametric Mann-Whitney t-test, 
*p<0.05). There were no differences in numbers of CD68+, MAC387+ macrophages and CD3 T-
lymphocytes in cardiac tissues of late natalizumab treated animals and untreated controls 
without pathology (Table 5.3).   
Significant reductions in the number of CD163+ and CD68+ macrophages were found in 
late treated animals compared to late untreated controls with cardiac pathology (Fig. 5.1A).  
There was a 4.53-fold and 1.59-fold decrease in the numbers of CD163+ and CD68+ 
macrophages present in cardiac tissues compared to late natalizumab treated animals (Fig 5.1C, 
Table 5.3, non-parametric Mann-Whitney t-test, * p<0.05, ** p<0.01).  Similar to early treated 
animals, late treated animals had a trend of decreased numbers of newly infiltrating 
macrophages expressing MAC387 and CD3 T-lymphocytes compared to late untreated animals 
with cardiac pathology (Table 5.3). 
 
Natalizumab treatment blocks traffic of macrophages to the cardiac tissues 
 BrdU experiments were used to further determine if natalizumab treatment blocks 
traffic of monocyte/macrophages to the heart.  Previously, we have shown that the majority of 
BrdU+ macrophages in the heart are MAC387+ macrophages.28  In early natalizumab treated 
animals there were few BrdU+ cells (4.38±0.64 cells/mm2) and a trend of decreasing numbers of 
BrdU+ cells compared to untreated controls (9.31±1.57 cells/mm2)(Fig. 5.1A, 5.1B, Table 5.2).  
Animals that began natalizumab treatment at 28 dpi, had decreased number of BrdU+ cells 
(16.42±3.19 cells/mm2) compared to untreated animals with cardiac pathology (22.51±5.23 
cells/mm2) (Fig. 5.1A, 5.1C, Table 5.3).  The number of BrdU+ cells in late natalizumab treated 
animals did not differ when compared to untreated animals without cardiac pathology (Fig. 
5.1A, 5.1C, Table 5.3). 
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   Decreased fibrosis in cardiac tissues of natalizumab treated animals correlates with significant 
decreases in macrophage numbers. 
Using a modified Masson’s trichrome stain, the percent collagen per total tissue area in 
cardiac tissues of natalizumab treated animals and untreated controls was quantified (Fig. 5.2A, 
5.2B).  Compared to controls, both early and late natalizumab treated animals had decreased 
amounts of collagen (Fig. 5.2C).  In early natalizumab treated animals, the average percent 
collagen per total tissue area was 5.58±2.56% compared to 9.6±2.06% for untreated controls, a 
significant 1.72-fold decrease in the percent collagen (Fig. 5.2C, left, * p<0.05, non-parametric 
Mann-Whitney t-test).  
Animals that began natalizumab treatment at 28 dpi (late) had a significantly higher 
average percentage of collagen per tissue area in the left ventricle (8.66±2.31%) compared to 
animals that began treatment early (5.58±1.47) (Fig. 5.2C, right, *p<0.05, non-parametric Mann-
Whitney t-test).  Late natalizumab treated animals had no significant differences in the percent 
of collagen per total tissue area compared to untreated animals without cardiac pathology 
(8.66±2.31% vs. 10.33±1.84%).  However, when compared to untreated animals with cardiac 
pathology, there was a significant decrease in the percentage of collagen per tissue area.  While 
late natalizumab treated animals had an average percentage of collagen of 8.66±2.31%, 
untreated animals with cardiac pathology had an average of 19.91±1.85%, a significant 2.29-fold 
decrease in the average percent collagen per total tissue area (Fig. 5.2C, right, * p<0.05, non-
parametric Mann-Whitney t-test). 
We next examined if there was a correlation between decreased fibrosis in natalizumab 
treated animals and changes in macrophage numbers in cardiac tissues if significant differences 
in macrophage numbers were found between groups.  There was a correlation between 
increased fibrosis and increased numbers of CD163+ (r=.9, p<0.05) and CD68+ (r=.86, p<0.05) 
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macrophages in untreated controls sacrificed at 21 dpi compared to early natalizumab treated 
animals (Fig. 5.2D).  A correlation also existed in late natalizumab treated animals compared to 
all late untreated controls for CD163+ (r=.85, p<0.05), CD68+ (r=.55. p<0.05) macrophages and 
fibrosis (Fig. 5.2E.) 
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DISCUSSION 
 Chronic inflammation persists within HIV infected individuals despite effective cART and 
decreased plasma viral load to undetectable levels.46-48  With chronic inflammation, there are 
increased co-morbidities compared to the general non HIV-infected population.49-51  In particular 
there is an increased incidence of CVD 4 where monocytes/macrophages are increasingly 
considered to play a role.52, 53  Previously, we have shown that SIV-infected, CD8-lymphocyte 
depleted monkeys have increased numbers of macrophages (CD163+, CD68+, and MAC387+) in 
cardiac tissues that positively correlate increased fibrosis.28 In this study we examined if an anti-
α4 antibody, natalizumab, diminishes leukocyte and monocyte/macrophage traffic to the heart 
resulting in decreased fibrosis. 
 Natalizumab blocks the interaction between α4 integrin and its ligand, vascular cell 
adhesion molecule-1 (VCAM-1).38  VCAM-1 is expressed on endothelial cells of the arterial lumen 
with atherosclerosis.54  Studies in mice showed that inhibiting the interaction between α4 and 
VCAM-1 decreased macrophage recruitment  to atherosclerotic plaques.41  Previously we have 
shown that there is a higher level of macrophages traffic to the heart later in SIV infection (>21 
dpi) and that there are few macrophages present in untreated animals sacrificed at 21 dpi.28 In 
the current study we found that natalizumab treatment beginning at 0 dpi resulted in decreased 
numbers of CD163+ and CD68+ macrophages compared to uninfected controls but cardiac 
pathology in early infection is minimal and most of the pathology occurred in the later stages of 
infection. 
When compared to untreated controls with cardiac pathology, late treated animals had 
significant decreases in the number of CD163+ and CD68+ macrophages. In fact, the numbers of 
macrophages in late natalizumab treated animals were similar to untreated animals without 
cardiac pathology.  Additionally, we found a correlation between decreased macrophage 
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numbers in natalizumab treated animals with decreased cardiac fibrosis.  Overall, these data 
show that blocking monocyte/macrophage traffic to the heart alleviates HIV and SIV-associated 
cardiac pathology resulted in reduced inflammation, fibrosis, and cardiomyocyte degeneration. 
  While not significant, we found a trend of decreasing numbers of MAC387+ 
macrophages in the left ventricle of late treated animals compared to untreated animals with 
cardiac pathology.  The finding of a decrease in newly recruited macrophages is supported our 
observation of fewer BrdU labeled macrophages (that traffic from the bone marrow); suggesting 
that macrophage traffic to the heart results in increased fibrosis.  While previous research 
showed natalizumab decreased traffic of CD3 T-lymphocytes and MAC387+ to the brain and 
gut,42 in the current study, we do not find significant differences in the number of CD3 T-
lymphocytes or MAC387+ macrophages in cardiac tissues of SIV infected animals with or 
without natalizumab treatment.  This possibly suggests that CD3+ T-lymphocytes and MAC387+ 
macrophages use different integrins to traffic to the heart than to the brain or gut, however we 
have previously shown that MAC387+ macrophages and not CD3+ T-lymphocytes correlate with 
increased fibrosis in cardiac tissues.28  Our lack of finding a statistically significant reduction in 
the number MAC387+ macrophages may be due to the relatively few numbers of those cells in 
cardiac tissues. 
Previously, we have shown that the rate of monocyte/macrophage traffic to the heart is 
increased later in infection (after 48 dpi) as opposed to early infection.28  Using BrdU labeling we 
found a trend of decreased traffic of monocytes/macrophages to the heart in late natalizumab 
treated animals compared to untreated animals that developed cardiac pathology.  Late 
natalizumab treated animals had a similar rate of traffic of newly released 
monocytes/macrophages from bone marrow to the heart as untreated animals without cardiac 
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pathology.  This provides evidence that potentially blocking traffic of monocyte/macrophages 
later during SIV infection can alleviate SIV-associated cardiac pathology.   
 While cART can decrease HIV to non-detectable levels in plasma, it does not necessarily 
target monocyte/macrophages that play a role in the development of cardiac pathology and 
cardiovascular disease.32  Chronic immune activation with HIV infected is posited to play a role 
in HIV-associated cardiovascular pathology. Previous studies show that HIV infected individuals 
have increased inflammation in the ascending aorta that correlates with levels of sCD163 in 
plasma.55  Increased inflammation in the aorta is also been linked to high-risk noncalcified 
plaques that are prone to rupture.8  FDG-PET imaging studies have demonstrated that such 
plaque areas are comprised of areas with accumulation of macrophages.8, 56, 57  While 
macrophage accumulation in the aorta and cardiac plaques are critical in HIV associated cardiac 
disease, it is not surprising that also there is increased macrophage inflammation in cardiac 
tissues at the same time.   Unpublished data from our laboratory (Chapter 4), using matched 
cardiac tissues (left ventricle) and aorta from HIV- and HIV+ individuals, shows that with HIV 
infection there is increased macrophage inflammation in ventricular tissues and the aorta.  
Moreover, increased macrophage inflammation in cardiac tissues correlates with increased 
fibrosis, macrophage accumulation in the aorta, and increased aortic intima-media thickness.  
To date, there are few therapies that target macrophages specifically or indirectly to diminish 
HIV-associated cardiovascular pathology. Emergent data underscores the importance of such 
therapy strategies. 
 Therapeutic agents that have been successful in the treatment noncalcified cardiac 
plaque in HIV+ individuals include 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors 
(statins), which fortuitously have anti-inflammatory effects on macrophages.58, 59  Statin therapy 
in conjunction with cART reduced serum levels of inflammatory markers including interleukin-6, 
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interleukin-8 and tumor necrosis factor-α, more so than cART alone.60  Statins have similarly 
been used in monkeys where they decreased the macrophage content in plaques in the 
abdominal aorta.34  A recent study in HIV infected individuals showed that statins significantly 
decreased the volume on noncalcified plaques but whether statin use in this study directly 
affected monocyte and/or macrophage activation and traffic was not studied.35  35  In rodent 
models of experimental autoimmune myocarditis (EAM) rosuvastatin reduced numbers 
macrophages, T-lymphocytes and multinucleated giant cells in the heart resulted in decreased 
numbers of apoptotic cardiomyocytes.  The effects of statins on myocarditis with HIV infection 
have not been examined.61 
   Other studies found maraviroc treatment decreased chemotaxis of 
monocyte/macrophages, in vitro,62 but in clinical studies with advanced HIV, it did not affect the 
development of immune reconstitution inflammatory syndrome (IRIS),63  Maraviroc is used 
primarily to inhibit viral replication of R5-tropic HIV by blocking interactions between the virus 
and CCR5 on host cells.64, 65  Studies using maraviroc in SIV-infected monkeys demonstrated 
fewer CD163+ macrophages in the heart, but this could have been due to a decreased CD163 
expression (activation) on macrophages already present in the heart and not a decrease in 
inflammatory cells.  All together, these experiments add further evidence to the role that 
monocyte/macrophages play in cardiac pathology with HIV and SIV infection, and suggest that 
therapies blocking monocyte/macrophage traffic to the heart could diminish HIV-associated 
cardiac pathology. 
In this study we showed that directly blocking monocyte/macrophage traffic to cardiac 
tissues with natalizumab successfully decreased the numbers of macrophages present in tissues.  
Studies examining if blocking traffic to vessels result in decreased in high risk vascular plaques 
with HIV infection are warranted.   Our data suggest that studies examining the efficacy of 
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blocking monocyte/macrophage traffic, or directly targeting monocyte/macrophage activation 
as an adjunctive therapy with cART, should be examined with an aim to decrease HIV-associated 
cardiac pathology. 
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MATERIALS AND METHODS 
Ethical treatment of animals 
 The treatment of animals in this study was in accordance with the Guide for the Care 
and Use of Laboratory Animals, 8th edition.  Animals were housed at The New England Regional 
Primate Center (NERPC) (Southborough, MA), Tulane National Primate Research Center (TNPRC) 
(Covington, LA), or BIOQUAL (Baltimore, MD).  The NEPRC Protocol Number for this study is 
04420 and the Animal Welfare Assurance Number is A3431-01.  The TNPRC Number for this 
study is 3497 and the Animal Welfare Assurance Number is A4499-01.  Animals were monitored 
daily for evidence of disease progression and changes in appetite or behavior, with clinical 
support administered under the direction of an attending veterinarian.   
 
Animals, SIV Infection, CD8 lymphocyte depletion 
Nineteen rhesus macaques (Macaca mulatta) were infected with SIV mac251 (2ng of 
SIV-p27) intravenously (kindly provided by Ronald Desrosiers, University of Miami) (Table 1).  All 
animals were CD8-lymphocyte depleted using cM-T807, a human anti-CD8 antibody, 
administered subcutaneously (10mg/kg) on day 6 post infection (pi) and intravenously (5 mg/kg) 
on days 8 and 12 pi, as previously described 1.  Ten animals (n=4 late natalizumab treated, n=6 
untreated) were sacrificed at similar time points with progression to AIDS (49 to 65 dpi).  All CD8 
–lymphocyte depleted animals had high viral load at peak viremia that remained elevated and 
was not different between early and late treated animals and controls.  Six early natalizumab 
treated animals were sacrificed at 21 dpi and three untreated controls sacrificed at 22 dpi.  
Sections of left ventricular myocardium (hereafter referred to as cardiac tissue) were analyzed 
by a board certified veterinary pathologist (ADM), and scored based on the degree of 
inflammation, fibrosis, and cardiomyocyte degeneration.  Sections were scored as either no 
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significant findings (NSF), mild, moderate, or severe, based on the degree of change in cardiac 
tissues as previously described.28 
 
Anti-α4 integrin (natalizumab) and BrdU administration 
The anti-α4 integrin mAB (natalizumab) was provided by Biogen Idec (Cambridge, MA) 
in a sterile concentrated solution.  Natalizumab has specificity for the α4 subunit of α4β1 and 
α4β7 integrins expressed on surfaces of all leukocytes, except neutrophils.43  Natalizumab was 
administered weekly for three weeks beginning on the day of infection (0 dpi, n=6) or on 28 dpi 
(n=4), as previously described.42  This treatment regimen maintains high levels of natalizumab in 
serum of rhesus macaques during treatment 44.  To study monocyte/macrophage traffic to the 
heart animals were administered BrdU (30mg/kg) at indicated time points (Table 5.1) as 
previously described.42  
 
Immunohistochemistry 
 The numbers of macrophages and T-lymphocytes present in formalin-fixed, paraffin-
embedded tissues were determined by immunohistochemistry and cell counting.  Cardiac 
tissues were stained with antibodies against CD163 (1:250, Serotec), CD68 (1:200, Dako), 
MAC387 (1:100, Dako) macrophages and CD3+ T-lymphocytes (1:300, Dako).  The number of 
macrophages that traffic to cardiac tissues was determined using a mouse monoclonal BrdU 
antibody (1:50), as previously described.28  Twenty random, non-overlapping 200X microscopic 
fields of view were taken for each animal and the number of positive cells/mm2 calculated for 
each.   The data are represented as the average number of positive cells/mm2 from the twenty 
random fields. 
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Masson’s Trichrome Stain 
The percent of collagen per tissue area used as  a marker of fibrosis, 29 was measured 
using a modified Massons Trichrome Stain kit (Newcomer Supply, Middleton, WI) according to 
the manufacturer’s recommendation.  Tissue sections were imaged using a Zeiss Axio Imager 
M1 microscope using Plan-Apochromat x20/0.8 Korr objectives, as previously described.28, 45  
The area of red and blue dyes corresponding to cytoplasm and collagen, respectively, were 
measured to determine the percentage of total tissue area.  
 
Statistical Analysis 
 Statistical analyses were conducted using Prism version 6.0 (GraphPad Software, Inc.).  P 
values were calculated using the non-parametric Mann-Whitney t-test with significance 
accepted at p<0.05 when comparing early and late natalizumab treated animals to early and late 
untreated controls.  Analysis of variance (ANOVA) was used to compare late natalizumab 
treated animals to late untreated animals with and without cardiac pathology.  If the ANOVA 
was significant (p<0.05), then a post-hoc non-parametric Mann-Whitney t-test were performed.  
To determine if changes in numbers of macrophages in the cardiac tissues correlates with 
changes in fibrosis, a non-parametric Spearman rank correlation was used where p<0.05 was 
significant. 
 
 
 
 
  
Table 5.1. Cardiac Pathology of Natalizumab Treated and Control Animals Used in this Study 
             Cardiac Pathology 
                 
Animal 
Groups 
 ID  Primate 
Center 
 Start of 
natalizumab 
(dpi) 
 BrdU 
Admin. 
(dpi) 
 Survival 
(dpi) 
 Inflammation  Fibrosis  Cardiomyocyte 
degeneration 
                 
Early 
untreated 
n=3 
 A1  TNPRC  -  6,20  22  NSF  NSF  NSF 
 A2  TNPRC  -  6,20  22  NSF  NSF  NSF 
 A3  TNRPC  -  22  22  Mild  Mild  NSF 
                 
 
Early 
natalizumab 
n=6 
 A4  NERPC  0  6,20  21  NSF  NSF  NSF 
 A5  NERPC  0  6,20  21  NSF  NSF  NSF 
 A6  BIOQUAL  0  6,20  21  NSF  NSF  NSF 
 A7  BIOQUAL  0  6,20  21  NSF  NSF  NSF 
 A8  BIOQUAL  0  6,20  21  Mild  Mild  Mild 
 A9  BIOQUAL  0  6,20  21  Mild  Mild  NSF 
                 
Late 
untreated 
without 
cardiac 
pathology 
n=3 
 A10  NERPC  -  49  56  NSF  NSF  NSF 
 A11  NERPC  -  pre, 7, 20, 
41, 54  
 56  NSF  NSF  NSF 
 A12  NERPC  -  pre, 7, 20, 
41, 54 
 55  Mild  Mild  NSF 
                 
Late 
untreated 
with cardiac 
Pathology 
n=3 
 A13  TNPRC  -  pre, 7, 26, 
55 
 56  Moderate  Moderate  Mild 
 A14  TNPRC  -  pre, 7, 26, 
55 
 65  Moderate  Moderate  Mild 
 A15  NERPC  -  6, 20  60  Severe  Moderate  Moderate 
                 
Late 
natalizumab 
n=4 
 A16  NERPC  28  pre, 26, 
47  
 49  Mild  NSF  NSF 
 A17  NERPC  28  pre, 26, 
47 
 49  Mild  NSF  NSF 
 A18  NERPC  28  33, 47  49  Mild  Mild  NSF 
 A19  NERPC  28  33, 47  49  Moderate  Mild  Mild 
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Nineteen animals were used in this study, housed at either The New England Regional Primate 
Center (NERPC), Tulane National Primate Research Center (TNPRC), or BIOQUAL, as indicated.  
Six animals began natalizumab treatment at the time of infection at 0 days post infection (dpi) 
and were sacrificed at 21 dpi.   Three early untreated controls were sacrificed at 22 dpi.  Four 
late natalizumab treated animals began treatment at 28 dpi and were sacrificed at 49 dpi.  Three 
animals each for late untreated controls without cardiac pathology and with cardiac pathology 
were sacrificed at 56-65 dpi.  Pathology was assessed based on the degree of inflammation, 
fibrosis, and cardiomyocyte degeneration.  To investigate if blocking monocyte/macrophage 
traffic to the heart decreased SIV-associated cardiac pathology, 10 randomly chosen, 200X fields 
of view were chosen and analyzed blindly by a veterinary pathologist.  Sections of cardiac tissue 
were scored based on the degree of change as having no significant findings (NSF), mild, 
moderate, or severe inflammation, fibrosis, and cardiomyocyte degeneration.      
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Table 5.2. Numbers of Macrophages and T-lymphocytes in Natalizumab Treated and Control Animals 
     
  Early  Late 
  Untreated 
(n=3) 
 NZ 
(n=6) 
 P 
value 
 Fold  
Change 
 Untreated 
(n=6) 
 NZ 
(n=4) 
 p 
value 
 Fold  
Change 
Immune 
Markers 
                
CD163  158.84 
(±55.78) 
 47.36 
(±18.77) 
 *  3.35  282.45 
(±36.97) 
 80.06 
(±10.95) 
 **  3.53 
                 
CD68  84.34 
(±16.67) 
 22.54 
(±5.09) 
 *  3.74  63.01 
(±4.71) 
 52.87 
(±10.83) 
 *  1.19 
                 
MAC387  9.33 
(±1.17) 
 7.43 
(±3.19) 
 ns  -  18.25 
(±2.11) 
 15.91 
(±7.46) 
 ns  - 
                 
CD3  8.05 
(±2.13) 
 5.13 
(±3.02) 
 ns  -  15.55 
(±3.60) 
 12.27 
(±5.42) 
 ns  - 
                 
BrdU  9.31 
(±1.57) 
 4.39 
(±0.64) 
 ns  -  21.19 
(±5.85) 
 16.42 
(±3.19) 
 ns  - 
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Numbers represent the mean number of positive cells (cells/mm2) ± the standard error of the 
mean, in bracket.  All animals were SIV-infected and CD8-lymphocyte depleted, with 10 of the 
animals receiving natalizumab.  Twenty random, non-overlapping, 200X fields of view were 
counted for each animal and the average number of positive cells/mm2 calculated.  P values 
were calculated by comparing the mean number of positive cells for the indicated groups using 
the non-parametric Mann-Whitney t-test (* p<0.05, ** p<0.01).  The fold change was calculated 
for the numbers of cells were there was a significant difference between the indicated groups.  
Early natalizumab treated animals began treatment at the time of infection, 0 days post 
infection (dpi).  Late natalizumab treated animals began treatment 28 dpi.  All treated animals 
were treated weekly for three weeks with a dose of 30 mg/kg of α-VLA-4.  NZ=Natalizumab 
treated. Ns=No significance 
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Table 5.3 Numbers of macrophages and T-lymphocytes in late natalizumab treated animals and controls without and with cardiac pathology 
 
 Late         
  Untreated 
w/o 
pathology 
n=3 
 Untreated 
w/ 
pathology 
n=3 
 NZ 
n=4 
 p 
value 
NZ 
vs. 
w/o 
 
 p 
value 
NZ 
vs. 
w/ 
 
 Fold 
Change 
NZ 
vs. 
w/o 
 
 Fold 
Change 
NZ 
vs. 
w/ 
 
               
Immune 
Markers 
              
CD163  195.33 
(±16.37) 
 363.23 
(±15.87) 
 80.06 
(±10.95) 
 *  **  2.51  4.53 
               
CD68  56.96 
(±7.37) 
 84.13  
(±4.38) 
 52.87 
(±10.83) 
 ns  *  -  1.59 
               
MAC387  14.01 
(±1.09) 
 22.51  
(±1.77) 
 15.91 
(±7.46) 
 ns  ns  -  - 
               
CD3  13.17 
(±3.76) 
 16.63  
(±7.92) 
 12.27 
(±5.42) 
 ns  ns  -  - 
               
BrdU  19.86 
(±10.08) 
 22.51 
(±5.23) 
 16.17 
(±3.19) 
 ns  ns  -  - 
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Numbers represent the mean number of positive cells (cells/mm2) ± the standard error of the 
mean, in bracket.  All animals were SIV-infected and CD8-lymphocyte depleted.  Twenty 
random, non-overlapping, 200X fields of view were counted for each animal and the average 
number of positive cells/mm2 calculated.  Analysis of variance (ANOVA) was used to compare 
late natalizumab treated animals to late untreated animals with and without cardiac pathology.  
If the ANOVA was significant (p<0.05), then a post-hoc Mann-Whitney t-tests were performed.  
NZ= natalizumab treated, w/o= untreated without cardiac pathology, w/ = untreated with 
cardiac pathology.  *p<0.05, **p<0.01. Ns=no significance. 
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     *from Walker et al. JAHA, 2015. 
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Figure 5.1.  Natalizumab treatment decreases the number of macrophages in cardiac tissues in 
SIV-infected, CD8-lymphocyte depleted rhesus macaques. 
 (A) Sections of left ventricular tissues from early and late natalizumab treated animals and 
matched controls were immunohistochemically stained with antibodies recognizing CD163+, 
CD68+, and MAC387+ macrophages and CD3+ T-lymphocytes.  (B, C) Twenty random, non-
overlapping 200X fields of view were taken for each animal and the average number of 
cells/mm2 calculated.  In both early and late natalizumab treated animals there is a decrease in 
the numbers of CD163+ and CD68+ macrophages when compared to controls, with no 
differences in T-lymphocytes detected.  Statistical analysis between early natalizumab treated 
animals and controls was done using a non-parametric Mann-Whitney t-test.  For late 
natalizumab treated animals and untreated controls with and without cardiac pathology an 
ANOVA was performed first, and if significant, a post-hoc non-parametric Mann-Whitney t-test 
was performed (*, p<0.05, **, p<0.01).  Scale bar= 50 microns, 400X magnification.  Error bars 
represent the average number of positive cells/mm2 ± the standard error of the mean (SEM).  
NZ, Natalizumab treated.  UN, untreated.  Early, treatment began at 0 dpi.  Late, treatment 
began at 21 dpi. 
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     *from Walker et al. JAHA, 2015. 
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Figure 5.2.  Natalizumab treatment decreases fibrosis in the left ventricle of SIV-infected, CD8-
lymphocyte depleted rhesus macaques. 
 (A, B) Modified Masson’s trichrome stain was used to compare the percent collage per total 
tissue area, a marker of fibrosis, in the left ventricle of early and late natalizumab treated 
animals compared to untreated controls.  (C) Natalizumab treatment resulted in decreased 
fibrosis in cardiac tissues compared to controls regardless of when treatment began.  In animals 
that began natalizumab treatment at 0 dpi there was a significant decrease in the amount of 
collagen per tissue area (5.58±2.56%) compared to untreated controls (9.6±2.06%, non-
parametric Mann-Whitney t-test, p<0.05).  Animals that began natalizumab treated at 28 dpi 
also showed a significant decrease in the amount of collagen per total tissue area (8.66±2.31%) 
when compared to untreated controls with cardiac pathology (19.91±1.85%).  There was no 
difference in the percent collagen per total tissue area in animals late natalizumab treated 
animals compared to untreated controls without cardiac pathology.  Spearman rank test was 
used to determine if there was a correlation between decreased fibrosis in natalizumab treated 
animals and decreased numbers of macrophages.  (D) In early natalizumab treated animals 
(closed square) there is a correlation between the decrease in numbers of CD163+ and CD68+ 
macrophages and decreases in fibrosis when compared to untreated controls (closed circle).  (E) 
In late natalizumab treated animals (closed square), there is a correlation between decreases in 
CD163+ and CD68+ macrophages  compared to untreated controls with (open circle) and 
untreated controls without pathology ( closed circle).  r= spearman coefficient, p<0.05.  
Statistical analysis between early natalizumab treated animals and controls was done using a 
non-parametric Mann-Whitney t-test.  For late natalizumab treated animals and untreated 
controls with and without cardiac pathology an ANOVA was performed first, and if significant, a 
post-hoc non-parametric Mann-Whitney t-test was performed (*, p<0.05).  Scale bar= 50 
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microns, 400X magnification.  Error bars represent the average number of positive cells/mm2 ± 
the standard error of the mean (SEM). 
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ABSTRACT 
Despite effective combination antiretroviral therapy (cART) HIV+ individuals develop co-
morbidities including cardiovascular disease (CVD), where activated macrophages play a key 
role.  To date, few therapies target activated monocytes and macrophages.  We evaluated a 
novel oral form of the polyamine biosynthesis inhibitor methylglyoxal-bis-guanylhydrazone 
(MGBG) on cardiovascular inflammation, carotid artery intima-media thickness (cIMT), and 
fibrosis in a SIV infection model of AIDS.  Eleven SIV-infected animals received MGBG (30 mg/kg) 
once daily and 8 received a placebo control both beginning at 21 dpi.  Animals were time 
sacrificed (49 dpi), when matched placebos developed AIDS, or at the study endpoint (84 dpi).   
Cardiac arteries and tissues were analyzed. Quantitative analysis of macrophage populations 
and T-lymphocytes were done and correlated with cIMT and fibrosis.  MGBG treatment resulted 
in a 2.19 (CD163+), 1.86 (CD68+), 2.31 (CD206+), and 2.12-fold (MAC387+) decrease in 
macrophages in carotid arteries and a significant 2.07 (CD163+), 1.61 (CD68+), 1.95 (MAC387+) 
and 1.62-fold (CD206+) decrease in macrophages in cardiac tissues compared to controls.  CIMT 
(1.49-fold) and fibrosis (2.05-fold) were significantly decreased in treated animals compared to 
controls.  Cardiac macrophage numbers and fibrosis in treated animals were similar to 
uninfected animals.  There was a correlation between decreased macrophage numbers in the 
carotid artery and cIMT and cardiac macrophages and fibrosis.  These data demonstrate directly 
targeting macrophages with MGBG can reduce cardiovascular inflammation, IMT, and fibrosis. 
They suggest therapies targeting macrophages with HIV should be used in conjunction with 
cART.  
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INTRODUCTION 
 Effective combination anti-retroviral therapy (cART) has increased the lifespan of HIV+ 
individuals1-3 and can successfully decrease viral load to low or undetectable levels.4,5  While 
effective in reducing plasma viral load chronic immune activation and inflammation persist 
leading to non-AIDS morbidities, including cardiovascular disease (CVD).6  HIV+ individuals on 
cART have elevated levels of soluble CD14, C-reactive protein, tumor necrosis factor (TNF)-α, 
and soluble CD163 (sCD163) many of which are myeloid derived, and activated monocytes and 
macrophages.7   Similar findings are reported in elite controllers, who have never been on cART, 
and have elevated sCD163, activated monocyte/macrophages and CVD, despite having low 
levels of viremia.8-10 
 HIV+ individuals have increased risk of cardiovascular disease (CVD) compared to the 
general population.11,12 Growing evidence suggests that chronic immune activation and 
inflammation are a cause for increased CVD risk. 13,14  HIV+ individuals have increased 
percentages of activated nonclassical (CD14+CD16++) and intermediate (CD14++CD16+) 
monocytes similar to non HIV infected individuals with CVD.15  Using FDG-PET imaging, we have 
shown increased arterial inflammation in the ascending aorta that correlates with levels of 
plasma sCD163, a marker of monocyte/macrophage activation.16  Additionally, monocyte 
activation markers sCD163, sCD14 and CCL2 were elevated in plasma of HIV+ individuals and 
associated with atherosclerosis.17   
Monocytes/macrophages play roles in the development of atherosclerosis, vascular 
calcification, and myocarditis.  Macrophages secrete tumor necrosis factor alpha (TNF-α) and 
transforming growth factor beta (TGF-β), which can enhance calcification in vitro18.  Studies 
showed that macrophages are associated with calcium deposits in carotid plaques19 and 
longitudinal studies provided evidence that inflammation precedes calcification.20,21  In the 
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heart, macrophages secrete pro-inflammatory and pro-fibrotic factors which correlate with the 
extent of fibrosis.22  Unpublished data from our lab (Chapter 4) showed increased macrophage 
accumulation in the aorta with HIV infection and levels of sCD163 in plasma correlate with 
increased aortic intima-media thickness (aIMT). Using a SIV-infected, CD8+ T-lymphocyte 
depletion model of rapid and consistent AIDS, we found macrophage infiltration of cardiac 
parenchymal tissue correlates with increased cardiac fibrosis.23  Directly blocking 
monocyte/macrophage traffic to the heart, using an anti-α4 antibody, decreased macrophage 
accumulation in cardiac tissues and cardiac fibrosis.24 These results suggest that by targeting 
macrophages it is possible to decrease HIV-associated cardiovascular inflammation and 
decrease HIV-associated CVD.   
Few therapies directly targeting macrophages and residual immune activation in 
conjunction with cART in HIV infection have been described.6  Glucocorticoid treatment of SIV-
infected animals depleted pro-inflammatory and pro-thrombic CD14+CD16++ monocytes.25  
Minocycline, a tetracycline antibiotic, previously was shown to prevent the development of SIV 
encephalitis (SIVE),26,27 decrease circulating activated monocytes that correlated with 
neuroprotection, and decrease monocyte/macrophage inflammation in lymph nodes .28  
However minocycline treatment in humans was not effective.29-31  SIV-infected monkeys treated 
with maraviroc, a CCR5 inhibitor, had decreased CD163 expression on macrophages in the 
myocardium32 and in humans, maraviroc in conjunction with effective cART decreased vascular 
cell adhesion molecule-1 (VCAM-1).  A clinical trial using low dose methotrexate treatment to 
reduce inflammation has been initiated (NCT01949116).   
Methylglyoxal-bis-guanylhydrazone (MGBG) is a polyamine biosynthesis inhibitor that 
inhibits S-adenosine methionine decarboxylase (SAMDC) resulting in decreased intracellular 
concentrations of spermine and spermidine in monocytes/macrophages.33,34 Polyamines are 
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necessary for macrophage activation, proliferation, and differentiation, suggesting MGBG might 
be useful in targeting macrophages to alleviate macrophage-mediated diseases associated with 
HIV infection.35,36 Previously, MGBG injected intravenously (i.v.) was used to treat HIV-
associated lymphomas37 but was discontinued.38  More recently the effects of MGBG, in vitro, on 
HIV expression in human macrophages have been studied.  MGBG inhibited  HIV-p24 expression 
and DNA integration in human monocytes/macrophages without cell associated toxicities.39  
Interestingly, MGBG is taken up and concentrated within macrophages, but not by T-
lymphocytes.  To date, most ART agents target T-lymphocytes and have limited uptake and or 
penetration into macrophages which are more resistant to antiretroviral agents.40    
We have used a CD8+ T-lymphocyte depletion model of rapids AIDS with consistent CNS 
and cardiac pathology and found that increased macrophage accumulation in cardiac tissues 
and vessels leads to cardiac fibrosis and cardiomyocyte damage.23  We used 19 SIV-infected, 
CD8+ T-lymphocyte depleted rhesus macaques and 6 uninfected controls, to examine if a novel 
oral form of MGBG treatment decreased inflammation in the aorta, carotid artery, and left 
ventricle (cardiac tissue) by directly targeting macrophages.  We sought to determine if 
decreased cardiac inflammation would decrease intima-media thickness and cardiac fibrosis. 
MGBG treatment significantly decreased macrophage associated inflammation and fibrosis in 
cardiac tissues to levels similar to that of uninfected animals.  Compared to placebo controls, 
MGBG treatment resulted in a trend towards decreased inflammation in the carotid artery and a 
significant decrease in cIMT.  These results suggest that therapies directly targeting 
monocyte/macrophages with HIV infection potentially could reduce HIV-associated CVD.  
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RESULTS 
MGBG treatment decreases cardiovascular pathology in SIV-infected rhesus macaques 
Aorta and carotid artery 
 Cardiovascular pathology was assessed for the aorta, carotid artery, and cardiac tissue 
for all animals.  Both MGBG treated and placebo control animals had no significant findings in 
the aorta for all animals.  MGBG treatment resulted in decreased inflammation in the carotid 
artery.  Five of 9 (55%) MGBG treated animals had no inflammation in the carotid artery 
compared to 2 of six (33%) placebo controls.  The remaining MGBG treated (4 of 9, 44%) and 
placebo controls (4 of 6, 66%) all had mild inflammation.  Six of 9 (66%) of MGBG treated had no 
significant carotid artery degeneration, compared to 3 of 6 placebo controls (50%).  Intimal 
thickening was noted in only 1 of 9 (11%) MGBG treated animals compared to 3 of 6 (50%) 
placebo controls (Table 6.2). 
Cardiac Tissue 
Cardiac tissues were assessed based on inflammation, fibrosis, and cardiomyocyte 
degeneration.  MGBG treatment reduced the frequency and severity of inflammation in cardiac 
tissues.  Five of 11 (45%) MGBG treated animals had no inflammation while placebo controls 
had either mild (7 of 8, 87%) or moderate (1 of 8, 13%) inflammation.  Seven of 11 (63%) of 
MGBG treated animals had no cardiac fibrosis compared to only 2 of 8 (25%) of placebo 
controls.  Four of 11 (37%) MGBG treated animals had mild fibrosis and 6 of 8 (75%) remaining 
placebo controls had mild to moderate fibrosis.  Five of 11 (45%) MGBG treated animals had no 
cardiomyocyte degeneration compared to only 1 of 8 (13%) of the placebo control animals, 
suggesting that MGBG decreased the frequency of cardiomyocyte degeneration. 
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MGBG decreases macrophage inflammation in the carotid artery and cardiac tissue in SIV-
infected rhesus macaques 
MGBG treatment resulted in a trend of decreased macrophage numbers in the carotid 
artery compared to placebo controls.  There was a 2.19-fold (CD163+), 1.86-fold (CD68+), 2.12-
fold (MAC387+), and  2.31-fold (CD206) decrease in the numbers of macrophages in the carotid 
artery of MGBG treated animals compared to placebo controls (Fig. 6.1A).  There were no 
differences between the numbers of CD3+ T-lymphocytes present in the carotid artery in 
placebo controls compared to MGBG treated animals. 
MGBG treatment significantly decreased cardiac tissue macrophages compared to 
placebo controls.  There was a significant 2.07-fold (CD163+), 1.61-fold (CD68+), 1.95-fold 
(MAC387+) and 1.62-fold (CD206+) decrease in numbers of macrophages in cardiac tissues of 
MGBG treated animals (Fig. 6.1B).  Similar to the carotid artery, there was no difference in 
numbers of CD3+ T-lymphocytes in cardiac tissues of placebo controls and treated animals.   
There were significantly increased numbers of macrophages in placebo controls 
compared to uninfected animals.  We did not find differences in the numbers of CD163+, 
MAC387+ and CD206+ macrophages in cardiac tissues of treated compared to uninfected 
animals.  We did find CD68 was significantly increased (2.71-fold increase) in treatment 
compared to uninfected animals (Fig. 6.1B). 
 
MGBG treatment results in a reduction of carotid artery intima-media  
MGBG treatment resulted in a significant 1.49-fold decrease of carotid artery intima-
media thickness (cIMT) compared to placebo controls.  The average cIMT for placebo controls 
was 0.41±0.05mm (n=6) compared to 0.28±0.02mm MGBG treated animals (n=9) (Fig. 6.2A, 
6.2B).  Spearman rank correlation analysis of tissues from placebo controls and MGBG treated 
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animals demonstrated a positive correlation between increased numbers of CD68+ (r=.52, 
p<0.05), CD206+, and MAC387+ (r=.42, p<0.05) macrophages present in the carotid artery and 
increased cIMT.  There was no correlation between the number of CD163+ macrophages and 
increased cIMT (Fig. 6.2C). 
 
MGBG treatment results in decreased cardiac fibrosis in SIV-infected rhesus macaques  
There was a significant 2.05-fold decrease in the percent collagen per tissue area in 
MGBG treated animals compared to placebo controls.  The average percent collagen per tissue 
area for MGBG treated animals was 5.79±0.67% (n= 11) compared to 11.85±0.98% for placebo 
controls (n=8) (Fig. 6.3).  SIV negative animals had a mean percent collagen per tissue area of 
6.74±1.91% (n=6).  Placebo control animals had a significant 1.76-fold increase in the percent 
collagen per tissue area compared to uninfected animals.  MGBG treated animals showed no 
significant differences in the percent collagen per tissue area compared to uninfected animals.  
Spearman rank analysis of tissues from uninfected, placebo controls, and MGBG treated animals 
demonstrated positive correlations between increased numbers of CD163+ (r=0.69, p<0.01), 
CD68+ (r=0.63, p<0.05), CD206+ (r=0.54, p<0.01), and MAC387+ (r=0.53, p<0.05) macrophages 
in cardiac tissues and increased fibrosis in cardiac tissues (Fig. 6.3C). 
 
In situ hybridization for SIV-RNA 
We did not find SIV-RNA or SIV-p28+ cells in the carotid artery or cardiac tissues of SIV-
infected placebo controls or MGBG treated animals at the study endpoint (84 dpi), consistent 
with previous findings.23  Viral loads in all animals peaked at 8 dpi and remained elevated in 
MGBG treated or placebo controls (data not shown). 
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DISCUSSION 
With effective combination anti-retroviral therapy (cART) mortality due to AIDS related 
causes has decreased,2,47 however secondary co-morbidities have increased.3  While cART 
decreases plasma virus to low or undetectable levels, chronic immune activation that potentially 
drives the progression of cardiovascular disease persists.48  Statins, that are likely to have a mild 
immune suppressive effect on myeloid cells,49  have been used successfully to decrease CVD 
with HIV infection50-52  Two studies used rosuvastatin in uninfected individuals50 and HIV+ 
individuals on cART with a moderate cardiovascular risk51 found a reduced rate of cIMT 
progression.  Additionally atorvastatin reduced non-calcified plaque volume and high-risk 
coronary plaque features (positive remodeling and low attenuation of plaques) among HIV+ 
individuals with arterial inflammation.52  Statins do not directly target macrophages that are key 
players in HIV- and SIV-associated CVD53-55 and myocarditis56,57 and to date few therapies target 
them. 
We and our collaborators previously showed that traditional risk factors of CVD are not 
associated with atherosclerotic plaques, but markers of monocyte/macrophage immune 
activation, sCD14 and sCD16358 are, suggesting that chronic immune activation with HIV 
infection plays a role in the development of HIV-associated CVD.  Increased sCD1459 and 
monocyte chemoattractant protein 1 (MCP-1) and tumor necrosis factor alpha (TNF-α)60 also 
associated with increased coronary artery calcium (CAC), a marker of coronary atherosclerosis.  
FDG-PET imaging showed that with HIV infection there is increased arterial inflammation in the 
ascending aorta that correlated with levels of sCD163,16 and an increase in high-risk plaque 
morphology.61 Soluble CD163 made by activated monocytes and macrophages also was 
associated with non-calcified plaques in HIV+ individuals.58  High-risk, non-calcified plaques tend 
to have large necrotic lipid rich cores and increased macrophage numbers compared to stable 
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plaques.53  HIV elite controllers, who control viremia, have elevated myeloid markers of immune 
activation 8,62 and an increased prevalence of non-calcified coronary plaques further suggesting 
a link between monocyte/macrophage activation and HIV-associated CVD.10 
Previously our lab showed that the SIV-infected, CD8+ T-lymphocyte depletion model of 
rapid AIDS in rhesus macaques can be used to study the effects of SIV on the development of 
cardiac fibrosis.23  We found that directly blocking macrophage traffic to the heart, using an anti-
α4 antibody, decreased overall cardiac pathology, macrophage inflammation, and cardiac 
fibrosis.24 The anti-alpha 4 antibody is less useful long term in HIV+ individuals because of the 
emergence of JC virus infection with long term usage seen in patients with MS and Crohns.63,64 In 
the current study, we examined the effects of an oral formulation of methylglyoxal-bis-
guanylhydrazone (MGBG), that is specifically taken up by and concentrated in 
monocytes/macrophages39 and not T-lymphocytes.  We investigated the effects of oral 
administration of MGBG on SIV-associated cardiovascular inflammation in the carotid artery and 
heart, cIMT, and cardiac fibrosis.  Animal groups consisting of placebo and MGBG treated 
animals were sacrificed early, when placebo controls developed AIDS, or study endpoint.  
We found a trend of decreased inflammation in carotid arteries of MGBG treated 
animals compared to placebo controls, as well as a significant decrease in the cIMT.  Carotid 
artery intima-media thickness, a marker of atherosclerosis and subclinical cardiovascular 
disease65-67 is associated with myocardial infarction and stroke.68,69 cIMT increases more rapidly 
in HIV+ individuals compared to age-matched control individuals70,71 and is associated with a low 
CD4+ T-lymphocyte count (<200cells/mm3)72.  A limitation of the current study is not having 
carotid arteries from uninfected animals to compare to MGBG treated animals.   
MGBG treatment decreased macrophage inflammation in cardiac tissues and cardiac 
fibrosis compared to placebo controls.  Cardiac inflammation and fibrosis in MGBG treated 
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animals was similar to levels seen in uninfected animals.  We did not find any effect of MGBG on 
the number of CD3+ T-lymphocytes present in cardiac tissues consistent with our findings that 
MGBG is selectively taken up and concentrated in monocytes and macrophages, and not T 
lymphocytes.39  We have previously shown in our rapid AIDS model that the accumulation of 
macrophages, and not T-lymphocytes nor viral infected cells, best correlates with cardiac 
fibrosis and cardiomyocyte damage.23  Plasma viral load for all placebo and MGBG treated 
animals in this study were not statistically different as these animals were CD8+ T-lymphocyte 
depleted and lacked early control of viremia.  We did not find SIV-RNA+ cells in the hearts of our 
monkeys, a result that is consistent with prior reports of low or scattered SIV- and HIV-infected 
macrophages in cardiac tissues.73,74  Together, these data underscore the role of macrophages in 
the development of SIV-associated CVD. Targeting macrophages directly might be a possible 
way to diminish inflammation in the heart and cardiac fibrosis. While the incidence of cardiac 
fibrosis has declined in the cART era among HIV+ individuals,75,76 recent studies demonstrate it is 
still prevalent among HIV+ individuals.77,78  Some animals in this study that received MGBG 
developed AIDS, others receiving the drug did not possibly due to animals being time sacrificed 
at the end of the study.  However, there were no differences in the levels of fibrosis and cIMT in 
MGBG treated animals with and without AIDS suggesting that disease progression is not the sole 
cause of cardiovascular disease, adding evidence that chronic inflammation with SIV and HIV 
infection likely plays a more central role.   
In this study we examined the effects MGBG has on SIV-associated cardiovascular 
inflammation and cardiac fibrosis by directly targeting macrophages.  Animals receiving daily 
doses of MGBG showed decreased inflammation in the carotid artery and cardiac tissue when 
compared to placebo controls. MGBG treatment also prevented an increase in cIMT and cardiac 
fibrosis that remained at levels similar to SIV negative animals. These data suggest that 
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therapies designed to target chronic inflammation and immune activation seen with HIV 
infection could be used as adjunctive therapies to cART to alleviate HIV-associated 
cardiovascular disease. 
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MATERIALS AND METHODS 
Ethics Statement 
All animals used in this study were handled in strict accordance with the American 
Association for Accreditation of Laboratory Animal Care with the approval of the Institutional 
Animal Care and Use Committee of Harvard University and housed at the New England Primate 
Research Center (NERPC) (Southborough, MA).  The NEPRC Protocol Number for this study was 
04420 and the Animal Welfare Assurance Number was A3431-01.  All animals were anesthetized 
with ketamine-HCl and euthanized by an intravenous pentobarbital overdose and 
exsanguinated.  The development of simian AIDS was determined post-mortem by the presence 
of opportunistic infections and presence of AIDS-defining lesions. 
 
Animals, SIV infection, CD8+ T-lymphocyte depletion, MGBG treatment 
 Twenty-five animals were used in this study.  Six animals were uninfected controls and 
19 animals SIV-infected and CD8 lymphocyte depleted.  Of these, 11 received MGBG (30 mg/kg) 
(provided by Pathologica, LLC; formulated as syrup by Wedgewood Pharmacy, Swedesboro, NJ) 
orally, once daily beginning at 21 days post infection (dpi), when significant CNS and 
cardiovascular inflammation is known to occur in this model.24,41  Eight received on oral placebo 
control at the same time point.  Previous experiments showed that an effective dose of 0.7μM 
MGBG in plasma and tissues was reached in animals that received a daily oral dose of 
30mg/kg.39  Infected animals receiving MGBG or placebo were assigned to one of six groups with 
at least one placebo control per group.  Six uninfected animals were group 1.  Animals in each 
group were sacrificed at 49 dpi (Group 2), when placebo controls developed AIDS (Groups 3-6), 
or at the end of the study (84 days) (Group 7) (Table 6.1). 
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Assessment of cardiovascular pathology  
Following exsanguination a full SIV necropsy was performed and major organs were 
collected in 10% neutral buffered formalin, embedded in paraffin, and sectioned at 5 μm.  
Sections of the carotid artery, aorta, and left ventricle (cardiac tissue) were stained with 
hematoxylin and eosin and graded blindly by a veterinary pathologist.  The carotid artery and 
aorta was assessed based on two criteria; inflammation and carotid artery or aortic 
degeneration.  Degeneration of the carotid artery or aorta was based on the alignment of 
smooth muscle fibers in the tunica intima. Cardiac tissues were assessed based on the degree of 
inflammation, fibrosis, and cardiomyocyte degeneration.  Sections were graded for each 
category based on the degree of change in cardiac tissues and scored as either having no 
significant findings (NSF) or being mild, moderate, or severe. 
 
Immunohistochemistry 
Numbers of macrophages in the carotid artery (n=11 MGBG treated, n=8 placebo) and 
left ventricle (cardiac tissue) (n=11 MGBG treated, n=8 placebo, n=6 SIV negative) were assessed 
using immunohistochemistry and cell counting as previously described.24  Formalin-fixed, 
paraffin-embedded sections of carotid artery and cardiac tissue were deparaffinized in xylenes 
and rehydrated in graded ethanols, followed by incubation with peroxidase block (Dako) for 5 
minutes.  Sections were incubated with serum free protein block (Dako) for 30 minutes then 
incubated with antibodies against CD163+, CD68+, CD206+, MAC387+ macrophage markers, and 
CD3+ T-lymphocytes for 1 hour at RT or overnight at 4°C.  Tissue sections were rinsed and 
incubated with an anti-mouse secondary antibody conjugated to horseradish peroxidase (Dako).  
The reaction product was visualized using 3, 3’-diaminobenzidine tetrahydrochloride (DAB, 
Dako).  The average number of immune positive macrophages/mm2 plus or minus the standard 
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error of the mean (SEM) was determined by counting the number of positive macrophages from 
twenty non-overlapping 200x fields of view (field area=0.148mm2) per section, using a Zeiss Axio 
Imager M1 microscope with Plan-Apochromat x20/0.8 Korr objectives (Carl Zeiss Microimaging 
Inc., Thornwood, NY). 
 
Measurement of carotid artery intima-media thickness 
 Sections of carotid artery were deparrafinzed and rehydrated in  xylenes and graded 
ethanols, followed by staining with a Verhoeff Van Gieson elastic stain (Sigma) to differentiate 
the intima, media, and adventitia of the carotid artery wall.42  The cIMT was measured optically 
using ImageJ Analysis Software for 10 non-overlapping fields of view per section.  Data were 
expressed as the average cIMT plus or minus the SEM.   
 
Measurement of cardiac fibrosis 
 Cardiac tissue were stained using a modified Massons Trichrome (Newcomer Supply, 
Middleton, WI) to determine the percent of collagen per tissue area.43,44  The percent collagen 
(blue dye) per tissue area was determined using ImageJ Analysis software from 20 non-
overlapping 200x fields of view (field area=0.148mm2).  Data were expressed as the average 
percent collagen per tissue area plus or minus the SEM. 
 
In situ hybridization for SIV-RNA 
 In situ hybridization for SIV-RNA  was performed using digoxigenin-labeled antisense 
riboprobes  from Lofstrand Labs (Gaithersburg, MD), as previously described.45  Formalin-fixed, 
paraffin-embedded sections of carotid artery and cardiac tissues were deparffinized and 
rehydrated in xylenes and graded ethanols.  Sections were treated with antigen unmasking 
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solution (Vector Labs, Burlingame, CA) for 20 minutes at high heat, washed, and prehybridized 
at 45°C for 1 hour with prehybridization buffer containing denatured herring sperm DNA and 
yeast tRNA at concentrations of 10mg/mL.  Digoxigenin-labeled probes (10ng/mL) were diluted 
in hybridization buffer and hybridized overnight at 45°C.  Following stringency washes with 
decreasing concentrations of SSC buffer, sections were blocked with a 1% blocking solution 
(Roche Diagnostics) for 30 minutes.  Digoxigenin-labeled probes were detected with NBT/BCIP 
(Roche Diagnostics) with levamisole (Dako) to inhibit alkaline phosphatases.  The NBT/BCIP 
substrate produces a visible blue reaction product.     
 Plasma SIV-RNA was quantified using real-time PCR for all animals used in this study, as 
previously described.46  500μL of EDTA plasma was collected and SIV virons were pelleted by 
centrifugation at 20,000 g for 1 hour.  The threshold sensitivity was 100 copy Eq/mL, with an 
average interassay coefficient variation of less than 25%. 
 
Statistical Analysis 
 Statistical analyses were done using Prism version 5.0 (Graphpad Software Inc., San 
Diego, CA).  For the carotid artery, comparisons of the mean number of macrophages/mm2 and 
carotid artery intima-media thickness (cIMT) were made between SIV-infected placebo controls, 
and SIV-infected MGBG treated animals using a non-parametric Mann-Whitney t-test with 
significance accepted at p<0.05.  For cardiac tissues, comparisons of the mean number of 
macrophages/mm2 and the percent collagen per tissue area were made between uninfected 
animals, SIV-infected placebo controls, and SIV-infected MGBG treated animals using analysis of 
variance (ANOVA).  If the ANOVA was significant (p<0.05) a posthoc non-parametric Mann-
Whitney t-test was performed.  A Spearman rank correlation analysis was used to determine if 
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changes in cIMT and the percent collagen per total tissue area correlated with decreased 
macrophage numbers in the carotid artery and cardiac tissues of MGBG treated animals 
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Table 6.1.  MGBG and Placebo Control Animals Used in this Study 
    Tissue Sections  
 Animal ID Survival 
(dpi) 
SIV/AIDS  Carotid 
Artery 
Left 
Ventricle 
Treatment  
G
ro
u
p
  
   
   
   
   
 1
 
373-03 NA SIV- N Y - 
257-00 NA SIV- N Y - 
417-08 NA SIV- N Y - 
454-08 NA SIV- N Y - 
96-10 NA SIV- N Y - 
428-08 NA SIV- N Y - 
       
G
ro
u
p
  
   
   
 2
 
5035 49 SIV+, SIVE N Y Placebo  
5038 49 SIV+, SIVE N Y Placebo 
5041 49 SIV+, AIDS N Y MGBG 
5042 49 SIV+, No AIDS N Y MGBG 
       
G
ro
u
p
   
   
   
 
3 
299-10 63 SIV+, AIDS Y Y Placebo 
264-10 63 SIV+, AIDS Y Y MGBG 
186-10 63 SIV+, No AIDS Y Y MGBG 
       
G
ro
u
p
   
   
   
   
 
4 
296-10 70 SIV+ SIVE Y Y Placebo 
291-10 70 SIV+, No AIDS Y Y MGBG 
273-10 70 SIV+, No AIDS Y Y MGBG 
       
G
ro
u
p
   
   
   
   
 
5 
291-09 77 SIV+, SIVE Y Y Placebo 
257-10 77 SIV+, AIDS Y Y MGBG 
328-10 77 SIV+ No AIDS Y Y MGBG 
       
G
ro
u
p
   
   
   
   
  
6 
326-10 83 SIV+, AIDS Y Y Placebo 
201-10 83 SIV+, No AIDS Y Y MGBG 
272-10 83 SIV+, AIDS Y Y MGBG 
       
G
ro
u
p
   
   
   
   
  
7 
434-10 84 SIV+, AIDS Y Y Placebo 
262-09 84 SIV+, No AIDS Y Y Placebo 
272-09 84 SIV+, No AIDS Y Y MGBG 
 
Twenty-five animals were used in this study to examine the effects of MGBG treatment on 
cardiovascular inflammation.  Six animals were uninfected (group 1).  The remaining 19 animals 
(groups 2-7) were either treated daily with MGBG or given a placebo control.  Animals were 
grouped and sacrificed at the indicated days post infection (dpi) when placebo controls 
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developed AIDS or at the end of the study (83, 84 dpi).  SIVE, SIV-encephalitis.  For tissue 
sections, N indicate no section was available, Y indicates that a tissue section was available.  
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Table 6.2.  Cardiovascular Pathology of MGBG and Placebo Control Animals 
           
  Aorta 
(n=15) 
 Carotid Artery  
(n=15) 
 Cardiac Tissue  
(n=25) 
  Inflammation Degeneration   Inflammation Degeneration   Inflammation Fibrosis Degeneration 
U
n
in
fe
ct
e
d
 
Animal ID          
373-03 NA NA  NA NA  NSF NSF NSF 
257-00 NA NA  NA NA  NSF NSF NSF 
417-08 NA NA  NA NA  NSF NSF NSF 
454-08 NA NA  NA NA  NSF NSF NSF 
96-10 NA NA  NA NA  NSF NSF NSF 
428-08 NA NA  NA NA  Mild Mild NSF 
SI
V
-i
n
fe
ct
e
d
, C
D
8+
 T
-
ly
m
p
h
o
cy
te
 d
e
p
le
te
d
 
p
la
ce
b
o
 c
o
n
tr
o
l 
5035 NA NA  NA NA  Mild Mild Mild 
5038 NA NA  NA NA  Mild NSF NSF 
299-10 NSF NSF  Mild NSF  Mild NSF Mild 
296-10 NSF NSF  NSF NSF  Mild Mild Mild 
291-09 NSF NSF  Mild Mild, with intimal thickening  Moderate Moderate Mild 
326-10 NSF NSF  Mild Mild, with intimal thickening  Mild Mild Mild 
434-10 NSF NSF  Mild Mild, with intimal thickening  Mild Mild Moderate 
262-09 NSF NSF  NSF NSF  Mild Mild Mild 
SI
V
-i
n
fe
ct
e
d
, C
D
8+
 T
-l
ym
p
h
o
cy
te
 
d
e
p
le
te
d
 M
G
B
G
 t
re
at
e
d
 
5041 NA NA  NA NA  NSF NSF NSF 
5042 NA NA  NA NA  NSF NSF NSF 
264-10 NSF NSF  NSF NSF  NSF NSF NSF 
186-10 NSF NSF  Mild NSF  NSF NSF NSF 
291-10 NSF NSF  Mild Mild  Mild NSF Mild 
273-10 NSF NSF  NSF NSF  Mild Mild Mild 
257-10 NSF NSF  NSF NSF  NSF Mild Moderate 
328-10 NSF NSF  NSF NSF  Mild NSF Mild 
201-10 NSF NSF  NSF NSF  Mild Mild Mild 
272-10 NSF NSF  Mild Mild, with isolated 
thickening 
 Mild Mild Mild 
272-09 NSF NSF  Mild Mild  Mild NSF NSF 
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Hematoxylin and eosin stained sections of matched aorta, carotid artery, and cardiac tissue 
were graded blindly by a board certified pathologist.  Sections of carotid artery and aorta were 
graded based on the following criteria; inflammation and degeneration with intimal thickening 
noted if present.  Degeneration was assessed based on the degree of alignment of smooth 
muscles fibers in the tunica intima.  Cardiac tissues were graded based on the following criteria; 
inflammation, fibrosis, and cardiomyocyte degeneration.  Sections were graded as having no 
significant findings (NSF) if they appeared normal or as either being mild, moderate, or severe, 
based on the degree of change in the tissue.   NA= not available.  Sections of the aorta and 
carotid artery were not available for analysis from all SIV negative animals and two placebo 
control and two MGBG treated animals, as indicated. 
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Figure 6.1.  Daily treatment with MGBG results in a trend of decreased inflammation in the 
carotid artery and a significant decrease in inflammation in cardiac tissues from SIV-infected 
CD8+ T-lymphocyte depleted rhesus macaques. 
(A)  Sections of carotid artery from MGBG treated (n=9) and placebo control (n=6) SIV-infected 
CD8+ T-lymphocyte rhesus macaques were immunohistochemically stained with antibodies 
recognizing CD163+, CD68+, CD206+, and MAC387+ macrophages.  MGBG treatment resulted in 
a trend of decreased numbers of CD163+ (2.19-fold), CD68+ (1.86-fold), MAC387+ (2.12-fold), 
and CD206+ (2.31-fold) macrophages present in the carotid artery when compared to placebo 
controls.  Statistical analysis was performed using a non-parametric Mann-Whitney t-test with 
significance accepted at p<0.05.  (B)  Sections of cardiac tissue from SIV- (n=6) MGBG treated 
(n=11) and placebo controls (n=8) rhesus macaques were immunohistochemically stained with 
the same antibodies.  MGBG treated animals had significantly decreased numbers of CD163+ 
(2.07-fold), CD68+ (1.61-fold), and MAC387+ (1.95-fold) and CD206+ (1.62-fold) macrophages 
when compared to placebo controls.  There was no difference in numbers of CD163+, MAC387+, 
and CD206+ macrophages when comparing uninfected and MGBG treated animals.  For cardiac 
tissues statistical analysis was performed between uninfected animals, SIV-infected placebo 
controls, and SIV-infected MGBG treated animals using analysis of variance (ANOVA).  If the 
ANOVA was significant (p<0.05) between two groups, a posthoc non-parametric Mann-Whitney 
t-test was performed. * p<0.05, ** p<0.01. 
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Figure 6.2  MGBG treatment prevents an increase in carotid artery intima-media thickness 
which correlates with a decreased trend in macrophage inflammation. 
(A) Sections of carotid artery were stained with a Verhoeff Van Gieson elastic stain in order to 
measure the carotid artery intima-media thickness (cIMT).  The cIMT was measured using 
calipers and ImageJ Analysis Software from 10 random non-overlapping fields of view with 
average cIMT calculated and expressed as plus or minus the standard error of the mean (SEM).  
(B) There was a significant 1.49-fold decrease in cIMT when comparing placebo control animals 
to MGBG treated animals.   Statistical analysis was performed using a non-parametric Mann-
Whitney t-test comparing placebo controls to MGBG treated animals with significance accepted 
at p<0.05.  (C)   Using a Spearman rank correlation analysis, in the carotid artery, there was a 
positive correlation between increased numbers of CD68+ (r=0.52) and MAC387+ (r=0.42) 
macrophages and increasing cIMT.  There was no correlation between numbers of CD163+ and 
CD206+ macrophages and cIMT. * p<0.05.  Scale bar equals 50 μm.  
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Figure 6.3.  MGBG treatment prevents an increase in cardiac fibrosis in cardiac tissues similar 
to levels seen in uninfected controls. 
(A) Collagen, a marker of fibrosis, in cardiac tissues was measured by staining cardiac tissue with 
a trichrome stain.  ImageJ Analysis software was used to determine the percent collagen (blue 
dye) per total tissue area from 20 200x non-overlapping fields of view with the average percent 
collagen per total tissue area calculated for each animal.  (B) There was a significant 2.05-fold 
decrease in the percent collage per total tissue area when comparing placebo controls to MGBG 
treated animals.  There was no significant difference between the percent collagen per total 
tissue area between uninfected and MGBG treated animals.  Statistical analysis was performed 
using analysis of variance (ANOVA).  If the ANOVA was significant (p<0.05) between two groups, 
a posthoc non-parametric Mann-Whitney t-test was performed.  (C)  Using Spearman rank 
correlation analysis, we found positive correlations between increasing numbers of CD163+ 
(r=0.69), CD68+ (r=0.63), MAC387+ (r=0.53) and CD206+ (r=0.54) macrophages and increasing 
percent collagen per total tissue area.  * p<0.05, ** p<0.01.  Scale bar equals 20 μm.  
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CHAPTER 7.  Summary and Discussion 
 Data in this thesis provide evidence supporting the role of monocyte/macrophage 
activation in the development of HIV and SIV-associated cardiovascular pathogenesis.  We show 
in Chapter 2 there are early differences in the numbers of activated monocytes that potentially 
predict the development of cardiac fibrosis in an SIV infection model of rapid AIDS.  We also 
found a correlation between cardiac and CNS inflammation, linked by immune activation and 
monocyte/macrophage activation and traffic.  Previously, cross sectional studies have found 
that increased monocyte activation correlates with cardiovascular disease development1-4.  The 
experiments in Chapter 2 are the first to examine whether longitudinal changes in monocyte 
activation correlate with cardiac fibrosis in SIV+ macaques.  While we show a positive 
correlation between monocyte activation as early as 8 dpi and cardiac fibrosis at necropsy it will 
be of particular interest in future studies, in humans and animals, to see if early changes in 
monocyte activation correlate with other markers of cardiovascular disease, such as intima-
media thickness.  Additionally, studies showed that SIV infection resulted in functional decline of 
the heart muscle itself using Doppler echocardiography5.  As we show that early changes in 
monocyte activation (8 dpi)  can distinguish between animals that did develop cardiac fibrosis 
and those that do not, it is possible that monocyte activation could be used to predict subclinical 
cardiovascular disease before there are any physical manifestations.  This would need to be 
confirmed by analyzing changes in monocyte phenotypes in HIV+ individuals and examining if 
they correlate with predictors of CVD using non-invasive methods such as cardiac MRS or B-
mode ultrasound for carotid artery intima-media thickness.  This would allow the individual to 
begin early therapy to treat cardiovascular disease before symptoms manifest. 
Having demonstrated a link between monocyte activation and macrophage 
inflammation in cardiac tissues, we examined in Chapter 3, cardiac tissues from SIV-infected 
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CD8+ T-lymphocyte depleted rhesus macaques to compare cardiac pathology with SIV-infected 
nondepleted animals and to determine if there is a correlation between increased cardiac 
inflammation and cardiac pathology.  We showed that with CD8 depletion there is a higher 
degree of cardiac inflammation and fibrosis compared to nondepleted and uninfected animals.  
We showed that increased macrophage inflammation in SIV-infected CD8+ T-lymphocyte 
depleted animals correlated with increased fibrosis, suggesting a role for 
monocytes/macrophages in cardiac fibrosis.  In the studies in Chapter 3, we show that 
uninfected animals and SIV+ nondepleted animals have few resident cardiac tissue macrophages 
that express CD68 and little cardiac fibrosis.  Immunohistochemistry showed there is an increase 
in newly infiltrating monocytes/macrophages that express MAC387 in SIV+, CD8+ T-lymphocyte 
depleted animals compared to uninfected and SIV+ nondepleted animals.  Along with BrdU 
experiments that showed increased traffic to the heart later during SIV infection (>21 dpi) this 
suggests that ongoing macrophage infiltration plays a role in the development of cardiac 
fibrosis.  
 In Chapter 4 we examined post-mortem cardiovascular tissues from HIV+ individuals on 
durable cART.  We found a correlation between macrophage aortic and cardiac inflammation 
with increased aortic intima-media thickness (aIMT) and cardiac fibrosis.  Additionally, we found 
increased levels of sCD163 in plasma of HIV+ individuals correlated with increased aIMT and 
cardiac fibrosis.  It is interesting that in the studies in Chapter 4 involving post-mortem human 
samples that we see evidence of aortic inflammation when in the animal studies in Chapter 6 
the aorta of all animals appeared normal.  This is possibly due to aortic disease not being 
present in nonhuman primate models unless they are fed a high-fat, “western” diet which would 
lead to the development of atherosclerosis. 
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In Chapters 3 and 4 we show that there are increased numbers of M2 macrophages that 
express CD163 and CD206.  Recent studies found that M2 polarized macrophages are present in 
unstable atherosclerotic plaques that occur in HIV+ individuals6,7.  Studies have begun to use 
radiolabeled labeled ligands against CD206 (Tilmanocept) in conjunction with PET imaging to 
target these macrophages specifically in order to image and stage atherosclerotic plaques8.  
Preliminary data from our lab shows that in Tilmanocept has a high degree of specificity for 
CD206+ macrophages in the aorta (Appendix A)  Tilmanocept and PET imaging, in theory, could 
also be used to visualize specific macrophage inflammation in vasculature as well as the heart.  
Knowing that there are specific macrophage subsets that are present in cardiovascular 
inflammation with HIV infection, therapies could be designed as well to target those specific 
macrophages in order to decrease their activation or expression of pro-inflammatory and pro-
fibrotic cytokines.  It is possible that other macrophage subsets are present in vulnerable 
atherosclerotic plaques.  Identifying specific surface markers on macrophage subsets would 
potentially allow them to be targeting by specific therapies or to be imaged as well.  Double 
label immunohistochemistry on post-mortem samples would also be beneficial to examine if 
other surface macrophage markers are present on CD206+ macrophages or if they are a unique 
population. 
In the final two chapters we examined the effects of blocking monocyte/macrophage 
traffic to the heart (Chapter 4) and the effects of targeting monocyte/macrophage activation 
directly (Chapter 5).  Blocking monocyte/macrophage traffic to the heart decreased cardiac 
fibrosis (Chapter 4) and using MGBG to target monocyte/macrophage activation directly we 
found that decreased inflammation in carotid arteries and cardiac tissues resulted in decreased 
intima-media thickness and cardiac fibrosis.  In both chapters we show that blocking leukocyte 
traffic to the heart correlated with decreased cardiac fibrosis (Chapter 4), and that targeting 
 238 
monocyte/macrophage directly (Chapter 5) we not only decreased cardiac inflammation and 
fibrosis, but also demonstrated a trend of decreased macrophage numbers in carotid arteries 
and decreased carotid artery intima-media thickness.  In the studies in Chapter 5 we did not find 
any difference in pathology, inflammation, or IMT in that aorta of placebo controls and treated 
animals, possibly be due to the model of acute infection we used.  It is also possible that diet 
might directly influence the pathology of the aorta in SIV+ animals and as these animals were 
not fed a high-fat diet it is likely that they would not spontaneously develop aortic disease.  
While cART does not decrease marker of immune activation, in fact they remain elevated during 
infection, these studies show that therapeutics targeting macrophages specifically used in 
conjunction with cART could be effective in decreasing inflammation and alleviating not only 
cardiovascular disease but also other macrophage mediated diseases associated with HIV 
infection including neurological, renal, and bone disorders.   
The data in this thesis adds evidence to the role of monocyte/macrophage activation in 
the development of HIV-associated cardiovascular disease.  While HIV has become a chronic 
condition with effective cART the lifespan of an infected individual will increase, but the 
prevalence of cardiovascular disease among this population is expected to rise.  Already current 
prediction models appear to underestimate the risk of cardiovascular disease development, 
likely due to the fact that they do not include HIV specific factors in their prediction algorithms.  
As the number of HIV infected individuals with cardiovascular disease continues to grow it will 
be important in the future to treat the symptoms of cardiovascular disease in order to continue 
to improve mortality of HIV+ individuals.  Here we show that significant macrophage 
inflammation is present in cardiovascular tissues and provide evidence of possible therapeutics 
to use as an intervention in developing cardiovascular disease.   
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APPENDIX A.  Tilmanocept as a diagnostic imaging agent 
INTRODUCTION 
 99mTc-tilmanocept (Lymphoseek®, Navidea Biopharmaceuticals, Inc.) is a diagnostic 
imaging agent that is approved for the identification of sentinel lymph nodes in multiple solid 
tumors.1-3  Mechanistically, Tilmanocept recognizes and binds to CD206 receptors on 
macrophages and dendritic cells.  In many diseases, cancers rheumatoid arthritis, cardiovascular 
disease, expression of CD206 is increased.  Combined with multiple binding sites for 
Tilmanocept, the high turnover rate of CD206 receptors on macrophages, and the upregulation 
of CD206+ macrophages in unstable atherosclerotic plaques4 the specificity of Tilmanocept for 
CD206 potentially makes this imaging agent useful in imaging HIV-associated cardiovascular 
disease.5  Previously, we and our collaborators published results using 18F-FDG-PET imaging to 
assess arterial wall inflammation in HIV+ individuals.  In this study we found that with HIV there 
was a significant increase in inflammation in the ascending aorta compared to controls that 
correlated with levels of soluble CD163 (sCD163).6  Now, patients from the same study are 
undergoing imaging with 99mTc-tilmanocept.  Here, we show preliminary data from 16 sections 
of aorta (n= 10, HIV-, n=10 HIV+) and 3 sections of carotid artery with atherosclerotic plaques 
that there is a high degree of co-localization between CD206 and CD163 on macrophages and 
that Tilmanocept specifically targets CD206+ macrophages. 
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METHODS 
Single Label Immunohistochemistry 
Single label immunohistochemistry for CD163+ and CD206+ macrophages was performed 
on formalin-fixed paraffin embedded sections of aorta from HIV- (n=10) and HIV+ (n=10) 
individuals and carotid artery (n=3) with atherosclerotic plaques, from different donors.  
Sections were provided by the National NeuroAIDS Tissue Consortium (NNTC) and the National 
Disease Research Institute (NDRI).  Tissue sections were deparaffinized and rehydrated in 
xylenes and graded ethanols followed by antigen retrieval (Vector) using high heat for 20 mins.  
Sections were then incubated with peroxidase block (Dako), washed in TBS-T, followed by a 30 
minute protein block.  Sections of the aorta were incubated with monoclonal antibodies 
recognizing CD163+ macrophage (Serotec) or CD206 (R&D Systems) for 1hr at RT (CD163) or 
overnight at 4°C (CD206).  Sectioned were washed in TBS-T and incubated with an anti-mouse 
secondary antibody conjugated to horseradish peroxidase (Dako).  The reaction product was 
visualized using 3, 3’-diaminobenzidine tetrahydrochloride (DAB, Dako).  The average number of 
immune positive macrophages/mm2 plus or minus the standard error of the mean (SEM) was 
determined by counting the number of positive macrophages from twenty non-overlapping 
200x fields of view (field area=0.148mm2) per section, using a Zeiss Axio Imager M1 microscope 
with Plan-Apochromat x20/0.8 Korr objectives (Carl Zeiss Microimaging Inc., Thornwood, NY). 
 
Immunofluorescence  
 Double label immunofluuorscence was performed on formalin-fixed paraffin embedded 
sections of aorta from 10 HIV- and 10 HIV+ individuals using antibodies against CD163 and 
CD206 and fluorescently labeled Tilmanocept.  Tissue sections were permeabilized in 0.1% 
TritonX-100/PBS/fish skin gelatin (FSG) and washed with PBS/FSG.  They were subsequently 
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blocked in PBS/FSG with 10% normal goat serum (NGS), followed by 1 hour or overnight 
incubation with primary antibodies diluted in PBS/FSG/normal goat serum.  After primary 
incubation sections were washed in PBS/FSG before adding the fluorescent secondary antibody 
diluted in PBS/FSG normal goat serum.  Finally the sections were washed in PBS/FSG and 
incubated in copper sulfate in ammonium acetate for 45 minutes to quench auto fluorescence.  
Tissue sections were stained with a combination of CD163 and CD206, CD163 and Tilmanocept, 
and CD206 and Tilmanocept antibodies and visualized using a Zeiss Axio Imager.Z2 with 
Apotome filter and x200 objective. 
 For sections double labeled with CD163 and CD206 antibodies, the percentage of 
CD163+CD206+, CD163+CD206-, and CD163-CD206+ cells was determined by counting the number 
of positive cells for each phenotype divided by the total number of cells in the field of view.  The 
average percentage was calculated from 20 random, non-overlapping x200 fields of view.  For 
sections double labeled with CD203 and Tilmanocept the percentage of Tilmanocept+ CD206+ 
and Tilmanocept- CD206+ was determined by counting the number of positive cells for each 
phenotype divided by the total number of CD206+ cells.   
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RESULTS 
Increased expression of CD163 and CD206 in the aorta with HIV infection 
 In the aorta there was increased expression of CD163+ and CD206+ macrophages with 
HIV infection.  The mean number of CD163+ macrophages/mm2 for HIV- individuals was 
22.95±3.66 compared to 46.78±5.40 for HIV+ individuals, a significant 2.03-fold increase (Fig. 
1A).  The mean number of CD206+ macrophages/mm2 for HIV- was 14.74±5.64 compared to 
30.08±6.27 for HIV+ individuals, a significant 2.13-fild increase (Fig. 1B). 
 
Co-localization of CD163 and CD206 on macrophages in the aorta 
 Sections of aorta from HIV- (n=10) and HIV+ (n=10) individuals were double labeled with 
antibodies against CD163+ and CD206+ macrophages.  There was a high degree of colocalization 
between CD163 and CD206 in sections from HIV- and HIV+ individuals.  The percentage of 
CD163+CD206+ macrophages in the aorta for HIV- individuals was 88.24±4.5% and 90.01±6.3% 
for HIV+ individuals.  The percentage of CD163+CD206- was 10.75±5.1 and 9.98±3.3%, 
respectively.  There were no cells in sections of the aorta from HIV- or HIV+ individuals that had 
a CD163-CD206+ (Fig. 1C). 
 
Co-localization of CD206 and Tilmanocept on macrophages in the aorta 
 Sections of aorta were doubled labeled with an antibody against CD206+ macrophages 
and its ligand, fluorescently labeled Tilmanocept.  The percentage of colocalization was 
determined by counting CD206+ macrophages and determining if they were also positive for 
Tilmanocept.  There was a similar degree of colocalization of Tilmanocept and CD206 in sections 
from HIV- and HIV+ individuals.  There was 89.03±3.7% colocalization between Tilmanocept and 
CD206 in sections of aorta from HIV- individuals and 91.73±6.4% in sections from HIV+ 
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individuals.  The percentage of Tilmanocept-CD206+ was 8.27±4.2 and 8.54±3.5% for sections of 
aorta from HIV- and HIV+ individuals, respectively (Fig. 1 D). 
 
Co-localization of CD163 and CD206 on macrophages in carotid arteries 
 Sections of carotid artery with atherosclerotic plaques (Fig. 2A) from individuals were 
double labeled with antibodies against CD163+ and CD206+ macrophages.  There was a high 
degree of co-localization between CD163+ and CD206+ macrophages in the shoulder and cap 
regions of plaques.  The percentage of CD163+CD206+ macrophages was 84.59±1.35%.  The 
percentage of CD163+CD206- was 14.56±3.45.  The percentage of CD163-CD206+ macrophages 
was 0.84±0.43%. 
 
Co-localization of CD206 and Tilmanocept on macrophages in carotid arteries 
Sections of carotid artery (n=3) were doubled labeled with an antibody against CD206+ 
macrophages and its ligand, fluorescently labeled Tilmanocept (Fig. 2B).  In shoulder and cap 
regions of plaques in the carotid artery there was a high degree of co-localization between 
CD206 and Tilmanocept.  We found that the percentage of Tilmanocept+CD206+ was 
87.94±4.26% and the percentage of Tilmanocept-CD206+ was 12.03±3.27%. 
 
 
 
 
 
 
 
 245 
Discussion 
 In this preliminary study we confirmed that  with HIV infection there is an increase in 
CD163 and CD206 expression in the aorta compared to controls, and demonstrated a high 
degree of co-localization between CD206 and Tilmanocept in macrophages in the aorta and 
carotid artery.  Currently there are several diagnostic techniques that can be used to detect 
cardiovascular inflammation associated with HIV; however, many of them do not target a 
specific macrophage subset.  Cardiac magnetic resonance (CMR) can be used to gain information 
about the presence of inflammation and fibrosis in the heart7, 8 and FDG-PET can assess arterial 
inflammation6, but this technique labels all metabolically active cells, likely macrophages.  
However, in this preliminary data we show that Tilmanocept specifically targets CD206+ 
macrophages in arteries.  Previous research showed that CD206 expression is upregulated in 
unstable atherosclerotic plaques.4  Using 99mTc-tilmanocept it is possible that only those specific 
macrophages involved in plaque instability and rupture could be identified and discriminate 
between stable and unstable atherosclerotic plaques. 
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Figure A.1.  Tilmanocept shows a high degree of specificity in targeting CD206+ macrophages 
in the intima of the aorta. 
(A)  Sections of aorta from HIV- (top, n=10) and HIV+ (bottom, n=10) were stained with 
antibodies recognizing CD163+ and CD206+ macrophages.  (B)  There was a significant 2.03 and 
2.13-fold increase in numbers of CD163+ and CD206+ macrophages in the aorta of HIV+ 
individuals compared to controls (*p<0.05).  (C)  Double label immunofluorescence showed a 
high degree of co-localization between CD163 and CD206 in the aorta of HIV- and HIV+ 
individuals.  The percentage of CD163+CD206+ macrophages in the aorta for HIV- individuals was 
88.24±4.5% and 90.01±6.3% for HIV+ individuals.  The percentage of CD163+CD206- was 
10.75±5.1 and 9.98±3.3%, respectively.  There were no cells in sections of the aorta from HIV- or 
HIV+ individuals that had a CD163-CD206+.  (D)  Fluorescently labeled tilmanocept shows a high 
level of colocalization with CD206+ macrophages in the aorta.  There was 89.03±3.7% 
colocalization between Tilmanocept and CD206 in sections of aorta from HIV- individuals and 
91.73±6.4% in sections from HIV+ individuals.  The percentage of  Tilmanocept-CD206+ was 
8.27±4.2 and 8.54±3.5% for sections of aorta from HIV- and HIV+ individuals, respectively. 
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Figure A.2.  Tilmanocept shows a high degree of specificity in targeting CD206+ macrophages 
in the carotid artery with atherosclerotic plaque. 
(A) Double label immunofluorescence showed a high degree of co-localization between CD163 
and CD206 in the aorta of HIV- and HIV+ individuals.  .  The percentage of CD163+CD206+ 
macrophages was 84.59±1.35%.  The percentage of CD163+CD206- was 14.56±3.45.  The 
percentage of CD163-CD206+ macrophages was 0.84±0.43%.  (B)  Fluorescently labeled 
tilmanocept shows a high level of colocalization with CD206+ macrophages in the aorta.  We 
found that the percentage of Tilmanocept+CD206+ was 87.94±4.26% and the percentage of 
Tilmanocept-CD206+ was 12.03±3.27%. 
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